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The immune system has been battling viral infections over the course of millions of years in 
primate evolution. The constant evolution of hosts and viruses to defeat the other has led 
to a high stakes genetic arms race. Here I present a detailed study of three antiviral proteins 
locked in antagonistic viral conflict called Tetherin, Viperin and SAMHD1. Using a combined 
approach of virology and evolutionary biology, I have reconstructed their evolutionary arms 
race between primates and lentiviruses, including HIV-1, HIV-2 and related SIVs. The broad 
themes that emerge from my research are two-fold. First, lentiviruses are able to evolve 
new functions within existing gene repertoires to counteract rapidly evolving host antiviral 
genes. Second, hosts escape from viral pressure either by single amino acid changes or by 
deletions of a ‘susceptibility domain'. Thus, my thesis research has helped define the rules 
by which host-virus arms races ensue. Based on my findings, we contend that the host 
evolutionary framework is a fundamental pillar of antiviral restriction. 
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CHAPTER ONE 
INTRODUCTION 
RETROVIRUSES AND LENTIVIRUSES  
 Retroviruses are a broad family of viruses that package a dimer of positive-sense 
single-stranded RNA genomes. The hallmark of a retrovirus is the reverse-transcription 
stage in its life cycle that transcribes DNA from RNA genetic material during its replication. 
Based on their genomes, retroviruses can be classified as simple retroviruses – alpha, beta 
and gamma retroviruses; or complex retroviruses – delta, epsilon, spuma and lentiviruses. 
The genome of simple retroviruses encodes the gag, pol and env genes within flanking long 
terminal repeat sequences (LTRs). In contrast, complex retroviruses encode accessory genes 
in addition to the gag, pol, env genes within their LTRs. While these accessory genes are 
dispensable for producing infectious virions, they afford utility in enhancing viral replication 
in different cell types 
HIV-1 and other primate lentiviruses encode accessory genes that serve to enhance 
virus replication and counteract host immune factors (151). Studies of these accessory 
proteins have led to the identification of important antiviral effector proteins encoded by 
host genomes called host restriction factors (123). Human immunodeficiency virus (HIV) 
and its close relative simian immunodeficiency virus (SIV) are prominent members of the 
lentivirus subfamily whose accessory genes have been characterized substantially.  
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There are five accessory genes in primate lentiviruses – Vif, Vpx, Vpr, Vpu and Nef 
(reviewed extensively in (151)).  
 Virion infectivity factor (Vif) plays an important role in HIV-1 replication in 
primary T cells, but is dispensible in certain cell types. The cellular gene called 
APOBEC3G is the target of Vif antagonism.  
 Viral protein R (Vpr) is encoded by all extant primate lentiviruses. Vpr is best 
associated with the phenotype of exerting arrest at the G2 phase of the cell 
cycle. While the cellular protein targeted by Vpr is still unknown, multiple 
lines of evidence point to the degradation of this factor that leads to the cell 
cycle arrest.  
 Viral protein X (Vpx) is a paralog of Vpr. While all extant primate lentiviruses 
encode a vpr, vpx is only found in 3 lineages of primate lentiviruses. This is a 
unique feature of HIV-2 and is absent from HIV-1. Vpx targets the cellular 
protein called SAMHD1 for degradation resulting in enhanced infection of 
monocyte-derived dendritic cells and macrophages, with the former having 
the highest effect.  
 Negative factor (Nef) is encoded by all primate lentiviruses. Nef displays 
pleiotropic effects that include cell surface receptor modulation, cholesterol 
biosynthesis, infectivity enhancement and immunoregulatory effects (12, 
281, 318). In several lineages, Nef antagonizes the host restriction factor 
called tetherin to enhance virus release. 
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 Finally, Viral protein U (Vpu) is encoded by HIV-1 and SIVmus/gsn lineages, 
but is absent from HIV-2 and several other lineages. Vpu also modulates the 
expression levels of cell surface proteins such as CD4 and NTB-A (243). Vpu 
encoded by some of these viruses have also evolved to antagonize tetherin.  
 
Due to their different origins, HIV-1 and HIV-2 are phylogenetically distinct and also 
differ in their genomic organization. HIV-1 encodes Vif, Vpr, Vpu and Nef accessory genes, 
while the related HIV-2 virus has a different repertoire of Vif, Vpx, Vpr and Nef (Figure 1). 
Another difference is that HIV-1 Nef open reading frame does not overlap with Env, 
whereas HIV-2 Nef maintains an overlap with the c-terminal portion of Env (196).  
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Figure 1  
Genomic organization of primate lentiviruses.  
HIV-1/SIVcpz lineages encode a unique vpu gene. HIV-2/SIVmac lineages encode a unique 
vpx gene. The third group of viruses including SIVagm lineages lacks vpx and vpu genes. 
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Figure 2 
This figure summarizes the HIV-1 life cycle. HIV-1 entry is mediated by binding to cell 
surface CD4 and co-receptors, followed by fusion. Virion uncoating occurs and reverse 
transcription proceeds in the cytoplasm. After provirus integration, viral transcription and 
translation lead to synthesis of viral proteins. Virion particles are assembled and bud from 
the plasma membrane. 
This figure is is from (214) with permission (License number 2798930993888). 
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HIV LIFE CYCLE 
Entry of HIV and SIV into target cells is mediated by the envelope protein (Figure 2). 
The Env protein is initially produced as a precursor glycoprotein 160 (gp 160) that is 
subsequently cleaved by cellular furin-like proteases into glycoprotein 120 (gp120) and 
glycoprotein 41 (gp 41). The gp 120 subunit is the surface unit (SU) that binds to the 
receptor and co-receptors and gp41 subunit is the transmembrane unit (TM) that allows for 
membrane fusion. The maturation process includes post-translational modifications that 
include disulfide bond formations and extensive glycosylation. Finally, the heterodimer of 
gp 120 and gp 41 are displayed on the virion membrane surface as trimers.  
While HIV-1 fusion is thought to occur at the plasma membrane, there is evidence 
usion may also occur in endosomes upon endocytosis (170). Upon membrane fusion, which 
is mediated by the gp 41 glycoprotein, the viral core is delivered into the cytoplasm. The 
conical viral core is comprised of mature p24 capsid (CA) proteins that harbor within it the 
dimer of RNA viral genome, nucleocapsid (NC), reverse transcriptase (RT), intergrase (IN) 
and Vpr. The viral core is undergoes an uncoating step that is linked to the formation of the 
reverse transcription complex (RTC). While the specific subcellular location of where 
uncoating occurs is unclear (10). 
HIV-1 binds cell surface CD4 molecule via gp120 that leads to a conformational 
change that allows the subsequent binding to the co-receptor CCR5 or CXCR4 (reviewed 
extensively in (83)). Thus, the target cells of HIV-1 are primarily CD4+ T cells and 
macrophages which express CD4 and either co-receptor molecules. However, virus isolates 
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may vary in their co-receptor tropism. In fact, the viruses established in early infections are 
predominantly CCR5 using. During progression towards late stage infections, there is often 
either a switch to CXCR4 specificity or to dual-tropic variants that have CCR5 and CXCR4 
usage (233). As such, humans who are homozygous for the CCR5Δ32 allele (a 32 bp deletion 
within CCR5 that results in a frameshift mutation) are protected from HIV-1 infection (160, 
225). Other well-document instances of selection on the co-receptor include red capped 
mangabeys (RCM), which are hosts of SIVrcm, that have a 24 bp deletion in CCR5 (CCR5Δ24) 
at an allele frequency of 87% (83). Sooty mangabeys (SM), which are hosts of SIVsm, also 
have a 2 bp deletion in CCR5 (CCR5Δ2) at 26% allele frequency (217).  
Cellular co-factors contribute to the uncoating process. Cyclophilin A (CypA), 
a host protein, binds CA at a proline-rich binding loop (66, 149, 271). It is 
hypothesized that the prolyl isomerase activity of CypA catalyzes the cis/trans 
isomerization of CA, resulting in conformational changes that regulate uncoating 
(29, 100). Inhibition of CypA by cyclosporine, a competitive inhibitor of the CypA, 
results in a marked decrease in infectivity due to a decrease in HIV-1 reverse 
transcripts in certain cell types (32, 221, 292). Pin1, also a prolyl isomerase like CypA, 
binds CA at a site neighboring the CypA-binding loop and facilitates the uncoating 
process (167). Overall, studies of host proviral factors involved in this process are 
largely based on mutations within CA. Nonetheless, they strongly suggest that CA is 
directly involved in early stages of infection. 
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Revese transcription in RTC is mostly completed in the cytoplasm, with a minor 
portion occurring in the nucleus (reviewed in (295)). The RTC is minimally comprised of viral 
genomic RNA, tRNA (Lys3) and RT. The tRNA(Lys3), notably of cellular origin, acts as a 
primer and is bound to the primer binding site (PBS) near the 5’ end of the viral genome 
(reviewed extensively in (1)). Reverse transcription is initiated and extends to the 5’ R by RT. 
This intermediate negative strand DNA, also referred to as (-)ssDNA, is released from the 
complementary RNA template by the RNase H activity of RT which degrades the template 
RNA strand. The first strand transfer occurs with this initial (-)ssDNA annealing to the 
complementary 3’R near the 3’ end of the viral genome, thus serving as the primer for the (-
) strand synthesis. Reverse transcription proceeds to generate the full length (-) strand 
cDNA, couple with the same RNase H activity to degrade RNA template. However, two 
regions are resistant to RNase H degradation: the 3’ polypurine tract within U3 (3’-PPT) and 
central polypurine tract (cPPT). These serve as the primers for the (+) strand cDNA 
synthesis. Following which, the second strand transfer occurs that anneals the (+) ssDNA to 
the 3’ end of the full length (-) strand cDNA. This allows for reverse transcription to proceed, 
generating the final full length (+) strand cDNA. Thus, double-stranded cDNA of the viral 
genome is produced with a 99 bp DNA flap in the center, flanked by two long terminal 
repeats (LTRs).  
The PIC is composed of the double-stranded viral genome DNA, MA, RT, IN and NC. 
Upon completion of reverse transcription, IN processes the 3’- ends of each LTR within the 
pre-integration complex (PIC) and proceeds with nuclear import for integration into the 
host genome. The mechanism of nuclear import is highly debated. In fact, multiple proteins 
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have been implicated in this process. TNPO3, a transportin involved in nuclear import of 
splicing factors, was identified through a yeast two-hybrid screen as factor that mediated 
nuclear import of the PIC (44). HIV-1 CA is the main determinant for TNPO3 dependency 
(128, 305). Several other proteins including NUP153, NUP155 and CPSF6 may also be 
involved in nuclear import (60, 128, 136). While the details remain unclear, it is evident that 
HIV-1 has multiple alternative pathways that facilitate nuclear import. Nonetheless, upon 
nuclear import, the 3’-processed viral DNA is inserted into host cellular chromatin by DNA 
strand transfer reaction (61). This is mediated by IN and always results in a 5 bp spacing 
between viral genome and host genome at each end. There is a high preference for 
integration at sites of actively transcribed genes (235).   
The integrated provirus serves as the template for viral transcription in a highly 
regulated process involving viral and cellular proteins. Transcription from HIV-1 provirus is 
regulated in 2 phases (Reviewed in (17, 138)). Initially, the transcription is driven by the 5’ 
LTR which has sequences that are recognized as cis-acting elements by cellular 
transcriptional machinery. The LTR promoter contains a TATAA box, 3 SP1 binding sites and 
a region of NF-kB binding site (197). The second phase is marked by Tat trans-activation that 
results in a dramatic increase in transcription up to several thousand times higher (138). Tat 
is synthesized early from a multiply spliced viral mRNA and binds to a stem-loop structure 
(TAR) on the RNA leader sequence. Through a series of kinase activity and phosphorylation 
events with the help of Tat-associated kinase (TAK), cyclin T1 and CDK9, the RNAPII complex 
is hyperphosphorylated at the carboxyl-terminal domain (CTD) resulting in promoter 
clearance and processive elongation.  
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Alternative splicing of viral transcripts regulates the translation of HIV-1 (Reviewed 
in (303)). Transcription of the provirus leads to full-length mRNA transcripts that are either 
unspliced, singly spliced or multiply spliced. The multiply spliced mRNA encodes for early 
regulatory proteins Tat, Rev and Nef. Singly spliced transcripts encode Vpu, Vpr, Vif and Env. 
Finally, the unspliced transcripts encodes for the GagPol polyprotein. Unspliced and singly-
spliced transcripts have a Rev Response Element (RRE) which is a secondary structure within 
an intron region. Intron-containing viral transcripts are retained in the nucleus by cellular 
splicing factors. As such, nuclear export of these RRE-containing transcripts is dependent on 
the viral protein Rev. Thus, in the initial stages of transcription, Rev is absent and only 
multiply spliced transcripts that no longer contain introns are exported out and proceed 
with translation (Tat, Rev and Nef). Tat transactivation coupled with increasing amounts of 
Rev shuttling back by importin-β into the nucleus regulate the nuclear export. Rev binds to 
the RRE and multimerizes to form a complex with cellular exportin 1 (CRM-1) and RAN 
GTPase (263). Hence, the cellular protein nuclear export machinery is usurped with the aid 
of the viral Rev protein to export the singly spliced and unspliced viral transcripts for protein 
translation. 
The full length unspliced viral transcript functions as the mRNA template for 
translating the GagPol polyprotein and the genomic RNA to be packaged within virion 
particles (Reviewed in (16)). Translation initiation occurs by ribosomal assembly at the 5’-
capped end of the mRNA (6, 36). Gag is synthesized most of the time, but a -1 frameshifting 
event occurs at about 5-10% frequency resulting in a GagPol precursor polyprotein. This 
results in about 20:1 ratio of Gag : GagPol intracellularly (248).  
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The expression of Gag protein alone is sufficient for the formation of virus-like 
particles and mediates the recruitment of other virion components for assembly. A dimer of 
full length genomic RNA associates with the nucleocapsid (NC) of Gag through the RNA 
packaging signal (Ψ) located in the 5’ end of the viral RNA (reviewed extensively in (192)). 
The RNA dimerization occurs in the cytoplasm and is mediated by a dimerization initiation 
site (DIS) also called as the kissing loop (146, 171). Additionally, viral proteins (Vpr) and 
cellular proteins (tRNA-Lys3 not a protein, CypA, HSP70 hsp70  not that much either and 
others) are recruited into the nascent virion (Reviewed in (189)). 
Assembly of HIV-1 occurs at the plasma membrane (115). The N-terminal 
myristoylated matrix (MA) domain targets Gag to phosphoinositide PI(4,5)P2  at the plasma 
membrane. Multimerization occurs with other Gag molecules, and notably, genomic viral 
RNA associated with NC is important in establishing the early-intermediate membrane-
bound assembly complex (117). While oligomerization of Gag occurs intrinsicly, the cellular 
endosomal sorting complex required for transport (ESCRT) complexes are required for the 
completion of assembly and budding. Virion particles that fail to engage the ESCRT 
complexes result in the formation of partially assembled immature particles that are 
arrested at the plasma membrane as stalks best described as lollipop-like structures.  
The late domain encoded within p6 of Gag (PTAP and YPLTSL) determine the 
recognition of TSG101 and ALIX (ESCRT-binding proteins) respectively. The PTAP motif is the 
predominant motif for budding and directly binds TSG101 and recruits the ESCRT-I complex 
(73). Gag-bound ESCRT-I complex recruits the ESCRT-III complex (also called as CHMP6, 
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CHMP4A-4C, CHMP3, CHMP2A and 2B) which is responsible for the scission of membrane 
neck. Finally, Vps4A arrives to disassemble the ESCRT-III complex via its ATPase activity. 
While PTAP is likely utilized in most instances of assembly, the alternative recruitment of 
ALIX by YPLTSL motif can serve as an intermediate complex that directly recruits ESCRT-III 
(63, 118). However, while ESCRT-III is recycled with the help of Vps4A, ALIX does not appear 
to be recycled (118). Curiously, some primate lentiviruses exclusively rely on the ALIX-
mediated recruitment of ESCRT-III (22, 259). Nonetheless, virion particles are released from 
the plasma membrane by hijacking host cellular machinery normally involved in 
multivesicular body formation and cytokinesis. 
The immature virion is initially non-infectious and requires the protelytic maturation 
by viral protease (PR). PR is activated at after budding and cleaves Gag at 5 sites resulting in 
MA, CA, SP1, NC, SP2, and p6. CA forms a fullerene cone formed that is made up of about 
250 hexameric subunits and 12 pentamers. The other newly processed proteins re-
assemble within the virion particle to form the MA layer at the inner viral membrane and 
NC is found associated with the viral RNA genome (Reviewed in (35, 69)). This structural 
morphology is a defining trait of retroviruses and the electron-dense conical core is a 
hallmark of the maturation process. Thus, the matured and infectious virion particle is ready 
to infect another target cell.  
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PRIMATE LENTIVIRUSES 
There are eight major lineages of primate lentiviruses (shown in Figure 3): (i) HIV-
1/SIVcpz, (ii) HIV-2/SIVsmm, (iii) SIVagm, (iv) SIVsun/lst/mnd1, (v) SIVsyk, (vi) SIVcol/olc/wrc, 
(vii) SIVmus/gsn/mon, (viii) SIVrcm/mnd2. These SIVs have been isolated from at least 30 
different nonhuman primate species in sub-Saharan Africa (9, 22). This number is likely to 
increase further as better methods of detection are developed and more survey efforts are 
initiated. There are several key differences between primate lentiviruses.  
First, lentivirus infections can have disparate outcomes in their primate hosts. For 
instance, Sooty mangabeys (SM) and African green monkeys (AGM) are found to be infected 
with SIVs that do not resolve the infection, and that do not lead to a pathogenic outcome. 
This is in contrast to HIV-1 that leads to a pathogenic outcome in humans (152, 253). Rhesus 
macaques experimentally infected with SIVmac also progress to immunodeficiency and 
develop AIDS-like symptoms (155, 172). Furthremore, HIV-1 infection of humans usually 
results in chronic IFN stimulation (152), whereas there is an absence of chronic stimulation 
of IFN production in SIVagm infection in naturally infected AGMs despite equivalent high 
levels of virus titers (54). In Chapter Three, I will present conclusive evidence that these 
differences in cellular immune environment during viral replication directly impact the role 
of viral factors to counteract host restriction factors that are induced by such responses. 
Second, besides gross differences in their genomic organization mentioned above 
(Figure 1), phylogenetic analyses of the 5’ coding sequences (gag or pol) and 3’ coding 
sequences (env or nef) reveal strong discordance suggesting that recombination occurred 
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between several lineages (111, 196, 224). For instance, SIVagm.Sabaeus is a recombinant of 
SIVagm and SIVsm/HIV-2 lineages (111). The recombinant origin of SIVcpz will be discussed 
in detail below.  
The precise evolutionary history of primate lentiviruses is further complicated by 
virus transmission between different primate species. In fact, cross-species transmission of 
primate lentiviruses is well-documented. For example, SIVagm has been detected in chacma 
baboons, and SIVsm was found in infected humans (71, 285). This is also supported by 
phylogenetic analyses which show that several phylogenetic relationships between SIV 
lineages are not congruent with their host species phylogeny (40). HIV-1 is the result of 
three independent cross-species transmission of SIVcpz from chimpanzees and one 
transmission of SIVgor from gorilla (itself the descendant of transmission from SIVcpz) 
(Figure 4); and HIV-2 arose from eight independent cross-species transmission of SIVsm 
from sooty mangabeys to humans (48, 70, 120, 208, 267, 284).  
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Figure 3 
There are eight major lineages of primate lentiviruses. This phylogeny was constructed from 93 HIV 
and SIV pol sequences (amino acids). However, the phylogenies constructed using other genes yield 
incongruent topologies due to recombinantion.  
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Figure 4 
HIV-1 is the result of three independent cross-species transmission of SIVcpz from 
chimpanzees and one transmission of SIVgor from gorilla (itself the descendant of 
transmission from SIVcpz); and HIV-2 arose from eight independent cross-species 
transmission of SIVsm from sooty mangabeys to humans. 
 
SIVcpz, the immediate precursor of HIV-1, is of hybrid origin (15). The 5’ region and 
3’ end of SIVcpz is derived from SIVrcm, but the middle region clusters more closely with 
SIVmus/gsn/mon viruses. A closer look at the genomic structure shows that the 
recombinant SIVcpz only has a single Vpr (compared to SIVrcm which has Vpx and Vpr) and 
Vpu (clearly acquired from SIVmus/gsn/mon that is absent in SIVrcm). Thus, the HIV-1 and 
SIVcpz lineages have an intriguing evolutionary history that traces to a unique 
recombination event and involves several cross-species transmissions. 
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In west Africa, both Pan troglodytes schweinfurthii and Pan troglodytes troglodytes 
species are infected with subspecies-specific SIVcpz. However, no SIVcpz has been found in 
either Pan troglodytes vellerosus or the geographically isolated Pan troglodytes verus 
species despite extensive surveying efforts (212, 226). Interestingly, all the HIV-1 viral 
sequences are more closely related to the SIVcpz that infects P.t.t., and no SIVcpz from P.t.s. 
that has been found in humans to date. This strongly suggests that HIV-1 originated from 
the SIVcpz-harboring P.t.t. species. Based on molecular clock estimates, the date of the 
most recent common ancestor of SIVcpz is about 1492 (1266–1685) (298). Therefore, SIV 
transmission into chimpanzees was likely a recent event.  
There are four groups of HIV-1: Group M (major), Group N (non-major), Group O, 
(outlier) and Group P (to be designated after Paris, the origin of the lab that discovered it). 
HIV-1 Group M is the pandemic virus accounting for more than 90% of current HIV 
infections, and can be further classified into at least 9 phylogenetically distinct subtypes 
(clades) and a growing list of circulating recombinant forms (CRFs). In comparison, HIV-1 
Group O accounts for about 1% and is mostly isolated to Central Africa, while Group N 
constitutes about 0.1% of infections (38). There are only 2 strains of HIV-1 Group P 
identified to date (208, 280). HIV-2 accounts for 1% of infections and is predominantly in 
West Africa (38).  
This raises the question: why is HIV-1 Group M the pandemic virus? This could be 
due to a combination of sociological factors and intrinsic viral properties. First, studies using 
molecular clock estimates place the inception of HIV-1 Group M at a time that coincides 
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with high population growth.The time of most recent common ancestor (tMRCA) for HIV-1 
Group M is around 1908 (1884 – 1924), whereas the tMRCA of HIV-1 Group O is about 1920 
(1890 – 1940) and HIV-1 Group N tMRCA is about 1963 (1948 – 1977) (298, 301). 
Demographic data from the early 1900s looking at the cities around the zone of cross-
species transmission (Cameroon, Central African Republic, DRC, Republic of Congo, Gabon 
and Equatorial Guinea) suggest that the early HIV infections coincided at a time when there 
was a surge in population size and expansion within these major cities (301). It is important 
to emphasize that HIV-1 infections were mostly undetected until its discovery in 1983 (68). 
Thus, the growth of cities in that region might have unknowingly provided a sufficient host-
population size and transmission network that facilitated the establishment of HIV-1.  
Secondly, there is also evidence of intrinsic properties of HIV-1 Group M strains that 
might allow for its more effective viral replication. Specifically, HIV-1 virus isolates from 
Group M have a higher replicative capacity and more effective viral countermeasures that 
antagonize host restriction factors (13, 229). My thesis research (presented in Chapter Four) 
will demonstrate that another key difference is the neofunctionalization of HIV-1 Vpu to 
antagonize Tetherin.  
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Figure 5 
 
This figure shows the recombinant origin of SIVcpz. The flanking 5’ and 3’ regions of SIVcpz 
are more closely related to the SIVrcm sequences (blue). However, SIVcpz Vpu and Env are 
more closely related to sequences from the SIVmus/gsn/mon lineages (red). 
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INNATE IMMUNITY  
 The innate immune response is the front line defense against pathogen invasion. 
Recognition and efficient control during the early stages of pathogen invasion is dictated by 
the innate immune response. This also provides the framework for the innate control of the 
adaptive immunity, a model proposed by Charles Janeway (106, 107, 164). The key concept 
is that the innate immune system uses germline-encoded pattern recognition receptors to 
mediate pathogen sensing, which instructs the adaptive immunity cells based on the 
pathogen recognition or costimulatory signals.  
 The first phase of the innate immune response is pathogen sensing. This was initially 
characterized in drosophila as the Toll receptor which is responsible for the sensing and 
signaling of the antifungal defense (137). It quickly became apparent that the mammalian 
homologs, toll-like receptors (TLR), were important for the activating the NF-kB signaling 
cascade (165, 219). In fact, the TLR family and C-type lectins have specificities for different 
microbial ligands: TLR1/TLR2 and TLR2/TLR6 recognize lipoteichoic acids of Gram-positive 
bacteria and bacterial lipoproteins; TLR3 detects double-stranded RNA (dsRNA); TLR4 
directly senses lipopolysaccharide (LPS) of Gram-negative bacteria; TLR5 recognizes 
flagellin; TLR7/8 detects single-stranded RNA (ssRNA); and TLR9 detect dsDNA (TLR9) 
(Reviewed in (106, 266)). Thus, TLRs can be organized as cell-surface TLRs (TLR1,2,4,5 and 6) 
that mostly recognize bacterial protein products, and the endosomal TLRs (TLR 3, 7, 8 and 9) 
detect microbial nucleic acids.  
 Upon engagement of pathogen-associated molecular patterns (PAMPs) with TLRs, a 
signaling pathway is initiated and is mediated by either MyD88 or TRIF. A series of 
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phosphorylation and ubiquitination leads to the activation and nuclear translocation of NF-
kB and AP1 transcription factors, triggering the expression of many cytokines, chemokines, 
chemokine receptors and costimulatory molecules.  
Cytosolic pathogen recognition receptors are composed of the retinoic acid-
inducible gene I (RIG-I)-like receptors (RLRs) and the nucleotide-binding domain and 
leucine-rich repeat–containing receptors (NLRs) (159, 205). While most TLRs and dectins are 
expressed on the specialized immune cells such as macrophages and dendritic cells, the 
cytosolic RLRs and NLRs are expressed in most cell types. This is likely due to the ‘cell-
intrinsic’ nature of the pathogen recognition that requires the cells themselves to be 
infected. The RLRs RIG-I and MDA5 primarily detect viral pathogens. Upon ligand binding 
and recruitment of the adaptor MAVS/IPS1, downstream activation of NF-kB, AP1 and IRF3 
occurs through a series of phosphorylation and ubiquitination events. IRF3 activation drives 
the transcription of interferon-β (IFNβ), leading to the production and secretion of IFNβ.  
IFN signaling is critical in establishing an ‘antiviral state’ in cells. Secreted IFNβ can 
act in an autocrine or paracrine fashion, and this happens by binding to type I IFN receptors. 
Upon engagement of IFN receptors, the JAK/STAT signaling pathway is activated through 
several kinases that culminate in the formation of ISGF3 complex – STAT1/STAT2/IRF9. The 
ISGF3 complex translocates into the nucleus and induces the transcription of numerous 
genes by binding to the IFN-stimulated response element (ISRE) within the 
promoter/enhancer region. These genes are collectively labeled as IFN-stimulated genes 
(ISGs). IRF7, itself a transcription factor that is interferon-induced, is produced. Upon 
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phosphorylation, IRF7 is thereby activated to bind virus-responsive elements (VRE) in the 
promoter of IFNα, leading to the production of IFNα. Thus, these signaling pathways lead to 
rapid amplification of IFN production and gene induction. 
There are three types of interferon: type I includes α (13 isotypes), β, δ, ε, κ, τ, and 
ω; type II IFN γ and type III IFN λ. Different sets of genes, sometimes up to several hundred 
genes, are induced by the various types of IFNs (18, 49, 52, 157). In fact, variation is also 
observed depending on the cell type used and might also partly be due to technical details 
or cutoff methodology. Nonetheless, many of these ISGs are potent antiviral effectors. 
Hence, interferon-stimulation is associated with an antiviral response or an ‘antiviral state’. 
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Figure 6 
Innate immunity signaling. Pathogen sensing triggers a signaling cascade that leads to IFNβ 
production and induction of ISGs such as Tetherin and Viperin. This figure is adapted from 
(67). 
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HOST RESTRICTION FACTORS 
There are several host restriction factors of HIV-1 and other retroviruses (also called 
antiviral effectors) that have been identified to date. The main function of host restriction 
factors is to provide protection at the cellular level against incoming viral pathogens. In 
contrast to the adaptive immune response, which involves somatic learning and memory, 
host restriction factors are germline-encoded. Many of these proteins are highly induced 
upon interferon stimulation as part of switch to an ‘antiviral state’ of the cell. However, 
their mode of action differs at the stage of infection targeted and mechanism which can be 
highly specific or autonomous in some cases. It is unlikely that the role of these restriction 
factors is solely limited to target retroviruses. Nonetheless, host restriction factors of 
retroviruses is still the most studied model system.  
 
FV1 AND FV4 
Fv1 and Fv4 were the first host restriction factors to be discovered. Friend murine 
leukemia virus (F-MLV) is a retrovirus that causes erythroleukemia in susceptible strains of 
mice. Resistance to F-MLV infection between resistant and sensitive mice strains was 
chromosomally mapped to the Fv4 locus (formerly called Akvr-1). Fv4 encodes a MLV-
related envelope protein that directly interferes with the ectopic receptor, thus preventing 
incoming virus from binding and infecting the cell. Indeed, expression of Fv4 in transgenic 
mice provided potent protection against F-MLV infection. Importantly, Fv4 is genetically 
dominant. Likewise, Fv1 also exerts a genetically dominant trait. Mice that were 
homozygous for the Fv1n allele were susceptible to N-tropic MLV strains but resistant 
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against B-tropic MLVs. Conversely, mice homozygous for the Fv1b allele could be infected by 
B-tropic MLV but were resistant to N-tropic MLV infection. The viral determinant of Fv1 
restriction specificity is the viral capsid protein at residue 110. Furthermore, Fv1 activity can 
be saturated at high amounts of virus. Surprisingly, Fv1 and Fv4 are of retroelement origin 
that arose from endogenization in the mouse lineages only. Thus, Fv1 and Fv4 are only 
found in mice and are absent from all other mammalian species. 
 
TRIM5α AND TRIMCYP 
Although humans have no ortholog of Fv1, several human cell lines restricted N-
tropic MLV (analogous to the Fv1b allele) in a manner that was dependent on viral capsid 
residue 110 and could be saturated. This restriction factor was called Ref 1 (restriction 
factor 1). On the other hand, nonhuman primates expressed a restriction factor that was 
called Lv1 (lentivirus restriction factor 1). Lv1 restricted HIV-1 and its specificity was 
determined by the viral capsid. Furthermore, Lv1 was saturable not only by paralogous 
lentiviruses but even by some distantly-related retroviruses. However, Lv1 was clearly 
species-specific in its restriction profile. Most importantly, Lv1 was a dominant protective 
trait that could be conferred to permissive cells through heterokaryon experiments. Finally, 
2004 marked the exciting discovery that Trim5α in rhesus macaques was responsible for the 
Lv1 phenotype. In fact, Trim5α was also responsible for the Ref1 activity in human cells (94, 
202).  
Trim5α is composed of an N-terminal tripartite motif (TRIM) defined by a RING, B-
Box2 and a coiled-coil domain, and a C-terminal PRY-SPRY (B30.2) domain (Reviewed in (24, 
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77, 228)). Trim5α binds and multimerizes around incoming viral capsid proteins to cause an 
accelerated uncoating of the viral core (201, 261). This results in an impaired reverse 
transcription and nuclear import (7, 260, 276). The exact mechanism of viral restriction is 
still poorly understood. The RING domain functions as an E3 ubiquitin ligase and is required 
for the antiviral activity of Trim5α, although the role of the ubiquitination is unclear. The B-
Box2 and coiled-coil domains are important for the high-order multimerization and low-
order dimerization of Trim5α – which is necessary for the restriction function. Nonetheless, 
the binding and recognition of viral capsid is clearly determined by the PRY-SPRY domain 
(150, 184, 239, 262, 309, 317). Amino acid differences within the PRY-SPRY domain are 
sufficient to account for the species-specific restriction profile of Trim5α (94, 231, 262, 309). 
In fact, a single amino acid change within the PRY-SPRY domain can cause human Trim5α to 
gain the ability of recognizing HIV-1 and thus acquire potent HIV-1 restriction capability 
(309). 
As a example of convergent evolution, owl monkeys encode a different variant 
called TRIMCyp in which the PRY-SPRY domain is replaced by Cyclophilin A (180, 232). In 
essence, the C-terminal role of capsid recognition is now determined by Cyclophilin A 
binding specificity. Surprisingly, this occurred independently at least twice in primate 
evolutionary history. In owl monkeys, the generation of TRIMCyp arose from a direct LINE-
1-mediated retrotransposition of Cyclophilin A into intron 7 of TRIM5 (180, 232). Yet, in 
macaque sub-species, the retrotransposition of Cyclophilin A within the 3’ UTR of TRIM5 in 
combination with a novel splice acceptor mutation leads to TRIMCyp expression (34, 139, 
289, 299). Analogous to the Trim5α PRY-SPRY domain, CypA determines the species 
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specificity of these fusion TRIMCyp proteins. Changes at two residues in the CypA domain 
allow rhesus macaque TRIMCyp to restrict HIV-1 to a similar potency of owl monkey 
TRIMCyp (289). Thus, the spectrum of viral recognition by Trim5α and TRIMCyp is dictated 
and refined by changes in the C-terminal domain (be it PRY-SPRY or CypA).   
Trim5α also functions in innate immune signaling. Trim5α stimulates AP1 and NFkb 
signaling by activating the TAK1 kinase complex (203, 270). The RING and B-BOX2 domains 
mediate the synthesis of K63-linked ubiquitin chains synthesis by E2 UBC13–UEV1A, which 
leads to TAK1 kinase complex activation. Furthermore, NFkB signaling by TRIM5α appears to 
be an evolutionary conserved property as the mouse homolog is also capable of performing 
this function (249). Signaling can be triggered by LPS treatment or retroviral capsid 
recognition. The strongest evidence that viral recognition correlates with signaling function 
comes from Human Trim5α which recognizes N-MLV at a higher avidity than B-MLV. NFkB- 
and MAPK-dependent genes were induced at a higher level by Trim5α upon N-MLV 
infection, compared to the unrestricted B-MLV infection (203). Since Trim5α recognizes the 
interface of the inter-hexamer capsid lattice (69, 317), it has been proposed that Trim5α 
could also be a pathogen recognition receptor that detects viral (capsid) proteins (203). 
 
APOBEC3G 
APOBEC3G (also known as CEM15) was identified because of its antagonism by HIV-
1 Vif (247). APOBEC3G is a host cellular cytidine deaminase enzyme that causes G to A 
hypermutations (93). In the absence of HIV-1 Vif, APOBEC3G is packaged into nascent virion 
particles and restricts the virus upon its next round of infection (247). APOBEC3G restriction 
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leads to a decrease in virus infectivity (247). APOBEC3G can induce hypermutations on the 
retroviral cDNA during reverse transcription that leads to an error catastrophe (92, 154, 
316). Indeed, APOBEC3G also causes hypermutations on hepatitis B virus (182). However, 
there is also evidence that APOBEC3G can also exert deaminase-independent restriction 
(25, 177). This could be caused by a simple physical block to RT, preventing reverse 
transcription elongation (26). In support of this, catalytically inactive mutants of APOBEC3G 
are capable of restricting HIV-1 and HTLV-1 (25, 227).  
APOBEC3G restriction of HIV-1 is antagonized by Vif (Reviewed in (81)). In the target 
cell, Vif directly binds to APOBEC3G and recruits the cellular E3 ubiquitin complex of Cullin-
5/elonginB/elonginC/Rbx1. This leads to the polyubiquitination of APOBEC3G, targeting it 
for the degradation by the 26S proteasome. However, there is species-specificity between 
APOBEC3G:Vif interactions. For example, human APOBEC3G can be targeted by HIV-1 Vif 
but not by SIVagm Vif; reciprocally, AGM APOBEC3G can be targeted by SIVagm Vif but not 
by HIV-1 Vif (158). A single amino acid change on APOBEC3G can toggle the species-specific 
switch of Vif sensitivity (28, 236). This means that host evasion from Vif antagonism 
requires a single adaptive change and consequently imposes a species-specific barrier. Thus, 
HIV-1 Vif acts as an adaptor protein that targets the host cellular machinery to remove 
APOBEC3G. As a result, APOBEC3G is not packaged into virion particles and virus is 
infectious in the next round of infection.  
 
TETHERIN 
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Tetherin is a host restriction factor capable of inhibiting the release of a broad range 
of viruses from the plasma membrane of infected cells (Figure 7). Tetherin, also called BST-
2/CD317/HM1.24, was first identified as a marker for cells involved in B-cell differentiation 
and was subsequently found to be overexpressed on multiple myeloma cells (84, 104, 190). 
Upon the discovery of its antiviral activity, the name “tetherin” was coined to describe the 
tethering phenotype that BST-2/CD317/HM1.24 causes during virion budding from the 
plasma membrane (176). In addition to inhibiting the release of HIV particles, tetherin also 
inhibits the release of filoviruses (Ebola and Marburg viruses), arenaviruses (Lassa virus), 
and other retroviruses including gammaretroviruses (murine leukemia virus) and 
spumaretroviruses (foamy virus) (90, 114, 176, 223). HeLa, Jurkat, and CEM cells 
constitutively express high levels of tetherin; however, in cells that express low levels of 
tetherin, such as 293T or HT1080 cells, tetherin can be upregulated by type I IFN (176). This 
results in permissive 293T cells becoming nonpermissive to infection by HIV-1 and Ebola 
virus (175). 
Tetherin restricts virus release by physical linkage between nascent virion and the 
cell plasma membrane (200). The tetramer structure is formed by two coiled coil-mediated 
parallel dimers of tetherin. Structural studies support an anti-parallel four-helix bundle 
configuration that is stabilized by three disulfide bridges, and allows for pronounced 
flexibility (237, 264, 306). In fact, restriction activity by an artificial “tetherin” demonstrates 
that the intrinsic protein topology determines its function rather than the coding amino acid 
(200).  
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Retroviruses have developed at least three strategies to counteract tetherin (62, 
135) (Figure 7). First, the Vpu protein from HIV-1 abrogates the retention phenotype in cells 
that express tetherin and has been observed to be colocalized with tetherin (176, 282). Vpu 
displays species specificity and counteracts human tetherin by targeting it for degradation 
(78, 163). Notably, Vpu is encoded by a unique lineage of primate lentiviruses, including 
HIV-1, SIVcpz from chimpanzees, and SIVmus, SIVgsn, and SIVmon from mustached 
monkeys (Cercopithecus cephus), greater spot-nosed monkeys (Cercopithecus nictitans), 
and Mona monkeys (Cercopithecus mona), respectively (46), but is not encoded by the 
other lineages of primate lentiviruses. HIV-1 Vpu directly binds to tetherin via their 
transmembrane domains (105, 125, 163, 183, 220, 251, 288, 311). Vpu recruits the β-TrCP 
subunit of a Skp1-Cullin1-F-box ubiquitin ligase complex leading to the ubiquitination of 
tetherin at the lysine and serine/threonine residues in the cytoplasmic tail domain (80, 274). 
This leads to the lysosomal degradation that is mediated by HRS, a component of the 
ESCRT-0 complex (108). It should be noted that tetherin overexpression studies can also 
lead to an artificatual proteasomal degradation phenotype due to excessive protein 
accumulation (8).  
Second, lentiviruses from the SIVsmm/SIVmac lineage have evolved the ability to 
counteract tetherin through the Nef protein (109, 315). The Nef proteins from SIVsmm and 
SIVmac display species specificity in their ability to counteract their hosts, sooty mangabey 
and rhesus macaque, respectively, and closely related tetherins. Nef binds to the 
cytoplasmic tail domain of tetherin via its C-terminal domain and recruits the AP-2 clathrin 
adaptor complex (314). Thus, Nef counteraction leads to internalization of cell-surface 
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tetherin and intracellular retention.  This raises an intriguing question about viruses that 
encode both Vpu and Nef: what determines their choice of tetherin antagonist? In Chapter 
Four, I will resolve this by tracing the tetherin antagonist viral evolution from HIV-1 back to 
when the switch occurred and reconstruct the evolutionary events that shaped its 
trajectory. 
Third, the HIV-2 envelope enhances virion particle release and is able to 
complement HIV-1 that lacks Vpu (31). HIV-2 Env antagonism of tetherin promotes the cell 
surface downregulation of tetherin, similar to Vpu. However, Env does not result in protein 
degradation, but leads to the intracellular sequestration of tetherin (95, 134). While the 
mechanistic details of antagonism are unclear, the gp41 cytoplasmic tail of Env might be 
involved (134). More convincingly, a revertant SIVmac that lacked Nef (the native tetherin 
antagonist) was isolated from infected rhesus macaques and found to have evolved Env to 
antagonize tetherin (242). Another case was identified in a strain of SIVagm that was 
capable of antagonizing tetherin through Env (89).  
Tetherin can also be antagonized by other viruses besides retroviruses. Kaposi’s 
sarcoma-associated herpesvirus (KSHV) is able to counteract Tetherin with its K5 protein 
(156, 193). KSHV K5 promotes the downregulation of cell surface tetherin through the 
ESCRT-mediated pathway. Tetherin is delivered to the late endosomes and undergoes 
endosomal degradation (193). Ebola virus, a member of the family Filoviridae, has a means 
to counteract tetherin through its full-length glycoprotein (GP) (119). However, the 
mechanism of tetherin antagonism by Ebola virus GP is unique in that it could antagonize 
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multiple primate species’ tetherin and can even antagonize the “artificial” tetherin (132, 
147). Importantly, this mechanism does not require the downregulation of cell surface 
tetherin nor does it result in decreased tetherin protein expression levels. Given the broad 
spectrum activity of tetherin, it is likely that other virus might evolve novel antagonism 
strategies. There is strong evidence that influenza might encode an antagonist as it has 
been shown that while tetherin can restrict influenza VLPs, tetherin restriction is 
circumvented in experiments using infectious influenza virus (296, 310). This might also be 
the case for vaccinia virus, a member of the poxvirus family. Vaccinia virus release was 
found to be unaffected by tetherin expression (252). While cell surface and total 
intracellular levels of tetherin were found to be unchanged (252), this phenotype would be 
expected if the antagonist mechanism is similar to that of Ebola and Marburg virus GP (132, 
147). In conclusion, the independent acquisitions of a viral tetherin antagonist by multiple 
viruses emphasize the role of tetherin and the strong selective pressure imposed by its 
potent restriction. 
 
 
 
33 
 
 
Figure 7  
Tetherin restricts virus release. Tetherin forms anti-parrallel dimers that tethers nascent 
virions to the plasma membrane, and subsequently internalized by endocytosis.  
This figure is from (91) with permission (License number 2818340284014). 
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VIPERIN 
A host protein with broad antiviral activity called Viperin (Virus inhibitory protein, 
endoplasmic reticulum-associated, interferon-inducible, also known as RSAD2) has been 
shown to modulate lipid rafts (43, 110, 293). Viperin inhibits the release of a wide range of 
viruses in cell culture including Influenza virus (293), Hepatitis C virus (96, 110), and 
Japanese Encephalitis virus (39) (Figure 8). Moreover, Viperin knockout mice show that this 
protein plays a role in controlling West Nile Virus pathogenesis in vivo (265). In the case of 
CMV, Viperin has been reported not only to inhibit expression CMV late viral gene products 
(43) but also to enhance CMV infectivity by remodeling cellular actin cytoskeleton (241).  
Lipid rafts are sphingolipid- and cholesterol-enriched microdomains on the plasma 
membrane that have been implicated in a number of processes including membrane 
signaling, polarization, and immunological synapse function (186, 250). Lipid rafts also play 
an important role in the entry and assembly stages of viral replication (162, 186). Indeed, 
the host sterol biosynthesis pathway is downregulated in response to viral infections as part 
of the innate immune response via type I interferon signaling (27). This suggests that the 
disruption of virus budding through host-encoded lipid rafts may represent a host defense 
against viruses.  
HIV is thought to assemble and bud from lipid rafts and depletion of cellular 
cholesterol leads to a reduction in HIV production (185, 187, 291). In addition to its other 
activities, Nef, an accessory gene encoded by HIV, has been shown to lead to an increased 
synthesis of cholesterol (281, 318), which may be related to the ability of Nef to increase 
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virus infectivity (318). Thus, cellular cholesterol and lipid raft integrity is important for HIV 
replication. 
 
 
Figure 8  
Schematic representation of the antiviral action of Viperin against influenza and HCV.  
Viperin prevents HCV assembly and/or budding by binding to lipid droplets. Influenza 
restriction is mediated by viperin binding to farnesyl diphosphate synthase, and thereby 
disrupts lipid rafts to prevent virus release.  
This figure is adapted from (64) 
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SAMHD1 
The accessory protein Vpx was previously shown to be critical for the ability of 
primate lentiviruses to efficiently infect monocytes, dendritic cells, and mature 
macrophages (14, 244). Recently, the target of Vpx has been identified as the restriction 
factor SAMHD1 (101, 133), where the binding of Vpx to SAMHD1 leads to the proteasomal 
degradation of SAMHD1 (Figure 9). Humans with missense mutations in SAMHD1 are 
associated with Aicardi Goutieres Syndrome (AGS), an encephalitis syndrome which mimics 
a state of viral infection leading to interferon production and an autoimmune syndrome 
(216, 256).  
SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Dimeric SAMHD1 
binds to dGTP, which acts as both substrate and activator, and hydrolyses deoxynucleotides 
using the HD domain (82, 211). As a result, in myeloid cells where SAMHD1 is highly 
expressed (302), cellular deoxynucleotide pools are suppressed and retrovirus reverse 
transcription would be hampered due to the limited deoxynucleotide substrate availability. 
Therefore, in AGS patients with defective SAMHD1 mutations, the aberrant availability of 
deoxynucleotide pools fuels endogenous reverse transcription activity that triggers an 
autoimmune response, resulting in the AGS clinical phenotype (Figure 10). Likewise, Vpx 
antagonism of SAMHD1 relieves the suppression of deoxynucleotide to allow for viral 
reverse transcription. Thus, Vpx appears to degrade a host restriction factor that allows 
primate lentiviruses to infect key immunomodulatory cells types.  
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Despite this important function, only two of the eight major lineages of primate 
lentiviruses (reviewed in (196)) encode Vpx:  HIV-2/ SIVsm-related viruses and a lineage 
represented by SIV from red-capped mangabeys (SIVrcm).  On the other hand, all extant 
primate lentivirus lineages encode a paralogous gene called Vpr that causes cell cycle arrest 
(246, 277, 278). Both Vpr and Vpx are incorporated in the core of budding viruses (312, 
313), and both bind to the Cul4 complex through interactions with DDB1 and DCAF1 
(reviewed in (14)). Despite its limited representation in primate lentiviruses, Vpx appears to 
be more critical than Vpr for replication of SIV in monkeys (74, 98). The important role 
played by Vpx has led to a conundrum as to why this protein is missing in lentiviruses like 
HIV-1. Therefore, is SAMHD1 antagonism an ancestral trait that was lost in some lineages or 
a newly acquired function? In Chapter Six, I will answer this by combining an extensive 
functional characterization of SAMHD1 and Vpr/Vpx with a detailed phylogenetic 
framework of primate lentivirus evolution.   
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Figure 9  
On infecting dendritic cells, retroviruses such as HIV-2 and sooty mangabey SIV (SIVsm) 
deliver their Vpx protein into the cell cytoplasm, where it could bind to SAMHD1. Vpx also 
recruits the CUL4–DDB1–DCAF1 protein complex, leading to the degradation of SAMHD1. 
The virus can now replicate unhindered. b, By contrast, when HIV-1, or other viruses that do 
not express Vpx, infect dendritic cells, SAMHD1 inhibits their replication, perhaps by 
recognizing viral nucleic acids and mediating their degradation. 
This figure is from (143). 
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Figure 10  
Dimeric SAMHD1 binds dGTP to activate the enzymatic cleavage activity of dNTPs 
Suppression of dNTPs pools protect terminally differentiated cells like myeloids cells from 
endogenous RT activity (a). Abberant endogenous RT results from the defective SAMHD1 
activity, leading to autoimmune AGS symptoms (b). HIV-1 restrcition results from SAMHD1-
mediated suppression of dNTP pools (c), and can be alleviated by Vpx counteraction (d). 
Figure is from (82) with permission (License number 2798951082907). 
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EVOLUTION OF HOST RESTRICTION FACTORS 
 The “Red Queen” hypothesis was proposed by Leigh Van Valen to describe an 
evolutionary system where continuous adaptation is required to maintain relative fitness 
levels (286). The underlying argument is that since every improvement in a species leads to 
a selective advantage in that species, genetic variation will normally continuously result in 
an increased fitness. However, in a system that involves two species sharing the same 
resources, improvement in one species implies a competitive advantage over the other 
species. Since resources are limited, this leads to a fitness advantage of one species that 
comes at the expense of the second species. Therefore, the only way for the second species 
to maintain its relative fitness while involved in a competition is to adapt in turn.  
Virus-host interactions are a prime example of where this “Red Queen” competition 
plays out. Host antiviral genes exert a potent selective pressure on virus fitness, and viruses 
encode antagonists in turn to counteract the effects of host restriction factors. Mutations 
that allow the host restriction factor to evade antagonism provides an increased fitness to 
the host. This imposes a selective pressure on the virus to evolve its antagonist to re-
establish the interaction (Figure 11). As a result, the selective pressure is shifted back on the 
host. Thus, this creates an escalating “arms race” dynamic.  
 The evolutionary “arms race” between host antiviral genes and the virally encoded 
antagonists of these antiviral genes can be inferred by observing adaptive evolution (also 
called positive selection) signatures in the antiviral genes that are indicative of repeated 
episodes of Darwinian selection due to ancient viral infections (59). In fact, the exact amino 
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acids under positive selection can describe the sites of host-virus interactions (231). When 
there are multiple viral antagonists, such detailed evolutionary analyses focused on positive 
selection can also reveal which type of viral antagonist exerted the greatest selective 
pressure during the course of primate evolution. These evolutionary signatures can also be 
used to infer the domains involved in the host-virus interaction. For instance, the Zinc 
Finger Antiviral Protein (ZAP) was shown to inhibit retroviruses, alphaviruses and filoviruses 
by specifically recognizing and degrading viral messenger RNAs (23, 72, 174). However, the 
positive selection on ZAP acts on a domain separate from the RNA-binding zinc finger 
domain, suggesting that rapid alterations of viral mRNA binding did not affect ZAP 
evolution, and some other (antagonistic) interaction did (121). 
 The nature of the antagonistic interactions determine the selective pressures, and 
hence, the distribution of the signals of positive selection. Some host restriction factors use 
a non-discriminating mechanism of action. For instance, the APOBEC3 cytidine deaminases 
or tetherin can restrict a wide array of viruses, an activity that is not dependent on the 
recognition of specific viral components (discussed above). Because of its non-
discriminating mechanism of restriction, the expectation is for multiple lineages of viruses 
to employ different modes of antagonism against these host restriction factors. Indeed, 
several groups have identified more than five viral strategies to antagonize tetherin. These 
antagonist-antiviral interactions are also akin to ‘arms-races’ and also result in positive 
selection of the antiviral genes. In most instances, a single difference at the amino acid level 
is sufficient to disrupt the binding interaction and lead to evasion. However, these 
interactions often result in a more diffuse signature of positive selection, as the pressure to 
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avoid many antagonists has shaped the evolution of antiviral factors. For instance, in 
APOBEC3G which can be susceptibile to Vif antagonism in some species (28, 236), avoidance 
of Vif-interactions cannot explain the majority of positively selected residues in Apobec3 
proteins (230). Hence, under antagonism evasion conditions, the sites of positive selection 
will be seen at the residues directly targeted by the antagonist but will vary depending on 
the antagonist specificity. 
In contrast, when the mechanism of the host restriction factor is dependent on 
discriminatory recognition for viral targets, the selective pressures are for adaptations that 
acquire new recognition specificities. For instances, restriction by TRIM5 and Fv1 requires 
the specific recognition of viral components by the restriction factors (discussed above). In 
such instances, ‘arms-races’ are played out by the evolution of viral variants to avoid 
restriction, and restriction factors to restore restriction (166). Thus, at the molecular level, 
specific domains or clusters of residues of the host restriction factors recurrently evolve 
under positive selection. Thus, the selective pressures exerted by antagonist evasion or viral 
recognition lead to different consequences for the host gene. 
Thus, a detailed look at how positive selection has affected an antiviral gene can 
thus provide valuable information about the history of antagonism, and even possibly the 
domains involved in the host-virus interaction. Such insights can complement the original 
findings of antiviral activity and trace the evolutionary history of the “arms race”.  
In this dissertation, I will present a three-dimensional perspective of the 
evolutionary host-virus arms race. In the following chapters, I will reconstruct two specific 
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examples that convincingly show how host genetics evolve barriers to cross-species 
transmission, and how viruses ultimately counter-evolve to their new hosts (Chapter Four 
and Six). I will also present conclusive evidence that the host immune environment directly 
impacts the role of viral factors (Chapter Three). Finally, I will demonstrate how to exploit 
the evolutionary signatures of host restriction factors to identify and characterize novel 
candidates (Chapter Five). My studies have helped define the rules of host-virus arms races. 
Based on my findings, we contend that the host evolutionary framework is a fundamental 
pillar of antiviral restriction.  
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Figure 11  
Genetic conflict between virus and host leads to an escalating “arms race”. Host antiviral 
genes (blue) evasion from viral antagonists (red) leads to rapid adaptive evolution of hosts 
genes.  
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CHAPTER TWO 
MATERIALS AND METHODS 
CELLS 
293T, COS-7, and TZM-bl cells were maintained in a solution containing Dulbecco’s 
modified Eagle’s medium, 8% bovine growth serum, and 1% penicillin-streptomycin in a 5% 
CO2 atmosphere at 37°C. TZM-bl cells were obtained from the AIDS Research and Reference 
Reagent Program, Division of AIDS, NIAID, NIH. Chlorocebus sabaeus fibroblasts were 
obtained from the Coriell Institute and were maintained in a solution containing Dulbecco’s 
modified Eagle’s medium, 10% fetal bovine serum, and 1% penicillin-streptomycin. SupT1 
and U937 cells were maintained in a solution containing RPMI 1640 medium, 10% fetal 
bovine serum, and 1% penicillin-streptomycin.  
 
PLASMIDS 
The SIVagm molecular clones pSAB-1 (SIVagmSab) and pSIVagmTan-1 (SIVagmTan) 
were obtained from the AIDS Research and Reference Reagent Program, Division of AIDS, 
NIAID, NIH. The SIVagmTan Env– Nef– provirus was a gift from Ned Landau (158). The 
HIV1VpuFS construct, containing a frameshift mutation in Vpu, is based on a molecular 
clone of HIV-1 described previously (87). The HIV1VpuFSLuc2 double mutant reporter clone 
was constructed by replacing the Nef gene of HIV1VpuFS with the Nef gene containing an 
insertion of the modified firefly luciferase, as described previously (304). Codon-optimized 
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HIV-1 Vpu was a gift from Stephen Bour (178), and codonoptimized (Genscript) SIVmus Vpu 
was constructed from a calculated ancestral sequence constructed from four SIVmus Vpu 
sequences reported previously (3). Both Vpu constructs were inserted into a pCDNA3.1 
expression vector as HindIII and NotI fragments. The empty pCDNA3.1 vector was used as a 
negative control. The Nef proteins from SIVagmTan and SIVagmSab were PCR amplified 
from pSIVagmTan-1 and pSAB-1, respectively, flanked by HindIII and XhoI restriction sites, 
and ligated into a pCDNA3.1 expression vector. Human, Cercopithecus cephus, AGM, and 
chimpanzee tetherins were cloned from human cDNA, C. cephus genomic DNA (Coriell Cell 
Repository), cDNA from CV-1 cells, and chimpanzee cDNA, respectively. Tetherin was 
amplified by PCR, resulting in fragments with NgoMIV and NotI sites. A hemagglutinin (HA) 
epitope tag was fused to the N terminus of tetherin and inserted into retroviral expression 
vector pLPCX. To construct untagged AGM tetherin, the HA epitope tag was removed by 
restriction digestion, overhangs were filled in with DNA polymerase I and large Klenow 
fragment (Invitrogen), and blunt-end ligation wasperformed with T4 DNA ligase (Roche). 
The empty pLPCX vector was used as a negative control. 
Human, chimpanzee, gorilla, C. cephus, and Francois’ leaf monkey Tetherins were 
cloned from the cDNAs of the respective species and were ligated into a pLPCX lentiviral 
expression vector as untagged constructs, as described above. Codon-optimized HIV-1 Q23-
17 Vpu, SIVcpzUS Vpu, SIVcpzUS Nef, SIVcpzTan3.1 Vpu, SIVgor Vpu, and SIVgor Nef were 
synthesized (GenScript). HIV-1 Lai Nef was cloned from the HIV-1 Lai proviral plasmid (195); 
HIV-1 Q23-17 Nef was cloned from the HIV-1 Q23-17 provirus, a gift from Julie Overbaugh 
(210); and SIVcpzTan3.1 Nef was cloned from the SIVcpzTan3.1 proviral plasmid, obtained 
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from the NIH AIDS Research and Reference Reagent Program (268). The Vpu and Nef 
constructs were ligated into a pCDNA3.1 expression vector. 
Chimeras between HIV-1 Q23-17 Vpu and SIVcpzUS Vpu were constructed with a 
QuikChange II XL site-directed mutagenesis kit (Stratagene) or by overlapping PCR 
approaches. For expression studies, a hemagglutinin (HA) epitope tag was fused to the C 
termini of chimeric Vpu constructs. The ancestral human Tetherin was constructed by 
overlapping PCR to insert 5 amino acids (aa) in the cytoplasmic tail domain (residues 14 to 
18) and to substitute E for K at aa 19.  
Human Viperin was cloned from human cDNA derived from 293T cells, and inserted 
into a retroviral expression vector pLPCX as an untagged construct. The five primate Viperin 
orthologs were similarly cloned from cDNA into the pLPCX retroviral expression vector as 
untagged constructs. HIV-1 Lai Nef and HIV-1 Q23-17 Nef was cloned into an expression 
vector driven by the HIV-1 LTR as described previously (142). Codon-optimized HIV-1 Lai 
Vpu was a gift from Stephan Bour (178). HIVLai, HIVLaiΔNef and HIVLaiΔVpuΔNef, 
SIVagmTANΔEnvΔNef were described previously (140, 142). HIVNL4-3ΔNef was obtained 
from the NIH Aids Research and Reference Reagent Program, 11100. HIVSF62ΔNef was 
generated by fill-on of the XhoI site (nt 8576) resulting in a 2bp frameshift mutation in the 
Nef open reading frame of the full length HIV-1SF162 provirus (41). HIV-1Q23-17ΔNef was 
constructed by introducing a luciferase gene in place of Nef into the full length HIV-1 Q23-
17 provirus (210). SIVcpzΔNef was generated by introducing a luciferase gene in place of 
Nef into the full length SIVcpzTAN3.1 provirus (268) (NIH Aids Research and Reference 
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Reagent Program, 11100) by overlapping PCR between the NdeI and NheI region and 
sequence verified. HIV-2Rod9ΔEnvΔNef was a gift from Masahiro Yamashita and 
SIVmac239ΔEnvΔNef was a gift from David Evans (215). pGIPZ vector-based control shRNA 
or shRNA targeting Viperin mRNA (hairpin construct: 
TGCTGTTGACAGTGAGCGCGATGAAAGACTCCTACCTTATTAGTGAAGCCACAGATGTAATAAGGT
AGGAGTCTTTCATCTTGCCTACTGCCTCGGA) were purchased from FHCRC RNAi core facility.  
Primate SAMHD1 was cloned from cDNA from the respective species and ligated 
into pLPCX construct, with a hemagglutinin (HA) epitope tag fused to the C-termini. Vpr and 
Vpx constructs ligated into a pCDNA3.1 expression vector, with a 3xFLAG epitope tag fused 
to the N-termini. The following genes were cloned from provirus plasmids: HIVLai Vpr, 
SIVagmGri677 Vpr, SIVagmVer 9648 Vpr, HIV-2 Rod9 Vpr and Vpx, HIV-2 7312a Vpr and Vpx 
(as previously described (257)); HIV-1 Q23-17 Vpr (provirus was a gift from Julie Overbaugh 
(210)); SIVmac239 Vpr and Vpx (provirus plasmid, obtained from NIH AIDS Research and 
Reference Reagent Program (215)); SIVcpzTan2.69 Vpr and SIVcpzTan3.1 Vpr (proviral 
plasmid, obtained from the NIH AIDS Research and Reference Reagent Program (268)). The 
following genes were codon-optimized and synthesized (Genscript): SIVolc 97CI12 Vpr 
(FM165200), SIVmnd1 GB1 Vpr (M27470), SIVrcm NG411 Vpr and Vpx (AF349680), SIVmnd2 
5440 Vpr and Vpx (AY159322), SIVdeb CM5 Vpr (AY523866) and SIVmus1 CM1239 Vpr 
(EF070330).  
 
TRANSFECTION AND VIRUS PSEUDOTYPING 
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293T and COS-7 cells were seeded at 1.67 x 105 and 8.33 x 104 cells/ml, respectively. 
DNA was transfected with Fugene6 reagent (Mirius) according to the manufacturer’s 
recommendations. To measure the tetherin restriction of HIV1VpuFS, 293T cells were 
transfected with HIV1VpuFS (100 ng), human tetherin (200 ng), cephus monkey tetherin 
(400 ng), AGM tetherin (400 ng), HIV-1 Vpu (125 ng), or SIVmus Vpu (100 ng). Transfections 
involving SIVagm provirus were performed with SIVagmTan (100 ng), SIVagmTan Env– Nef– 
(100 ng) with vesicular stomatitis virus G protein (VSV-G) (50 ng), and SIVagmSab (100 ng). 
AGM titration was performed with 0, 3.12, 6.25, 12.5, 25, 50, and 100 ng of native 
(untagged) AGM tetherin, VSV-G (50 ng), and SIVagmTan (100 ng) or SIVagmTan Env– Nef– 
(100 ng). For experiments involving Nef, 293T cells were transfected with HIV1VpuFSLuc2 
(100 ng), human tetherin (100 ng), chimpanzee tetherin (100 ng), AGM tetherin (100 ng), 
and SIVmus Vpu (100 ng), SIVagmTan Nef (250 ng), or SIVagmSab Nef (250 ng). In all 
experiments, the total amount of DNA was maintained constant by adding the respective 
amounts of empty vectors. Forty-eight hours after transfection, supernatant containing 
virus was filtered through a 0.22-μm filter and analyzed by a Western blot or infectivity 
assay. Cells were washed with Dulbecco’s phosphate-buffered saline and removed with 
0.05% trypsin for Western blot analysis. VSV-G-pseudotyped viruses for electron microscopy 
and Western blot experiments were prepared by the cotransfection of a VSV-G expression 
vector (pLVSV- G) (50 ng) with SIVagmTan Env– Nef– (100 ng) or SIVagmTan (100 ng) in 293T 
cells, as described previously (304). Forty-eight hours after transfection, the supernatant 
containing pseudotyped viruses was pooled and filtered through a 0.22-μm filter. Virus was 
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concentrated by ultracentrifugation, and titers were determined by infecting reporter TZM-
bl cells with serial dilutions of virus stock as described previously (290). 
 
INFECTIVITY ASSAY 
An infectivity assay was performed with TZM-bl cells as described previously (21). 
TZM-bl cells were seeded at 2 x 105 cells/ml in 96-well plates. Serial dilutions of virus 
supernatant were used to infect TZM-bl cells by spinoculation at 1,200 relative centrifugal 
force (RCF) for 2 h in the presence of 20 μg/ml DEAE-dextran. Forty-eight hours 
postinfection, 200 _g/ml of 4-methylumbelliferyl-β-D-galactopyranoside was added to cells, 
and the resulting fluorescence (lacZ activity) was measured using a spectrophotometer at 
30-s intervals at 360 nm/460 nm. The relative infectivity was determined by the linear rate 
of increasing lacZ activity over time. An HIV1VpuFSLuc2 infectivity assay was performed 
with SupT1 cells at 2.5 x 105 cells/ml in 96-well plates. Serial dilutions of virus supernatants 
were used to infect SupT1 cells by spinoculation at 1,200 RCF for 1 h in the presence of 20 
μg/ml DEAE-dextran. Forty-eight hours postinfection, the level of luciferase expression was 
determined by use of the Bright-Glo luciferase assay system (Promega) according to the 
manufacturer’s instructions. 
For the second tetherin study (Chapter Four), 293T cells were cotransfected with 
200 ng of an HIV-1 reporter provirus (HIV1VpuFSLuc2), 25 ng of a Vpu or Nef construct, and 
native Tetherin as indicated in the figures. The total amount of DNA in all transfections was 
maintained constant with appropriate empty vectors. The HIV-1 double mutant reporter 
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virus (HIV1VpuFSLuc2) expresses a frameshift mutation in Vpu and a luciferase gene 
inserted into the Nef open reading frame (24). Forty-eight hours after transfection, an 
infectivity assay was performed with SupT1 cells at 2.5 x 105/ml in 96-well plates as 
described above. 
For the Viperin study (Chapter Five), 293T cells were seeded at 1.67 x 105 cells/ml in 
12-well plates, and DNA was transfected with TransIT LT-1 (Mirius) according to the 
manufacturer's recommendations. The total amount of DNA in all transfections was 
maintained constant with appropriate empty vectors. Forty-eight hours after transfection, 
supernatant was collected, filtered through a 0.2μM filter and serially diluted for the 
following infectivity assay. SupT1 cells at 2.5 x 105 cells/ml in 96-well plates as described 
previously (142), or TZM.bl cells at 1.0 x 105 cells/ml in 96-well plate as described above. 
The β-Galactosidase activity was detected using the Galacto-Star system (Applied 
Biosystems) according to the manufacturer's recommendations. 
 
SAMHD1 TRANSFECTION 
293T cells were transfected with 100 ng of SAMHD1 (in LPCX expression vector, C-
terminal HA epitope tag) with or without 100 ng of Vpr/Vpx constructs (in pCDNA3.1 
expression vector, N-terminal 3xFLAG epitope tag) using TransIT-LT1 (Mirus Bio). The 
amount of codon optimized Vpr/Vpx was reduced to normalize for similar levels of protein 
expression. The total amount of DNA in all transfections was maintained constant with 
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appropriate empty vectors. Forty-eight hours post-transfection, cells were harvested for 
western blot analysis. 
 
WESTERN BLOTTING 
Forty-eight hours after transfection or infection, cells were analyzed by Western 
blotting as described previously (38), with the following modifications. Lysis was performed 
with NTE medium (10 mM Tris [pH 8.0], 1 mM EDTA, 50 mM NaCl) in the presence of 
protease inhibitor cocktail (Roche) for 5 min, followed by NP40-doc (1%NP-40, 0.2% sodium 
deoxycholate, 0.12 M NaCl, 20 mM Tris [pH 8.0]) for 10 min. Proteins were separated on a 4 
to 12% NuPAGE Novex Bis-Tris precast gel (Invitrogen). The membrane was probed with the 
following primary antibodies: HA-specific antibody (HA.11 mouse immunoglobulin G; 
Babco) at a 1:1,000 dilution and anti-actin rabbit antibody (Sigma-Aldrich) at a 1:500 
dilution. Primary antibodies were detected with horseradish peroxidase-conjugated goat 
anti-mouse or anti-rabbit antibodies, respectively. SIVagm was detected with sera from 
rhesus macaques infected with SIVagmsab92018 (Cristian Apetrei, Tulane National Primate 
Research Center) and probed with horseradish peroxidase-conjugated goat anti-monkey 
immunoglobulin G secondary antibody (Cappel). 
For the second tetherin study (Chapter Four), forty-eight hours posttransfection, 
cells were analyzed by Western blotting as described previously above. An HA-specific 
antibody (HA.11 mouse immunoglobulin G; Babco) at a 1:1,000 dilution and a rabbit anti-
actin antibody (Sigma-Aldrich) at a 1:2,000 dilution were used. The primary antibodies were 
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detected with a horseradish peroxidase-conjugated goat anti-mouse or anti-rabbit 
antibody, respectively. 
In the Viperin study (Chapter Five), western blot analysis was performed with the 
following antibodies: HA-specific antibody (Babco), anti-Viperin (Enzo Life Sciences), anti-
caveolin-1 (Santa Cruz Biotechnologies), anti-transferrin receptor (Abcam), anti-actin 
(Sigma-Aldrich), anti-tubulin (Sigma-Aldrich), HIV-1 p24 antibody (NIH Aids Research and 
Reference Reagent Program, 183-H12-5C) (42), SIVmac p27 antibody (NIH Aids Research 
and Reference Reagent Program, 55-2F12) (97), and HIV-1 Nef antiserum (Aidsreagent, 
2121) (179). Primary antibodies were detected with a corresponding horseradish 
peroxidase-conjugated secondary antibody.  
For the SAMHD1 study (Chapter Six), western blot analysis was performed with the 
following antibodies: HA-specific antibody (Babco), anti-FLAG M2 antibody (Sigma-Aldrich), 
anti-actin (Sigma-Aldrich). Primary antibodies were detected with a corresponding 
horseradish peroxidase-conjugated secondary antibody.  
 
INTERFERON STUDIES 
Recombinant human IFN-α2A and IFN-β1b were obtained from PBL Biomedical 
Laboratories (catalog numbers 11100-1 and 11420-1). Cells were exposed to 0, 100, or 
1,000 units/ml IFN for 24 or 48 h and analyzed for tetherin RNA expression by 
semiquantitative reverse transcription-PCR (RTPCR) or fixed for thin-section electron 
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microscopy, respectively. For the analysis of endogenous tetherin effects, COS-7 cells were 
infected with VSV-Gpseudotyped SIVagmTan or VSV-G-pseudotyped SIVagmTan Env– Nef– 
by spinoculation at 1,200 RCF for 2 h in the presence of 20 μg/ml DEAE-dextran. IFN-β1b 
was added 6 h later, followed by an additional 42 h of incubation before fixing for thin-
section electron microscopy or analysis by Western blotting as described above. 
 
SEMIQUANTITATIVE RT-PCR 
Cells were removed by use of 0.05% trypsin- EDTA, and RNA was extracted by use of 
an RNeasy minikit (Invitrogen) according to the manufacturer’s protocol. Human tetherin, 
AGM tetherin, and β-actin were reverse transcribed with a OneStep RT-PCR kit (Qiagen) for 
30 min at 50°C, followed by inactivation at 95°C for 15 min. Four microliters of cDNA was 
amplified by PCR with Taq DNA polymerase (Roche), and amplified products were separated 
on a 1.25% agarose gel. AGM and human β-actin were amplified with the following set of 
primers: TGACATTAAGGAGAAGCTGTGCTA and ACTCGTCATACTCCTGCTTGCT. AGM tetherin 
spanning exon 2 to exon 4 was amplified with the following set of primers: 
CAAGGACGAAAGAAAGTGGAG and AAGCCCAGCAGCAGAATCAG. Human tetherin spanning 
exon 1 to exon 4 was amplified with the following set of primers: 
ATCTCCTGCAACAAGAGCTGAC and GTACTTCTTGTCCGCGATTCTC. 
 
THIN-SECTION ELECTRON MICROSCOPY  
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Cells were fixed with 2% paraformaldehyde– 2.5% glutaraldehyde in 0.1 M 
cacodylate buffer and removed with a cell scraper. All washes were performed with 0.1 M 
cacodylate buffer. As a postfixative, 1% OsO4 was added, followed by 4% aqueous uranyl 
acetate. Cells were dehydrated in a series of ethanol gradients (50 to 100%), embedded in 
Epon 812 resin, and cured for 48 h at 60°C. Thin sections (70 to 100 nm) of the samples 
were obtained and stained with uranyl acetate, followed by lead citrate. Electron 
micrographs were taken using a Jeol 1230 transmission electron microscope with an 
Ultrascan 1000 camera.  
 
NUCLEOTIDE SEQUENCE ACCESSION NUMBER  
The sequences of the 20 primate tetherin genes have been entered into the 
GenBank database under accession numbers NM_004335, GQ864267, and HM136905 to 
HM136922. 
The sequences of the 18 primate viperin genes have been entered into the GenBank 
database under accession numbers NM_080657, JQ437821 to JQ437837. 
 The sequences of the 31 SAMHD1 genes have been entered into the GenBank 
database under accession numbers NP_056289, and JQ231123-JQ231152. 
 
SEQUENCING OF PRIMATE TETHERIN GENES 
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The tetherin genes from the following primates were amplified from RNA isolated 
from cell lines obtained from Coriell Cell Repositories (Camden, NJ): bonobo (Pan 
panisucus), gorilla (Gorilla gorilla), Sumatran orangutan (Pongo pygmaeus), white-cheeked 
gibbon (Nomascus leucogenys), agile gibbon (Hylobates agilis), rhesus macaque (Macaca 
mulatta), patas monkey (Erythrocebus patas), mustached monkey (Cercopithecus cephus), 
kikuyu colobus (Colobus guereza kikuyuensis), douc langur (Pygathrix nemaeus), Francois’ 
leaf monkey (FLM) (Trachypithecus francoisi), tamarin (Saguinus labiatus), pygmy marmoset 
(Callithrix pygmaea), white-faced saki (Pithecia pithecia), Bolivian red howler (Alouatta 
sara), and woolly monkey (Lagothrix lagotricha). African green monkey (Chlorocebus 
aethiops) Tetherin was amplified by reverse transcription-PCR (RT-PCR) from an RNA extract 
of COS-7 cells. Tetherin was amplified by RT-PCR with a OneStep RT-PCR kit (Qiagen), and 
the cDNA derived was directly sequenced. Tetherin was amplified with “forward” primer 
CD317upstreamForward (5’-CCCCTAACTTCAGGCCAGACTC-3’) or CD317ATGForward (5’-
CAGCTAGAGGGGAGATCTGGATG-3’) in combination with “reverse” primer 
CD317downstreamReverse (5’-CTCACTGACCAGCTTCCTGGG-3’). 
 
SEQUENCING OF PRIMATE VIPERIN GENES 
The viperin genes from the following primates were amplified from RNA isolated from cell 
lines obtained from Coriell Cell Repositories (Camden, NJ): chimpanzee (Pan troglodytes), 
gorilla (Gorilla gorilla), Sumatran orangutan (Pongo pygmaeus), Siamang gibbon (Hylobates 
syndactylus), agile gibbon (Hylobates agilis), rhesus macaque (Macaca mulatta), greater 
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white-nosed monkey (Cercopithecus nictitans), kikuyu colobus (Colobus guereza 
kikuyuensis), Francois' leaf monkey (FLM) (Trachypithecus francoisi), spider monkey (Ateles 
geoffroyi), owl monkey (Aotus trivirgatus), dusty titi monkey (Callicebus moloch) and woolly 
monkey (Lagothrix lagotricha). Human (Homo sapiens), African green monkey (Chlorocebus 
aethiops) and Baboon (Papio anubis) Viperin was amplified by reverse transcription-PCR 
(RT-PCR) from an RNA extract of 293T cells, COS-7 cells and B-LCL cells. Viperin was 
amplified by RT-PCR with a OneStep RT-PCR kit (Qiagen), and the cDNA derived was directly 
sequenced. Viperin was amplified with "forward" primer (5'-
ATGTGGGGTGCTTACACCTGCTGCTTTTGCTG-3') or (5'-
ATGTGGGTACTCACGCCTGCTGCTTTTGCTG-3') in combination with "reverse" primer (5'-
CTACCAATCCAGCTTCAGATCAGCCTTACTC-3') or (5'-
CTACCAATCCAGCTTCAGATCAGCCTTACTC-3'). Sequences for prosimian grey mouse lemur 
(Microcebus murinus) and tarsier (Tarsius syrichta) viperin gene were acquired by tblastx 
search on the NCBI database from cont1.216710 (ABDC01216711.1) and contig1.93320 
(ABRT010093321.1) respectively. 
 
SEQUENCING OF PRIMATE SAMHD1 GENES 
The SAMHD1 genes from the following primates were amplified from RNA isolated 
from cell lines obtained from Coriell Cell Repositories (Camden, NJ): Chimpanzee (Pan 
troglodytes), Bonobo (Pan panisucus), Gorilla (Gorilla gorilla), Sumatran orangutan (Pongo 
pygmaeus), White-cheeked gibbon (Nomascus leucogenys), Agile gibbon (Hylobates agilis), 
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Siamang gibbon (Hylobates syndactylus), Rhesus macaque (Macaca mulatta), patas monkey 
(Erythrocebus patas), Talapoin monkey (Miopithecus talapoin), Greater white-nosed 
monkey (Cercopithecus nictitans), De Brazza’s monkey (Cercopithecus neglectus), Wolf’s 
guenon (Cercopithecus wolfi), Allen’s swamp monkey (Allenopithecus nigroviridis), Sooty 
mangabey (Cercocebus atys), Red-capped mangabey (Cercocebus torquatus), Mandrill 
(Mandrillus sphinx), Drill (Mandrillus leucophaeus), Kikuyu colobus (Colobus guereza 
kikuyuensis), Francois' leaf monkey (FLM) (Trachypithecus francoisi), Proboscis monkey 
(Nasalis larvatus), Tamarin (Saguinus labiatus), Pygmy marmoset (Callithrix pygmaea), 
White-faced saki (Pithecia pithecia), Spider monkey (Ateles geoffroyi), Owl monkey (Aotus 
trivirgatus), Dusty titi monkey (Callicebus moloch ) and Woolly monkey (Lagothrix 
lagotricha). Human, African green monkey (Chlorocebus aethiops) and Baboon (Papio 
anubis) SAMHD1 was amplified by reverse transcription-PCR (RT-PCR) from an RNA extract 
of 293T cells, Vero cell (AGM Vervet subspecies), COS-7 cells (AGM Sabaeus subspecies) and 
B-LCL cells. SAMHD1 was amplified by RT-PCR with SuperScript III One-Step RT-PCR 
(Qiagen), and the cDNA derived was directly sequenced. SAMHD1 was amplified with 
"forward" primer SAMHD1-Hominoid-F (5'-ATGCAGCGAGCCGATTCCGAGCAGCC-3'), 
SAMHD1-OWM-F (5'-ATGCAGCAAGCCGACTCCGACCAGCC-3') or SAMHD1-NWM-F (5’-
ATGCAGCAAGCCGACTTCGAGCAGCC-3’) in combination with "reverse" primer SAMHD1-
Hominoids-r (5'-TCACATTGGGTCATCTTTAAAAAGCTG-3') , SAMHD1-OWM-r (5'-
TCACTTTGGGTCATCTTTAAAAAGCTG-3') or SAMHD1-NWM-r (5’-
TCACACCGGGTCATCCTTAAAAAGCTG-3’). 
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TETHERIN SEQUENCE ANALYSIS  
DNA sequences were aligned by ClustalX (272) and were edited by hand based on 
amino acid sequences. A phylogeny of tetherin genes was constructed from DNA sequences 
with ClustalX by the neighbor-joining method using the Jukes Cantor method of correction 
and with MrBayes by the maximumlikelihood method. The two methods yielded trees with 
identical topologies. Maximum-likelihood analysis was performed with CODEML from the 
PAML suite of programs (308). To detect selection in Tetherin, we fitted the data to site-
specific models (nonsynonymous [NS] sites) that disallowed (NSsites model 7) or permitted 
(NSsites model 8) positive selection and compared the results by likelihood ratio tests. 
Consistent results were obtained when M1 (a two-state neutral model) was compared with 
M2 (a selection model allowing a nonsynonymous/synonymous change [dN/dS] ratio of >1). 
Sequence alignments were obtained when the data were fitted with an F61 model of codon 
frequency, and consistent results were obtained when the data were fitted with an F3 x 4 
model of codon frequency. We calculated the global ratios of dN to dS by a free-ratio model 
that allows dN/dS to vary along individual branches. 
 
VPU SEQUENCE ANALYSIS 
HIV-1 group M Vpu sequences and SIVcpz Vpu sequences were obtained from the 
HIV sequence database (http://www.hiv.lanl.gov) (148), aligned by ClustalX (272), and 
edited by hand. A total of 1,271 sequences representing HIV-1 group M Vpu were analyzed 
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to generate the consensus. Sequence logos of the alignment were plotted using WebLogo 
(http://weblogo.berkeley.edu) (47). 
 
VIPERIN SEQUENCE ANALYSIS 
 DNA sequences were aligned by ClustalX (272) and were edited manually. The amino 
acid positions are annotated in reference to the human Viperin sequence. A phylogeny of 
viperin genes was constructed from DNA sequences with ClustalX by the neighbor-joining 
method using the Jukes Cantor method of correction and with PhyML (86) by the maximum-
likelihood method. The two methods yielded trees with identical topologies. Maximum-
likelihood analysis was performed with CODEML from the PAML suite of programs (308) as 
previously described (141, 142). Sequence alignments were obtained when the data were 
fitted with an F61 model of codon frequency, and consistent results were obtained when 
the data were fitted with an F3 x 4 model of codon frequency. Viperin sequences were 
fitted to NSsites models that disallowed (NSsites model 1 and 7) or permitted (NSsites 
model 2 and 8) positive selection. Likelihood ratio tests were performed to evaluate 
whether permitting codons to evolve under positive selection gave a better fit to the data. A 
cutoff of posterior probability of p>0.95 was implemented in these analyses (M8) to identify 
amino acid residues having evolved under positive selection. Analyses were also validated 
with REL from the HyPhy package (209). Free ratio analysis in PAML was used to calculate 
the ω (dN/dS) ratios of individual branches. Likelihood ratio test statistics was performed 
for models of variable selective pressures along branches of primate viperin genes between 
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M0 (same dN/dS ratio for all branches) and M1 (different dN/dS ratio for each branch). The 
degree of freedom is equal to one less than the total number of branches in the phylogeny. 
  
SAMHD1 SEQUENCE ANALYSIS 
SAMHD1 DNA sequences were aligned by ClustalX (272) and were edited by hand 
based on amino acid sequences or with PhyML (86) by the maximum-likelihood method. 
The two methods yielded trees with identical topologies. Maximum-likelihood analysis was 
performed with CODEML from the PAML suite of programs (308) as previously described 
above. Briefly, SAMHD1 sequences were fitted to NSsites models that disallowed (NSsites 
model 1 and 7) or permitted (NSsites model 2 and 8) positive selection. Likelihood ratio 
tests were performed to evaluate whether permitting codons to evolve under positive 
selection gave a better fit to the data. Data were fitted with an F61 model of codon 
frequency, and consistent results were obtained when the data were fitted with an F3 x 4 
model of codon frequency. These analyses (M8) identified amino acid residues with high 
posterior probability (p>0.95) of having evolved under positive selection. Analyses were also 
validated with PARRIS  and REL from the HyPhy package (209). Free ratio analysis in PAML 
was used to calculate the ω (dN/dS) ratios of individual branches. 
 
VPR AND VPX PHYLOGENETIC ANALYSIS  
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Phylogenetic trees were constructed from amino acid alignments of vpr and vpx 
sequences obtained from the Los Alamos HIV sequence database (148). Alignments were 
performed using ClustalX (272) and edited by, or fast statistical alignment (FSA) (33) for a 
more conservative alignment that maximizes on accuracy. Phylogenies were constructed 
with PhyML (10) by the maximum-likelihood (ML) method; and MrBayes v3.1.2 (102)  and 
BEAST v1.6.2 (57) using a Bayesian MCMC inference. Support for ML trees was assessed by 
1000 non-parametric bootstraps. MrBayes analyses were run for 10,000,000 steps with a 
sample frequency set to 1000 and burn-in length of 1,000,000. BEAST analyses were run 
until convergence with a minimum of 1,000,000 generations, sampling every 1000 and 
discarding the initial 10% as burn-in. Convergence and mixing for both MrBayes and BEAST 
were assessed using Tracer v1.5 (56). Analyses from both Bayesian methods were 
performed at least twice. 
 
FLOW CYTOMETRY 
To analyze the expression of Tetherin on the cell surface, 293T cells were 
cotransfected with 250 ng native human Tetherin in the presence of 750 ng of the 
respective Vpu constructs. Twenty-four hours posttransfection, cells were gently rinsed 
with 1_ Dulbecco’s phosphate-buffered saline (DPBS) and were resuspended in DPBS 
containing 4% calf serum. Cells were incubated first with an anti-human BST-2 (anti-human 
Tetherin) antibody obtained from the NIH AIDS Research and Reference Reagent Program 
(169) and subsequently with an anti-rabbit antibody conjugated with fluorescein 
isothiocyanate (FITC) (BD Pharmingen). Unbound antibodies were washed away, and 
 
 
63 
 
labeled cells were resuspended in DPBS containing 4% calf serum. Flow cytometry was 
performed with a BD FACSCalibur platform and CellQuest software (BD). To analyze the 
downregulation of Tetherin expression on the cell surface by Vpu, cell events were plotted 
by the forward scatter (FSC) parameter versus the FL-1 parameter (Tetherin). To analyze the 
downregulation of CD4 expression by Vpu, 293T cells were cotransfected with 125 ng of the 
bicistronic pIRES-eGFP2 vector, expressing human CD4 and green fluorescent protein (GFP), 
and 1 μg of the respective Vpu constructs. Twenty-four hours posttransfection, cells were 
incubated with an allophycocyanin (APC)-conjugated mouse anti-human CD4 antibody (BD 
Pharmingen) or an APC-conjugated mouse IgG1(κ) isotype control antibody (BD 
Pharmingen). For analysis, cell events were plotted by the FL-1 (GFP) parameter versus the 
FL-4 parameter (APC). To analyze the downregulation of CD4 expression by Vpu, GFP-
positive events were gated, and the percentages of CD4-positive event counts in the 
presence or absence of the various Vpu constructs were compared. 
 
VIRUS PRODUCTION p24 ELISA  
Virus were serially diluted and measured by HIV-1 p24 antigen capture assay 
(Advanced BioScience Lab Inc) and detected with QuantaRed enhanced chemifluorescent 
HRP substrate (Thermo Scientific) according to the manufacturer’s protocol. 
 
PBMC ISOLATION AND SEPARATION  
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Patient pall filters were obtained from Puget Sound Blood Center. PBMCs were 
isolated by standard ficoll histopaque gradient methods. Monocytes and CD4+ T cells were 
isolated by Human CD14 selection and CD4+ magnetic bead isolation (EasySep), and the 
isolation purity (>97-99%) was confirmed by flow cytometry staining (BD Pharmingen). 
Monocytes were maintained in RPMI containing 10% FBS. CD4+ T cells were activated with 
2.5μg/ml PHA and 20U/ml IL-2 for 3 days before interferon treatment. Monocytes and CD4+ 
T cells were treated with 500 IU/ml human interferon β1b for 20 hours, followed by 
western blot analysis on total cell lysates. 
 
SPREADING INFECTIVITY ASSAY  
U937 cells stably transduced with either a Viperin-targeting shRNA or control shRNA 
constructs were infected with a wild type HIV-1Lai virus or HIV-1LaiΔNef at an moi of 0.5. 
Cells were washed with PBS three times and maintained in media containing  
500 IU/ml human interferon β1b throughout the course of the experiment. Supernatant 
was collected at indicated time points and virus was quantified by p24 ELISA. 
 
CO-IMMUNOPRECIPITATIONS 
293T cells were transfected by TransIT-LT1 (Mirus Bio) with the appropriate plasmids 
36 hours prior to lysis, and were treated with 25µM MG-132 (Calbiochem) for 12 hours.  
Cells were washed twice with PBS and lysed with IP Lysis Buffer (50mM Tris pH 7.4, 250mM 
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NaCl, 0.4% (v/v) NP-40, 1mM DTT, plus Protease Inhibitor Cocktail (Roche)).  Lysates were 
cleared at 15,500g for 15 minutes and immunoprecipitations were performed for 1 hour at 
4˚C with EZview Red anti-HA affinity gel (Sigma-Aldrich).  Following immunoprecipitation, 
affinity gel was washed 4 times with IP Lysis Buffer; proteins were eluted in 2X Lammelie 
Sample Buffer, and analyzed by Western blotting. 
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CHAPTER THREE 
Simian Immunodeficiency Virus SIVagm from African Green Monkeys Does Not Antagonize 
Endogenous Levels of African Green Monkey Tetherin/BST-2 
 
SUMMARY 
The Vpu accessory gene that originated in the primate lentiviral lineage leading to 
human immunodeficiency virus type 1 is an antagonist of human tetherin/BST-2 restriction. 
Most other primate lentivirus lineages, including the lineage represented by simian 
immunodeficiency virus SIVagm from African green monkeys (AGMs), do not encode Vpu. 
While some primate lineages encode gene products other than Vpu that overcome 
tetherin/BST-2, I found that SIVagm does not antagonize physiologically relevant levels of 
AGM tetherin/BST-2. AGM tetherin/BST-2 can be induced by low levels of type I interferon 
and can potently restrict two independent strains of SIVagm. Although SIVagm Nef had an 
effect at low levels of AGM tetherin/BST-2, simian immunodeficiency virus SIVmus Vpu, from 
a virus that infects the related monkey Cercopithecus cephus, is able to antagonize even at 
high levels of AGM tetherin/BST-2 restriction. We propose that since the replication of 
SIVagm does not induce interferon production in vivo, tetherin/BST-2 is not induced, and 
therefore, SIVagm does not need Vpu. This suggests that primate lentiviruses evolve tetherin 
antagonists such as Vpu or Nef only if they encounter tetherin during the typical course of 
natural infection. 
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BACKGROUND 
Although human tetherin inhibits the release of SIVagm virus-like particles and HIV-1 
virus-like particles, SIVagm does not encode Vpu (116). However, SIVmus, which can be 
found in naturally infected Cercopithecus cephus monkeys, a species closely related to 
AGMs, does encode a Vpu protein (283). The compelling evidence of an independent 
acquisition of antitetherin factors in multiple viruses, coupled with the presence of Vpu in a 
SIV from a closely related host species, led me to the hypothesis that SIVagm might also 
possess a non-Vpu tetherin counterdefense. 
The Vpu accessory gene that originated in the primate lentiviral lineage leading to 
human immunodeficiency virus type 1 is an antagonist of human tetherin/BST-2 restriction. 
Most other primate lentivirus lineages, including the lineage represented by simian 
immunodeficiency virus SIVagm from African green monkeys (AGMs), do not encode Vpu. 
While some primate lineages encode gene products other than Vpu that overcome 
tetherin/BST-2, I find that SIVagm does not antagonize physiologically relevant levels of 
AGM tetherin/BST-2. AGM tetherin/BST-2 can be induced by low levels of type I interferon 
and can potently restrict two independent strains of SIVagm. Although SIVagm Nef had an 
effect at low levels of AGM tetherin/BST-2, simian immunodeficiency virus SIVmus Vpu, 
from a virus that infects the related monkey Cercopithecus cephus, is able to antagonize 
even at high levels of AGM tetherin/BST-2 restriction. I propose that since the replication of 
SIVagm does not induce interferon production in vivo, tetherin/BST-2 is not induced, and 
therefore, SIVagm does not need Vpu. This suggests that primate lentiviruses evolve 
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tetherin antagonists such as Vpu or Nef only if they encounter tetherin during the typical 
course of natural infection. 
SIVagm displays several key differences from pathogenic HIV-1. SIVagm isolates from 
African green monkeys (AGMs) cluster phylogenetically into four distinct clades, named 
SIVagmVer, SIVagmGri, SIVagmTan, and SIVagmSab, for their host species, vervet, grivet, 
tantalus, and sabaeus monkeys, respectively (4, 5, 111, 173, 297). Chronic infection in agms 
(and the non-pathogenic sooty mangabeys) is associated with lower levels of immune 
activation and less apoptosis of bystander T cells (reviewed in (253)). It has also been 
proposed that primate natural hosts have a protected pool of central memory CD4+ T cells 
to explain the non-pathogenic outcome of infections in these hosts (30, 191). Importantly, 
these SIVagm viruses cause a nonpathogenic infection in their natural AGM hosts, in 
contrast to pathogenic HIV infections of humans (53). Both HIV-1 and SIVagm reach high 
levels of viral titers in vivo and replicate chronically in infected individuals. However, HIV-1 
infection of humans usually results in chronic IFN stimulation (152), whereas there is an 
absence of chronic stimulation of IFN production in SIVagm infection in naturally infected 
AGMs despite equivalent high levels of virus titers (54).  
Initially, it was proposed that SIVagm infection of AGMs represent an ancient 
relationship of virus-host coevolution. This was an appealing model as it could explain the 
observation that the infected AGMs (up to 70% prevalence) do not usually progress to 
immunodeficiency (113, 204). In support of this, phylogenetic analyses of CD4 and CCR5 
genes from the AGM subspecies showed congruence with the SIVagm phylogeny suggesting 
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a coevolution model (65, 130). However, the ancient coevolution model has since been 
legitimately questioned. Resolution of the AGM mitochondrial genomes showed the AGM 
subspecies were significantly different from the SIVagm phylogeny (297). Moreover, 
preferential host switching of SIVs between genetically-similar host species may account for  
some of the apparent codivergence observed (40). Thus, SIVagm was likely the result of a 
west-to-east transmission after the radiation of the AGM subspecies, and not an ancient 
codivergence.  
 
Figure 12  
SIVagm Transmission Pattern across sub-Saharan Africa 
Phylogenetic relationship (based on the full genome) of the four SIVagm viruses that infect 
their host-specific AGM subspecies is shown on the left. Distribution of the four AGM 
subspecies across the African continent is depicted on the right, showing the likely 
transmission route of SIVagm. C. sabaeus was likely the first AGM to be infected with SIV. 
The arrows depict a possible route of transmission of the virus across already established 
AGM ranges.  
This figure is from (297). 
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Here, I report that SIVagm is restricted by endogenous AGM tetherin. Surprisingly, 
AGM tetherin causes a virion retention phenotype against the wild types (WTs) from both 
tantalus monkeys and sabaeus monkeys. Furthermore, I show that endogenous AGM 
tetherin expression is induced by type I IFNs, resulting in virion retention phenotypes for 
WT SIVagm. While I did see an effect of SIVagm on low levels of tetherin, I find that this 
effect is minor compared to the effects of SIVmus Vpu to overcome AGM tetherin 
restriction. Thus, SIVagm has not acquired an antagonist of AGM tetherin that is as potent 
as the antagonists encoded by HIV-1 or SIVmac. I propose that since SIVagm infection 
occurs in the absence of chronic IFN production (54), SIVagm does not encounter tetherin 
during the course of infection and does not require Vpu or Nef activity to counteract 
tetherin. 
 
RESULTS 
HIV-1 Vpu and SIVmus Vpu overcome restriction from tetherins from the host and related 
species.  
Cercopithecus cephus (also called mustached monkey), AGM, and human tetherins 
were tested for antiviral activity. I was interested in tetherin from C. cephus because C. 
cephus monkeys are related to AGMs and because SIVmus that infects C. cephus encodes a 
Vpu protein, unlike SIVagm (46, 275). We cloned the gene that encodes tetherin from C. 
cephus and from Chlorocebus tantalus (AGM) into a retroviral vector expressing an N-
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terminal HA epitope tag. Since HIV-1 Vpu is known to counteract human tetherin (176), I 
tested the ability of these tetherins to restrict HIV-1 expressing a frameshift mutation in 
Vpu (HIV1VpuFS). I also complemented these transfections with either HIV-1 Vpu or SIVmus 
Vpu expression vectors in trans. For this, plasmids encoding HIV1VpuFS, tetherin, and/or 
Vpu were transiently cotransfected into 293T cells (which express low levels of endogenous 
tetherin (176)), and the activity of tetherin or Vpu was measured by the infectivity of 
released virus on indicator cells (see Materials and Methods).  
I found that human, cephus monkey, and AGM tetherin all restricted the release of 
infectious HIV-1 virions by equal amounts in the absence of Vpu (Figure 13A). HIV-1 Vpu was 
able to overcome human tetherin restriction but was unable to overcome restriction by C. 
cephus or AGM tetherin (Figure 13A). Conversely, SIVmus Vpu was able to overcome 
restriction by C. cephus and AGM tetherins but had only a mild effect on human tetherin 
(Figure 13A). This indicates that while tetherins from all three species are functional, the 
Vpu proteins of HIV-1 and SIVmus display a species-specific antagonism of tetherin, which 
corroborates previous findings (78). Furthermore, I found that HIV-1 Vpu resulted in 
decreased levels of expression of human tetherin but had a minimal effect on C. cephus and 
AGM tetherin levels (Figure 13B). Conversely, SIVmus Vpu decreased the levels of C. cephus 
and AGM tetherins but had little effect on human tetherin (Figure 13B). This result indicates 
that the mechanism of SIVmus Vpu activity is likely similar to that of HIV-1 Vpu, likely 
through the degradation of tetherin (78).  
 
 
72 
 
 
Figure 13  
AGM and cephus tetherins restrict HIV1VpuFS and are counteracted by SIVmus Vpu.  
(A) 293T cells were cotransfected with HIV1VpuFS (100 ng), human (200 ng), C. cephus 
(Cephus) (400 ng), or AGM tetherin (400 ng); HIV-1 Vpu (125 ng); and SIVmus Vpu (100 ng) 
for 48 h. The respective empty vectors were used, indicated by no tetherin or no Vpu. Equal 
amounts of virus-containing supernatant were used to infect TZM-bl reporter cells for 48 h. 
Relative infectivity was determined by the rate of β-galactosidase activity. Bars represent 
the average data for eight infections, normalized to the relative infectivity of the respective 
Vpu proteins in the absence of tetherin. Error bars indicate standard deviations.  
(B) 293T cell lysates (A) were collected 48 h after transfection and analyzed by Western blot 
analysis for HA-tagged tetherin and β-actin expression levels.  
 
 
73 
 
SIVagmTan and SIVagmSab are restricted by AGM tetherin and do not encode a tetherin 
counterdefense.  
Since AGM tetherin is able to restrict HIV-1 (Figure 13), I determined whether AGM 
tetherin could restrict SIVagm. HIV-2, which does not encode a Vpu protein, has Vpu-like 
activity in its viral envelope (31). Although SIVagm does not encode Vpu, I suspected that 
the SIVagm envelope protein (Env) or Nef might encode a Vpu-like activity, as seen in HIV-2 
and SIVmac/SIVsmm, respectively (31, 109). To test this, I compared the infectivity of 
SIVagmTan to that of a construct containing a deletion in Env and Nef (SIVagmTan Env– Nef–
) in the presence of AGM tetherin. SIVagmTan Env– Nef– was pseudotyped by cotransfection 
with VSV-G to produce infectious virus. Viral constructs and tetherin were cotransfected in 
293T cells, and viral production was analyzed in an infectivity assay. As described above, I 
found that HIV1VpuFS was restricted by both human and AGM tetherins. Surprisingly, I also 
found that SIVagmTan and SIVagmTan Env– Nef– were restricted by both human and AGM 
tetherins (Figure 14A, left). This means that unlike HIV-2, SIVagmTan Env does not contain a 
Vpu-like activity, nor is this activity encoded by the Nef gene. Although both SIVagmTan 
constructs have a premature stop codon in the Vpr coding region, there was no effect on 
tetherin restriction when virions were complemented with Vpr from SIVagm or HIV-1 (data 
not shown). 
To verify these findings, I also tested the full-length molecular infectious clone of 
SIVagmSab against human and AGM tetherins. SIVagmSab is closely related to SIVagmTan 
and is the most basal taxon of the SIVagm lineage (18, 37). Like SIVagmTan, SIVagmSab does 
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not encode a Vpu protein (18, 26, 37), and all of the accessory genes of the SIVagmSab 
clone are intact. I also independently cloned the tetherin gene from primary fibroblasts of 
Chlorocebus sabaeus and found it to be identical to the AGM tetherin that I used previously 
(data not shown). Strikingly, similar to the findings with SIVagmTan, I also found that a full-
length SIVagmSab clone was restricted by both human and AGM tetherins to the same 
extent as HIV1VpuFS (Figure 14A, right). I also compared the levels of production of cell-free 
SIVagm virions in the presence of sabaeus monkey tetherin. 293T cells were transfected 
with SIVagmTan or SIVagmSab in the presence or absence of AGM tetherin. Supernatant 
fractions containing cell-free virions were filtered and probed with sera obtained from 
rhesus macaques infected with SIVagmsab92018 (provided by Cristian Apetrei, Tulane 
National Primate Research Center). There was less cell-free SIVagmTan and SIVagmSab p27 
capsid detected in the presence of AGM tetherin (Figure 14B). In contrast, intracellular 
levels of p55 and p27 were similar regardless of the level of expression of AGM tetherin. 
Thus, WT SIVagmSab virions are prevented from release in the presence of AGM tetherin. 
These results indicate that in at least two SIVagm lineages, viral isolates do not encode a 
viral antagonist against its host tetherin. 
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Figure 14  
SIVagm does not encode Vpu-like activity.  
(A) 293T cells were cotransfected with HIV1VpuFS, SIVagmTan Env
− Nef− (and VSV-G for 
pseudotyping), SIVagmTan Env
+ Nef+ (left), or SIVagmSab (right) and no tetherin (empty 
vector) or human or AGM tetherin for 48 h. Virus was used to infect TZM-bl reporter cells 
for 48 h to determine the relative infectivity.  
(B) 293T cells were transfected with SIVagmTan (left) or SIVagmSab (right) with or without 
AGM tetherin. Virions from the supernatant were collected and pelleted, while cells were 
lysed to yield intracellular virions. Western blot analysis was performed to compare the 
amounts of cell-free virions.  
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I also examined the fate of SIVagm virions produced in the presence of AGM tetherin 
by electron microscopy. Human 293T cells were cotransfected with SIVagmSab and AGM 
tetherins for 48 h and subsequently visualized by thin-section electron microscopy. In the 
absence of AGM tetherin, SIVagmSab virions were observed to bud from the plasma 
membrane in a single layer (Figure 15A and B). In the presence of AGM tetherin, we 
observed that SIVagmSab virions budding from the plasma membrane were markedly 
tethered together and extended outward in a layered arrangement (Figure 15C and D). 
Notably, most of the tethered virions were mature, as indicated by the condensed capsid. 
This indicates that AGM tetherin restricts WT SIVagm virion release by tethering mature 
virions to the plasma membrane (similar to the effect of human tetherin on Vpu mutant 
HIV-1 (176)). 
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Figure 15  
AGM tetherin retains SIVagmSab on the plasma membrane.Shown is thin-section electron 
microscopy of 293T cells transfected for 48 h with SIVagmSab in the absence of AGM tetherin 
(A and B) or in the presence of AGM tetherin (C and D).  
(A) SIVagmSab budding from the plasma membrane in a single layer in the absence of 
tetherin. The arrow indicates the location of the magnified image.  
(B) Magnified image from A. 
(C) Accumulation of budding SIVagmSab cells on the plasma membrane in the presence of 
AGM tetherin. Note that mature virions form multiple layers. The arrow indicates the 
location of the magnified image.  
(D) Magnified image of C. Scale bars, 2 μm (A and C) and 200 nm (B and D).  
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Since the SIVmac/SIVsmm lineage has evolved Nef to counteract its host and closely 
related tetherins (109, 315), I directly tested if SIVagmTan Nef had the ability to counteract 
tetherins from other species. I cloned the Nef gene from SIVagmTan into an expression 
vector and verified its activity by showing that it could downregulate CD4 levels (data not 
shown), which is consistent with previously reported findings (234). SIVagmTan Nef was 
then cotransfected in 293T cells with SIVagmTan Nef; human, chimpanzee, or AGM 
tetherin; and an HIV-1 construct that had a luciferase gene inserted into the Nef open 
reading frame and expressed a frameshift mutation in Vpu. The ability of Nef to counteract 
tetherin was assayed by the infectivity of released virus on SupT1 cells (see Materials and 
Methods). Consistent with the findings shown in Figure 14, SIVagmTan Nef did not 
overcome AGM tetherin restriction (Figure 16A). SIVagmTan Nef also did not counteract 
human tetherin restriction; however, chimpanzee tetherin was antagonized by SIVagmTan 
Nef. Thus, SIVagmTan Nef has the ability to antagonize other species’ tetherin but not its 
host tetherin. 
To verify that the N-terminal HA epitope tag did not interfere with tetherin 
interactions with viral proteins, we performed a titration of native (untagged) AGM tetherin 
against WT SIVagmTan and SIVagmTan Env− Nef−. Both viruses were pseudotyped with VSV-
G, and the relative infectivity was normalized in the absence of tetherin. There was a 
difference between WT SIVagmTan (Figure 16B) and the mutant virus lacking Env and Nef 
(Figure 16B) at low levels of AGM tetherin; however, a dramatic restriction was observed at 
higher levels of tetherin. Importantly, both viruses displayed dose-dependent restriction by 
AGM tetherin, even at the low levels of tetherin expression (Figure 16B). Since I saw an 
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effect of WT SIVagm on tetherin only at low levels of tetherin expression, we then directly 
compared the effects of SIVagmSab Nef, SIVagmTan Nef, and SIVmus Vpu for the ability to 
counteract AGM tetherin restriction by using the HIV-1 reporter virus lacking Vpu and Nef. 
Indeed, I found that SIVmus Vpu was able to effectively antagonize AGM tetherin when 100 
ng of SIVagm tetherin plasmid was transfected, but the Nef proteins from SIVagmTan and 
SIVagmSab did not counteract AGM tetherin (Figure 16C). Thus, even if SIVagm Nef genes 
encode activity against AGM tetherin, the effects are minor compared to those of SIVmus 
Vpu. 
I also complemented HIV1VpuFS and SIVagmTan with SIVmus Vpu. I found that in 
the presence of SIVmus Vpu, HIV1VpuFS counteracted AGM tetherin restriction. Similarly, 
SIVagmTan was rescued by SIVmus Vpu to overcome AGM tetherin restriction (Figure 16D). 
Thus, AGM tetherin retains the ability to be counteracted by SIVmus Vpu, yet the SIVagm 
lineage does not appear to take advantage of this susceptibility to antagonize tetherin. 
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Figure 16  
AGM tetherin is not antagonized by SIVagm Nef but retains interface with SIVmus Vpu.  
(A) 293T cells were cotransfected with HIV1VpuFSLuc2 (100 ng), SIVagmTan Nef (250 ng), and 
human (100 ng), chimpanzee (100 ng), or AGM (100 ng) tetherin. Virus was assayed on 
SupT1 cells, and relative infectivity was normalized in the absence of tetherin. Bars 
represent average data for four infections, and error bars indicate standard deviations.  
(B) 293T cells were cotransfected with VSV-G and SIVagmTan (solid circles) or SIVagmTan Env
− 
Nef− (open circles) with increasing amounts of untagged AGM tetherin (0, 3.12, 6.25, 12.5, 
25, 50, and 100 ng). Virus infectivity was assayed on TZM-bl reporter cells, and relative 
infectivity was normalized in the absence of tetherin. Points represent average data for four 
infections, and error bars represent standard deviations.  
(C) 293T cells were cotransfected with HIV1VpuFSLuc2 (100 ng), AGM tetherin (100 ng), 
SIVmus Vpu (100 ng), SIVagmTan Nef (250 ng), or SIVagmSab Nef (250 ng). Virus was assayed on 
SupT1 cells, and relative infectivity was normalized in the absence of tetherin. Bars 
represent average data for four infections, and error bars indicate standard deviations.  
(D) 293T cells were cotransfected with HIV1VpuFS or SIVagmTan, AGM tetherin, and SIVmus 
Vpu where indicated for 48 h. Virus was added to TZM.b1 reporter cells for 48 h, and 
relative infectivity was determined as described in the legend of Figure 13A, normalized to 
the respective virus in the absence of tetherin. Bars represent average data for eight 
readings, and error bars indicate standard deviations.  
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Type I IFNs induce AGM tetherin.  
Human tetherin expression is induced by type I IFN (176, 282). Thus, we considered 
the possibility that SIVagm has not evolved to inhibit tetherin because tetherin is not 
induced by IFN in AGM cells. I determined whether endogenous AGM tetherin is induced by 
IFN and if it is functional and active against SIVagm. Two AGM cell lines, COS-7 (C. tantalus) 
and sabaeus primary fibroblasts (C. sabaeus), and human 293T cells were incubated with 
increasing amounts of type I IFNs: IFN-α2a or -β1b (0, 100, and 1,000 IU/ml). Tetherin mRNA 
expression was measured by RT-PCR of equal amounts of RNA. To ensure that I amplified 
mRNA and not genomic DNA, primer sets specific to human and AGM tetherins were 
designed to flank introns. As a control, I measured the expression of β-actin, which is not 
affected by type I IFNs. Twenty-four hours after exposure to IFN-α2a or -β1b, human 
tetherin mRNA levels were upregulated in 293T cells (Figure 17A, top). Similarly, in both 
species of AGM cells, AGM tetherin mRNA levels increased 24 h after exposure to IFN-α2a 
or -β1b (Figure 17A, middle and bottom). I conclude that type I IFNs induce AGM tetherin 
mRNA expression in AGM cells. 
Next, I determined if type I IFN induces a tetherin-associated virion retention 
phenotype in AGM cells. SIVagmTan (pseudotyped with VSV-G) was used to infect AGM 
COS-7 cells, and 6 h after infection, cells were exposed to 1,000 IU/ml IFN-_1b for a further 
42 h before being fixed for thin-section electron microscopy. Upon exposure to IFN-β1b, I 
observed a marked retention of matured SIVagm virions on the plasma membrane of 
infected AGM cells (Figure 17C), similar to the retention phenotype seen when AGM 
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tetherin was expressed exogenously (Figure 17C and D). In comparison, virion budding in 
the absence of type I IFN (Figure 17B) was similar to the phenotype observed in the absence 
of AGM tetherin (Figure 15A and B). Thus, type I IFN induces a tetherin-associated retention 
phenotype in AGM cells, which SIVagm is unable to overcome. Although experiments here 
were not performed using primary peripheral blood mononuclear cells from AGMs, these 
findings are consistent for primary fibroblasts from AGMs and thus not a result of 
subspecies specificity or transformed cells.  
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Figure 17  
Type I IFNs induce AGM tetherin and the 
tetherin virion retention phenotype.  
(A) 293T (human), COS-7 (AGM), and C. 
sabaeus primary fibroblast (AGM) cells were 
incubated with 0, 100, or 1,000 IU/ml IFN-
α2a or IFN-β1b for 24 h. Cells were 
harvested and lysed for RT-PCR analysis.  
(B and C) Thin-section electron microscopy 
of accumulated SIVagmTan budding from 
COS-7 cells exposed to no IFN (B) or 1,000 
IU/ml IFN-β1b  
(C). COS-7 cells were infected with VSV-G-
pseudotyped SIVagmTan. Six hours after 
infection, cells were exposed to 1,000 IU/ml 
IFN-β1b and fixed for thin-section electron 
microscopy after an additional 42 h. Scale 
bars, 0.2 nm. 
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Finally, I verified the restriction of cell-free virus release by endogenous AGM 
tetherin at lower doses of IFN. The amount of IFN seen in SIVagm-infected AGMs is about 
100 to 1,000 IU/ml, peaking at 2,500 IU/ml (54). Therefore, COS-7 cells were infected with 
equivalent amounts of VSV-G-pseudotyped SIVagmTan or SIVagmTan Env− Nef−, and at 6 h 
postinfection, cells were exposed to increasing amounts of IFN-β1b (0, 10, and 100 IU/ml). 
Cell-free virions were compared to cell-associated virions by Western blot analysis. Cell-free 
SIVagmTan and SIVagmTan Env− Nef− displayed a dose-response decrease upon the addition 
of 10 and 100 IU/ml IFN regardless of the presence or absence of Env and Nef (Figure 17). 
Importantly, there was a major effect on viral release at 100 IU/ml. Thus, relatively low 
levels of IFN are able to induce the tetherin-associated cell-free virus restriction phenotype. 
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Figure 18  
Type I IFNs induce AGM tetherin restriction of virus release.  
COS-7 (AGM) cells were infected with VSV-G-pseudotyped SIVagmTan Env
− Nef− (top) or VSV-
G-pseudotyped SIVagmTan (bottom) and exposed to 0, 10, or 100 IU/ml IFN-β1b 6 h 
postinfection. Virions from the supernatant were collected and pelleted, while cells were 
lysed to yield intracellular virions. Western blot analysis was performed to compare the 
amounts of cell-free virions. 
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DISCUSSION 
 Many primate lentiviruses encode a viral antagonist against tetherin, such as Vpu in 
HIV-1, Env in HIV-2, or Nef in SIVmac/SIVsmm. In contrast, I show here that SIVagm does 
not encode a major viral antagonist against its AGM host tetherin despite AGM tetherin 
being functionally active, able to be inhibited by Vpu from SIVmus, and induced by type I 
IFN. Since tetherin is an IFN-regulated gene (even in AGM cells), we propose that SIVagm 
has evolved to replicate without inducing an IFN response, thus obviating its need for a 
virally encoded activity to counteract the antiviral effects of tetherin.  
Primates naturally infected with their own species of lentiviruses can have a 
nonpathogenic outcome. In AGMs and other primates naturally infected with SIV, such as 
sooty mangabeys (SIVsmm), viral replication can reach high titers in the blood (54, 85, 152). 
However, these primates do not develop AIDS-like symptoms and often have 
nonpathogenic outcomes. A hallmark of these nonpathogenic SIV infections is the lack of 
chronic immune activation. In SIVagm-infected AGMs, IFN-α levels in plasma peak 8 days 
postinfection and quickly recede to undetectable levels by 35 days postinfection (54). The 
transient immune response correlates with the peak and decrease in plasma viral loads, 
after which the viral load stabilizes at a set level. The decrease in plasma viral loads 
observed after the production of type I IFN is consistent with evidence that antiviral factors 
such as tetherin are induced. Needless to say, the effects of other concurrent cellular 
responses, such as cytotoxic T lymphocytes, on the decrease in viral titer cannot be 
discounted.  
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While the manuscript was under review, Zhang et al. showed that SIVagm Nef had 
an effect against AGM tetherin (315). I observed that at low levels of AGM tetherin, WT 
SIVagmTan was more infectious than SIVagmTan Env− Nef− (Figure 16B). However, the 
effect of SIVagm Nef is minor compared to that of SIVmus Vpu (Figure 16C). For example, 
SIVmus Vpu counteracts even high levels of tetherin, whereas SIVagm Nef and/or Env had 
only a two- to threefold effect at low levels of AGM tetherin. When I looked at endogenous 
levels of AGM tetherin induced by IFN, I observed a restriction of WT SIVagmTan even at 
low levels of IFN (Figure 17C and Figure 18). Since SIVagmTan Nef can counteract 
chimpanzee tetherin, SIVagm Tan Nef has the ability to antagonize other species’ tetherins 
but not its host tetherin (Figure 16A). Sequence differences between chimpanzee tetherin 
and AGM tetherin point to an evolution of AGM tetherin that has resulted in the inability of 
SIVagmTan Nef to recognize target sequences within AGM tetherin. Therefore, although 
SIVagm Nef has an effect at low levels of AGM tetherin, we believe that the activity is 
insufficient to overcome endogenous levels during the course of acute infection. 
 
Host cellular environment determines the role of viral antagonists 
The host cellular immune environment directly impacts virus replication. Likewise, 
IFN modulation can alter the outcome of viral infections. First, viruses can be capable of 
actively inhibiting the production of type I IFN. An example is the Ebola virus IFN antagonist 
VP35. VP35 inhibits the transcriptional activation of the IFN regulatory factor 3 promoter, 
essentially blocking the host from initiating an IFN response (20). Second, hosts can evolve 
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to decrease their immune response to specific viral agonists, such as the polymorphisms of 
IFN regulatory factor 7 in sooty mangabeys, which result in attenuated type I IFN production 
when SIVsmm engages Toll-like receptor 7 or Toll-like receptor 9 (152). To date, there is no 
evidence that the lack of chronic IFN production during SIVagm infection of AGMs is due to 
either a virally directed or host-adapted response. Nonetheless, given that the stealth 
replication of SIVagm does not induce chronic immune activation, we expect that tetherin 
would not be constantly induced. Thus, SIVagm would not need Vpu activity to counteract 
tetherin (, left). Collectively, retroviruses that do not encounter tetherin during their 
replication lack the selective pressure to maintain “Vpu” activity 
Conversely, the host cellular immune status allows us to predict whether viruses 
encode a viral antagonist of tetherin. SIVmac-infected rhesus macaques and HIV-1-infected 
humans often display AIDS-like symptoms. These hosts maintain chronically elevated IFN 
production levels throughout infection (152). As a result, overt viral replication occurs in an 
environment of chronic tetherin induction. This creates a need for these lentiviruses to 
acquire and maintain the ability to counteract tetherin restriction, as depicted by Vpu of 
HIV-1 (, right). In the same manner, SIVmac/SIVsmm has adapted Nef to act as a viral 
counterdefense against tetherin (109, 315). In conclusion, lentiviral replication in an 
environment of chronic innate immune responses may distinguish pathogenic from 
nonpathogenic infections (152), and this may subsequently play an important role in 
determining the viral factors that arose volutionarily to counteract factors such as tetherin 
that are induced by such responses. 
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Figure 19  
Schematic summary of host-virus consequences in non-pathogenic (left) and pathogenic 
(right) infections of HIV/SIV. 
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CHAPTER FOUR 
Ancient Adaptive Evolution of Tetherin Shaped the Functions of Vpu and Nef in  
Human Immunodeficiency Virus and Primate Lentiviruses 
 
SUMMARY 
Tetherin/BST-2 is a host-encoded protein that restricts a wide diversity of viruses at 
the stage of virion release. However, viruses have evolved antagonists of Tetherin, including 
the Vpu and Nef proteins of primate lentiviruses. Like other host genes subject to viral 
antagonism, primate Tetherin genes have evolved under positive selection. I show here that 
viral antagonists acting at three independent sites of selection have driven the evolution of 
Tetherin, with the strongest selective pressure on the cytoplasmic tail domain. Human 
Tetherin is unique among the Tetherins of simian primates in that it has a 5-amino-acid 
deletion that results in the loss of the residue under the strongest positive selection. I show 
that this residue at amino acid 17 is the site of the functional interaction of Tetherin with 
Nef, since single amino acid substitutions at this single position can determine the 
susceptibility of Tetherin to Nef antagonism. While the simian immunodeficiency viruses 
SIVcpz and SIVgor are able to antagonize their hosts' Tetherin with Nef, human 
immunodeficiency virus type 1 (HIV-1) Vpu has evolved to counteract Tetherin in humans. I 
mapped the adaptations in the N-terminal transmembrane domain of Vpu that allow it to 
counteract human Tetherin. Our combined evolutionary and functional studies have 
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allowed us to reconstruct the host-pathogen interactions that have shaped Tetherin and its 
lentivirus-encoded antagonists. 
 
BACKGROUND 
Humans and other primates encode a wide repertoire of proteins that intrinsically 
inhibit retroviral infections (300). Tetherin, also known as BST-2 or CD317, is an example of 
such an intrinsic antiviral protein that inhibits virus release by anchoring in the envelope of 
budding virions and directly tethering virions to the plasma membrane (199). This relatively 
nonspecific antiviral mechanism allows Tetherin to potently restrict a wide array of viruses, 
including HIV and other primate lentiviruses (116, 119, 144, 176, 222, 282). 
 A characteristic of host antiviral factors is that they often result in viruses evolving 
antagonists to counteract restriction. Indeed, viruses have evolved multiple independent 
antagonists to counteract Tetherin (reviewed in reference (273)). For example, HIV-1 
encodes a Vpu protein that potently antagonizes human Tetherin (176, 282) through 
interactions with the transmembrane domain of Tetherin, leading to its degradation via β-
TrCP (55, 79, 88, 153, 163, 168, 220). However, Vpu is exclusive to HIV-1 and a specific 
lineage of primate lentiviruses including the simian immunodeficiency virus SIVcpz, the 
precursor of HIV-1, and the closely related SIVgor (46, 151, 267, 284). Primate lentiviruses 
that do not encode Vpu, such as SIVmac and SIVsm, instead use Nef to antagonize Tetherin 
(109, 315). HIV-2, which does not encode Vpu, encodes an antagonist of Tetherin in its 
envelope (31, 134). Viruses other than primate lentiviruses have also evolved antagonists of 
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Tetherin. These include Ebola virus, which antagonizes Tetherin through its glycoprotein 
(GP) (119), and Kaposi's sarcoma-associated herpesvirus (KSHV), which is able to counteract 
Tetherin with its K5 protein (156). 
While the consensus is that tetherin potently restricts the release of cell-free 
nascent virus particles, there is debate over its implication for cell-transmission. Several 
studies suggest that cell-to-cell transmission of HIV-1 is unaffected by tetherin or even 
enhanced in some instances (45, 112). On the other hand, there is evidence that the 
aggregation of virion particles at virological synapses by tetherin are unable to transfer 
efficiently and thus inhibits cell-to-cell transmission (37, 129). Nonetheless, the 
independent acquisitions of a viral tetherin antagonist by multiple viruses emphasize the 
role of tetherin and the strong selective pressure imposed by its potent restriction. 
Two previous studies using a set of primate sequences primarily from Old World 
monkeys (OWM) and hominoids found that tetherin has evolved under positive selection 
(88, 163). Here I examine all three lineages of simian primates (including the New World 
monkeys [NWM]) with a larger data set that allows us to determine which part of tetherin 
has been under the strongest positive selection during specific periods in primate evolution. 
I find that during simian primate evolution, three separate types of antagonists have shaped 
tetherin, specifically the cytoplasmic tail of Tetherin, with distinct amino acid residues 
evolving rapidly in New World monkeys versus Old World monkeys and hominoids. Changes 
in the amino acid under the strongest positive selection correspond exactly to the specificity 
of Nef. 
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Consistent with ongoing selective pressure on tetherin genes, I show that both 
SIVcpz Nef and SIVgor Nef are potent antagonists of chimpanzee and gorilla Tetherins but 
are unable to antagonize human Tetherin. Conversely, the Vpu proteins of SIVcpz and 
SIVgor are unable to antagonize Tetherin, while this function has been gained by HIV-1 type 
M strains. While this article was in preparation, similar results were published by Sauter et 
al. (229) and Yang et al. (307). I demonstrate that the site of Nef interaction in the 
cytoplasmic domain of Tetherin is under the strongest selective pressure in hominoids and 
Old World monkeys. However, a deletion covering this site is fixed in human tetherin. 
Therefore, cross-species transmission of HIV-1 to humans necessitated a gain of function by 
Vpu through adaptations in two regions within the N-terminal transmembrane domain of 
Vpu in order for the virus to downregulate Tetherin and escape its antiviral effects.  
Our combined evolutionary and functional studies allow us to reconstruct the host-
pathogen interactions that have shaped Tetherin as well as two antagonists encoded by 
lentiviruses. We propose that the Nef interaction interface of Tetherin was subject to strong 
positive selection in primates but that this interaction domain was completely lost in the 
human lineage, potentially to escape antagonism by an ancient Nef-like factor. 
Subsequently, a modern lentivirus adapted to grow in humans by neofunctionalization of 
Vpu through evolving changes in the N terminus of Vpu. 
 
RESULTS 
SIVcpz and SIVgor use a Tetherin antagonist different from that of HIV-1 type M strains. 
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HIV-1 Vpu potently antagonizes Tetherin, whereas SIVmac or SIVsm does not encode 
a Vpu protein and instead uses Nef to antagonize Tetherin (109, 176). In order to 
understand the evolutionary pressures on both viral antagonists and on hominoid Tetherin, 
I tested the capabilities of Vpu and Nef from multiple strains of HIV-1, SIVcpz (the precursor 
virus of HIV-1), and the closely related SIVgor for antagonistic activity against Tetherin from 
their own host species. 293T cells were used for my experiments, because they express very 
small endogenous amounts of human Tetherin (176). 293T cells were cotransfected with an 
HIV-1 reporter virus lacking Vpu and Nef, along with constant amounts of different Vpu or 
Nef constructs, and increasing amounts of plasmids encoding different tetherin genes. The 
release of the infectious HIV-1 reporter virus was assayed by infecting SupT1 cells as 
previously described (144).  
Consistent with previous observations, I found that human Tetherin potently inhibits 
virus release and that this restriction is effectively antagonized by Vpu but not by Nef 
proteins from either the Lai (clade B) or the Q23-17 (clade A) strain of HIV-1, even at high 
levels of Tetherin (Figure 20A, compare filled circles with open circles). In contrast, 
chimpanzee Tetherin is antagonized by Nef, but not at all by Vpu, from SIVcpzTan3.1 and 
only very slightly by Vpu from SIVcpzUS (Figure 20B). The potency of Nef antagonism differs 
between SIVcpz strains; SIVcpzTan3.1 Nef did not antagonize chimpanzee Tetherin as 
efficiently as did SIVcpzUS Nef. Nonetheless, Nef is the primary antagonist in SIVcpz (Figure 
20B, compare open circles with filled circles). As with SIVcpz, SIVgor Nef, but not SIVgor 
Vpu, is a potent antagonist of gorilla Tetherin (Figure 20C, compare open circles with filled 
circles). Although SIVcpz and SIVgor Vpu proteins were poorly active against their respective 
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hosts’ Tetherins, they were still able to downregulate the levels of human CD4 expression 
efficiently (Figure 20D). These results demonstrate that primate lentiviruses have selectively 
evolved antagonists against their hosts’ Tetherins. SIVcpz and SIVgor use Nef as a potent 
antagonist against Tetherin, whereas HIV-1 accomplishes that task with Vpu. Similar results 
have recently been reported by others (229, 307).  
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Figure 20  
HIV-1 Vpu, SIVcpz Nef, and SIVgor Nef are potent antagonists of their hosts' Tetherins.  
(A) Viral infectivity assay of an HIV-1 ΔVpu ΔNef reporter virus (HIV1VpuFSLuc2) released 
into the supernatant, with increasing amounts of untagged human Tetherin (0, 3.125, 6.25, 
12.5, 25, and 50 ng) in the presence of either 25 ng Vpu (filled circles) or 25 ng Nef (open 
circles) from HIV-1 strain Lai (orange) or Q23-17 (blue). The relative infectivity was 
normalized to the viral infectivity when the respective Vpu/Nef was expressed in the 
absence of Tetherin.  
(B) Native chimpanzee Tetherin was titrated in the presence of either 25 ng Vpu (filled 
circles) or 25 ng Nef (open circles) from strain SIVcpzUS (orange) or SIVcpzTan3.1 (blue).  
(C) Native gorilla Tetherin was titrated in the presence of either 25 ng Vpu (filled circles) or 
25 ng Nef (open circles) from SIVgor.  
(D) 293T cells were cotransfected with a bicistronic vector expressing human CD4 and 
enhanced GFP (eGFP) and the indicated Vpu constructs. Cells were stained (with APC) for 
CD4 expression and were analyzed by flow cytometry. GFP-positive events were gated, and 
the percentages of CD4-positive event counts in the presence versus the absence of the 
indicated Vpu constructs were compared. 
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Species-specific antagonism of SIVcpz and SIVgor Nef.  
To determine the specificity of Tetherin antagonists in the event of cross-species 
transmission, I tested a panel of Vpu and Nef proteins from HIV-1, SIVcpz, and SIVgor 
against human, chimpanzee, and gorilla Tetherins by using an infectivity assay as a measure 
of viral release (Figure 21A). The relative infectivity of the released virus was also plotted on 
a radar chart in order to visualize the ability of Vpu (Figure 21B) or Nef (Figure 21C) to 
counteract each species’ Tetherin. HIV-1 Vpu potently antagonized human, chimpanzee, 
and gorilla Tetherins (Figure 21A, blue) while HIV-1 Nef was inactive (Figure 21B, blue). 
However, Vpu encoded by SIVcpz or SIVgor could not antagonize the Tetherins of closely 
related species (Figure 21A, red and green). Nef encoded by SIVcpz or SIVgor was able to 
counteract both chimpanzee and gorilla Tetherins but not human Tetherin (Figure 21B, red 
and green). These results show that differences between human Tetherin, on the one hand, 
and chimpanzee and gorilla Tetherins, on the other, have determined the landscape of 
species-specific antagonism by SIVcpz and SIVgor Nef proteins. 
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Figure 21  
Species-specific antagonism by HIV-1, SIVcpz, and SIVgor viral antagonists.  
(A) Heat map of Vpu/Nef antagonism of human, chimpanzee, and gorilla Tetherins. The 
infectivity of an HIV-1 ΔVpu ΔNef reporter virus released into the supernatant (normalized 
to that in the absence of Tetherin) was assayed in the presence of human (25 ng), 
chimpanzee (25 ng), or gorilla (25 ng) Tetherin (columns) and of the indicated Vpu/Nef 
construct (rows). The percentages in each column indicate the infectivity of the virus 
relative to that in the absence of exogenous Tetherin (first column). (B and C) The results for 
HIV-1 Q23-17, SIVcpzUS, and SIVgor are plotted on radar charts.  
(B) Relative infectivity (expressed as a percentage) of an HIV-1 ΔVpu ΔNef reporter virus 
released into the supernatant in the presence of human, chimpanzee, or gorilla Tetherin, as 
indicated, and of Vpu from HIV-1 Lai (blue), SIVcpzUS (red), or SIVgor (green).  
(C) Relative infectivity (expressed as a percentage) of an HIV-1 ΔVpu ΔNef reporter virus 
released into the supernatant in the presence of human, chimpanzee, or gorilla Tetherin, as 
indicated, and of Nef from HIV-1 Lai (blue), SIVcpzUS (red), or SIVgor (green). 
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Positive selection in primate Tetherin. 
Tetherin has a unique topology consisting of an N-terminal cytoplasmic tail, a 
transmembrane domain, and a coiled-coil domain followed by a C-terminal 
glycosylphosphatidylinositol (GPI) anchor (131, 199). Previous findings have demonstrated 
that the cytoplasmic tail domain of Tetherin harbors the sites of interaction with SIVsm Nef, 
while HIV-1 Vpu interacts with the transmembrane domain of Tetherin (88, 109, 163). 
Although recent studies have shown that tetherin has evolved under positive selection 
among primates (88, 163), both of these studies had a limited diversity of sequences in their 
data sets; hence, they lacked the power to detect which part of tetherin was under the 
strongest positive selection and, therefore, which viral antagonist has exerted the most 
selective pressure during primate evolution. Thus, I sequenced the tetherin coding 
sequence (approximately 555 bp) from 20 primate genomes representing 33 million years 
of evolution, including 7 hominoids, 8 Old World monkeys (OWM), and 5 New World 
monkeys (NWM). The phylogeny constructed from the primate tetherin sequences was 
congruent with the generally accepted primate phylogeny (213), confirming that the 
sequences are orthologous (Figure 23). There was no evidence of recombination as 
ascertained by a GARD analysis (127). Using a maximum-likelihood approach with CODEML 
from the PAML suite of programs (308), I compared the likelihood of tetherin evolution 
under models that disallowed (NSsites model 7) or permitted (NSsites model 8) positive 
selection. In agreement with previous studies, I found that tetherin had evolved under 
positive selection (Figure 22A). To determine the selective pressures across the different 
primate lineages, I performed a free ratio analysis of primate tetherin that allows for 
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variation in the ω (dN/dS) ratios for each lineage. Several branches of the phylogeny, mainly 
the branches leading up to the New World monkeys, Old World monkeys, and hominoids, 
showed dN/dS ratios of >1 (Figure 23), suggesting an ancient positive selection in primate 
lineages. 
To determine which domains are responsible for the signatures of positive selection, 
I performed PAML analyses on the separate domains of tetherin: the cytoplasmic tail 
domain (aa 1 to 25), the transmembrane domain (aa 26 to 53), and the remaining 
extracellular domains, consisting of the coiled-coil domain and the GPI anchor (aa 54 to 
185). I found that the cytoplasmic tail and transmembrane domains have evolved under 
positive selection, whereas the extracellular domains have not (Figure 22A). 
Next, I sought to identify the specific residues that have been subjected to positive 
selection. Three amino acid residues (codons 9, 17, and 43) were found to evolve under 
positive selection with strong confidence (posterior probability, >0.95) as determined by 
PAML (Figure 22B and C). This was confirmed by random-effect likelihood (REL) analyses 
(Figure 22D) (126). Previous analyses have suggested that a number of additional residues 
within Tetherin’s cytoplasmic tail and transmembrane domain have evolved under positive 
selection, although the statistical power of those studies was hampered by a small data set 
(88, 163). However, we find no detectable signal for positive selection when we omit 
residues 9, 17, and 43 of primate Tetherin (Figure 22E). Therefore, the use of the more-
extensive sequence divergence in our data set allows us to conclude that only three codons 
(residues 9, 17, and 43) of Tetherin display evidence of recurrent positive selection in the 
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primates. Residue 9 evolved rapidly primarily in the NWM lineage (although some OWM 
also are divergent at this position) but is highly conserved in hominoids. Indeed, NWM 
Tetherins primarily display a signature of positive selection at residue 9, whereas OWM and 
hominoid Tetherins display a signature of positive selection at residues 17 and 43 instead. 
Importantly, we find that residue 52 (the boxed isoleucine in boldface in Figure 22B), which 
is critical for resistance against HIV-1 Vpu (88), has not evolved under positive selection 
(Bayes factor, 17.3). 
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Figure 22  
Tetherin was under strong positive selection in the cytoplasmic tail domain.  
(A) Likelihood ratio tests were used to determine if any codons were associated with dN/dS 
ratios significantly greater than 1 (hence under positive selection). Neutral models (M7) 
were compared to selection models (M8) under the F61 model of codon substitution. 
Similar results were obtained in a comparison of M1 (neutral) versus M2 (selection) (data 
not shown).  
(B) An alignment of the cytoplasmic tail and transmembrane domains of Tetherins from the 
20 primates used in the analyses is shown, with three positively selected codons (codons 9, 
17, and 43) shaded (indicated by stars); these were identified by PAML and REL as being 
subjected to positive selection with high posterior probabilities (P, >0.95). Codon 52, which 
is critical for resistance against HIV-1 Vpu but was not identified as evolving under positive 
selection, is boxed.  
(C) PAML omits regions that have deletions in the alignment from the analysis. Therefore, 
PAML analyses were repeated without human tetherin. Codons with a posterior probability 
of >95% were highlighted in a PAML analysis of tetherin genes from all primates, excluding 
humans.  
(D) Summary of the REL analysis of whole tetherin genes from 20 primates. Sites displaying 
positive selection signals with a significance (Bayes factor) greater than 50 (codons 9, 17, 
and 43) are shown in boldface. Codon 52, which did not meet the cutoff, is included for 
reference.  
(E) Likelihood ratio tests were performed between the M7 (neutral) and M8 (selection) 
models for the full tetherin gene, without human tetherin, or without human tetherin and 
with amino acids 9, 17, and 43 omitted from the alignment. 
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Figure 23  
Ancient positive selection of primate tetherins.  
(A) Tetherin from 20 primates were sequenced, representing 33 million years of 
evolutionary divergence. The global ratios of non-synonymous changes (dN) / synonymous 
changes (dS) by a free-ratio model that allows dN/dS to vary along individual branches. The 
dN/dS ratios are indicated at the nodes, the number of non-synonymous changes and 
synonymous changes are indicated in parenthesis, respectively. 
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Positive selection of tetherin was driven by Nef-like antagonism. 
Residue 17, which lies within the cytoplasmic tail domain, shows the strongest 
recurrent signature of positive selection during primate evolution (Figure 22D). Previous 
work has shown that amino acids in this part of Tetherin are important for the ability of Nef 
to antagonize Tetherin (109, 315). Thus, I wanted to determine if changes at this single 
position, amino acid 17, are responsible for the species specificity of Nef. To do this, I 
analyzed the specificity of Nef against Tetherins from different species that differ at amino 
acid 17. 
I have shown previously that although SIVagm is unable to effectively antagonize 
endogenous levels of African green monkey (AGM) Tetherin, SIVagm Nef can potently 
antagonize chimpanzee Tetherin (Chapter four, (144)). Importantly, chimpanzee and AGM 
Tetherins differ at residue 17, which is a cysteine in AGM and a tryptophan in chimpanzees. 
I altered residue 17 in AGM Tetherin from cysteine (as encoded in AGMs) to tryptophan (as 
encoded in chimpanzees) and tested it against SIVagm Nef (Figure 24A). Both AGM Tetherin 
constructs were able to inhibit virus release and were potently antagonized by SIVmus Vpu, 
as previously shown (Chapter four, (144)). Although SIVagm Nef had a minor effect against 
AGM Tetherin, a single substitution at residue 17 (AGM C17W) conferred a dramatic 
susceptibility to SIVagm Nef antagonism (Figure 24A, right).  
Next, to determine if changes in residue 17 could confer resistance against current 
SIV Nef antagonists, I performed a reciprocal mutation of residue 17 in chimpanzee Tetherin 
from tryptophan (as encoded in chimpanzees) to cysteine (as encoded in AGMs) and tested 
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it against SIVcpz Nef. Both chimpanzee Tetherin constructs potently inhibited virus release 
and were potently antagonized by HIV Vpu. However, although SIVcpz Nef potently 
antagonized chimpanzee Tetherin, the construct with the single substitution at residue 17 
(Chimp W17C) displayed markedly increased resistance to SIVcpz Nef antagonism (B, right). 
These results demonstrate that the exact amino acid under positive selection in Tetherin is 
the determinant for Nef antagonism.  
The congruence of the 5-amino-acid deletion in human Tetherin with the site that displayed 
the highest degree of adaptation in other primates suggests that the deletion was itself 
driven by the need to escape antagonism by a Nef-like factor early in the human lineage. To 
test this hypothesis, I reconstructed human Tetherin as it likely existed prior to the deletion 
event (Figure 24C, Anc. Human) (the DDIWK deletion was restored, and the glutamine, the 
amino acid following the deletion, was replaced with a lysine) and tested a panel of primate 
lentiviral Vpu and Nef proteins against it. The ancestral human Tetherin effectively 
restricted virus release but was antagonized by HIV-1 Vpu. However, the ancestral human 
Tetherin was antagonized by Nef proteins from SIVcpz and SIVgor, whereas the extant 
human Tetherin (after the deletion) was resistant to both Nef proteins (Figure 24C). I also 
introduced the same 5-amino-acid deletion into chimpanzee Tetherin (Chimp ΔDDIWK) and 
found that the deletion conferred resistance against SIVcpz Nef (Figure 24B). Therefore, I 
conclude that an ancient Nef-like factor likely drove both the positive selection of residue 
17 in the cytoplasmic tail domain of Tetherin in simian primates and the deletion of this 
residue in humans. 
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Amino acid 43 in the transmembrane region is also under positive selection, albeit the signal 
is much weaker than that for amino acid 17 (Figure 22D). Because the determinants for the 
action of HIV-1 Vpu on Tetherin lie in the transmembrane region of Tetherin (88, 163, 220), 
we wanted to determine whether amino acid 43 was driven to positive selection by Vpu. To 
do this, we chose to examine C. cephus and Francois’ leaf monkey (FLM) Tetherins, which 
differ at amino acid 43 by an isoleucine-to-leucine change (Figure 24B). Human, C. cephus, 
and FLM Tetherins were able to potently restrict virus release (Figure 24D, left). HIV-1 Vpu 
was not able to antagonize either C. cephus (Chapter four, (144)) or FLM (data not shown) 
Tetherin, consistent with an inability of HIV-1 Vpu to antagonize Tetherin from other Old 
World monkeys (144, 229, 307). Likewise, the Vpu from SIVmus was unable to antagonize 
human Tetherin (Figure 24D, right). However, SIVmus Vpu could antagonize both C. cephus 
and FLM Tetherins equally well (Figure 24D, right). This indicates that, in contrast to my 
findings for Nef (or a Nef-like factor), Vpu has not driven positive selection either in 
hominoids or in Old World monkeys. 
  
 
 
111 
 
 
 
 
112 
 
Figure 24  
An amino acid under selection in the cytoplasmic tail of Tetherin explains the specificity of 
Nef.  
Shown are results of assays to determine the infectivity of an HIV-1 ΔVpu ΔNef reporter 
virus released into the supernatant. The relative infectivity was normalized to the viral 
infectivity obtained when the indicated Vpu/Nef protein was expressed in the absence of 
Tetherin. Error bars indicate standard deviations. 
(A) Infectivity was assayed either in the absence of Tetherin (open bars) or in the presence 
of AGM (shaded bars) or AGM C17W (filled bars) Tetherin and in the presence of the 
indicated Vpu or Nef construct.  
(B) Infectivity was assayed either in the absence of Tetherin (open bars) or in the presence 
of chimpanzee Tetherin (shaded bars), chimpanzee W17C Tetherin (filled bars), or 
ChimpΔDDIWK Tetherin (hatched bars).  
(C) Infectivity was assayed either in the absence of Tetherin (open bars) or in the presence 
of human Tetherin (shaded bars) or ancestral human Tetherin (filled bars) and in the 
presence of the indicated Vpu or Nef construct.  
(D) Infectivity was assayed either in the absence of Tetherin (open bars) or in the presence 
of human Tetherin (shaded bars), C. cephus Tetherin (filled bars), or Francois' leaf monkey 
(FLM) Tetherin (hatched bars) and either without Vpu or with SIVmus Vpu. The “ancestral” 
human Tetherin is the human Tetherin with the amino acids DDIWK restored in place of the 
deletion, and with the E following this deletion replaced with a K (Figure 22).  
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The transmembrane domain of Vpu determines Tetherin antagonism activity.  
Since HIV-1 Vpu, but not SIVcpz Vpu, is a potent antagonist against Tetherin (Figure 
21A), I sought to determine how the Vpu protein of HIV-1 type M might have evolved in 
order to antagonize human Tetherin. I constructed a panel of chimeric proteins between 
HIV-1 and SIVcpz Vpu (Figure 25A, left). The chimeric Vpu proteins were all expressed at 
similar levels in transfected cells (Figure 25A, right).  
I found that although full-length SIVcpz Vpu was unable to counteract human 
Tetherin, substitution of the N-terminal transmembrane domain from HIV-1 Vpu for that of 
SIVcpz Vpu conferred the ability to counteract Tetherin (Figure 25B). This was specific to the 
transmembrane domain of Vpu, since substitution of the cytoplasmic domain (α-helix) 
leading up to the β-TrCP binding motif (DSGxxS) was insufficient to rescue the restriction 
phenotype (data not shown). Two regions in the transmembrane domain of Vpu were 
necessary for Tetherin antagonism activity: amino acids 1 to 8 and amino acids 14 to 22. 
Replacement of either region alone was insufficient to counteract Tetherin [Figure 25B, 
HIV(1-8) and HIV(14-22)]. Further chimeras within each region yielded intermediate 
phenotypes, suggesting that these regions harbored several minor determinants (data not 
shown). More importantly, SIVcpz Vpu was able to completely rescue the Tetherin 
restriction phenotype when it encoded both regions 1-8 and 14-22 from HIV (Figure 25B). 
The ability of each Vpu to antagonize Tetherin function correlated with an effect on 
Tetherin expression on the cell surface (282) in a cotransfection experiment (Figure 25C). 
However, here, it is clear that there is a threshold effect, since each of the Vpu proteins has 
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some effect on cell surface Tetherin levels, but those that rescue virus infectivity (Figure 
25B) are more effective than those that do not (Figure 25C). As a control, I examined each 
of the chimeric proteins for its ability to downregulate the expression of human CD4 on the 
cell surface (Figure 25D). All the chimeric Vpu proteins (including the singly substituted 1-8 
or 14-22 region of HIV-1 in SIVcpz [Figure 25D]) effectively downregulated CD4 expression, 
consistent with the evidence that the ability of Vpu to modulate CD4 levels is separable 
from its viral release activity (238). Thus, adaptations in two regions within the N-terminal 
transmembrane domain conferred on HIV-1 Vpu the specific ability to antagonize Tetherin. 
 
 
115 
 
 
  
 
 
116 
 
Figure 25  
The N-terminal transmembrane domain of Vpu confers Tetherin antagonism activity.  
(A) (Left) Alignment of the N-terminal transmembrane domains of the chimeric Vpu 
constructs between HIV-1 strain Q23-17 (shaded areas) and strain SIVcpzUS (open areas). 
(Right) Expression of chimeric Vpu constructs. Western blot analysis was performed to 
determine the expression levels of C-terminally HA epitope-tagged Vpu and β-actin.  
(B) Assay of the infectivity of an HIV-1 ΔVpu ΔNef reporter virus (HIV1VpuFSLuc2) in the 
presence of human Tetherin (25 ng) and native Vpu proteins (untagged) as indicated.  
(C) Expression of Tetherin on the cell surface as determined by flow cytometry in the 
presence or absence of different native Vpu proteins (untagged). Forward scatter is shown 
along the y axis, and Tetherin (detected with an FITC-labeled secondary antibody) is shown 
along the x axis. The solid line represents gating, determined by using untransfected 293T 
cells as controls, and the percentage of cells expressing cell surface Tetherin is given on the 
upper right.  
(D) Flow cytometric analysis of 293T cells cotransfected with a bicistronic vector (expressing 
human CD4 and eGFP) and the indicated native Vpu constructs (untagged). GFP-positive 
events were gated, and the percentages of CD4-positive (APC-labeled) event counts in the 
presence or absence of the indicated Vpu constructs were compared. 
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Since the difference between the abilities of HIV-1 Vpu and one strain of SIVcpz Vpu 
to antagonize human Tetherin mapped to two regions of the transmembrane domain, I next 
examined how likely it was that other strains of SIVcpz Vpu might also encode HIV-1-like 
activity. Thus, I compared an alignment of Vpu proteins from multiple strains of SIVcpz 
against the Vpu from HIV-1 groupMstrains. In contrast to the highly conserved 
transmembrane domain of HIV-1 group M Vpu, the N-terminal transmembrane domain was 
divergent across SIVcpz strains, as might be expected based on their more ancient 
divergence (Figure 26). Although none of the Vpu proteins of SIVcpz strains were identical 
to the consensus Vpu of HIV-1 group M, among several strains of SIVcpz (LB7, CAM5, EK505, 
and MB66) that include the closest relatives of HIV-1 group M (120), the SIVcpz strain LB7 
would be predicted to require seven minimal adaptations within the two critical regions of 
Vpu (amino acids 1 to 8 and 14 to 22) in order to gain the ability to antagonize human 
Tetherin. 
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Figure 26  
The N-terminal transmembrane domain of SIVcpz Vpu is divergent from that of the highly 
conserved HIV-1 Vpu.  
Shown is an alignment of the consensus sequence for the N-terminal transmembrane 
domain (aa 1 to 28) of HIV-1 group M Vpu with the transmembrane domains of Vpu 
proteins from SIVcpz strains. Sequence logos were plotted from 1,271 sequences of HIV-1 
group M Vpu (top) and from the indicated SIVcpz strains (bottom). The two regions 
important for Tetherin antagonism activity (aa 1 to 8 and aa 14 to 22) are shaded. 
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DISCUSSION 
Host proteins locked in genetic conflict often display signatures of positive selection. 
Here, we find that tetherin has been evolving under positive selection in primates, and the 
highest recurrent signal of positive selection during primate evolution corresponds to the 
amino acid that is a determinant for Nef, but not Vpu, antagonism of Tetherin. Chimpanzee 
and gorilla Tetherins are antagonized by SIVcpz Nef and SIVgor Nef but not by the Vpu 
proteins encoded by these two viruses. However, because of a unique 5-amino-acid 
deletion in the cytoplasmic tail domain of human Tetherin that eliminates the site under the 
greatest positive selection in tetherin, the cross-species transmission of SIVcpz to humans 
involved the evolution of Vpu to counteract human Tetherin through adaptations in two 
regions of the N-terminal transmembrane region of HIV-1 Vpu. 
Our study differed from previous analyses of positive selection on Tetherin (88, 163, 
188) in having less intraspecies sampling but more sampling of deeper, interspecies 
divergences. Our conclusions differ qualitatively from those reached previously. In 
particular, because of the increased statistical power of our data set, we can rule out any 
significant contribution to the positive selection of Tetherin outside of residues 9, 17, and 
43. Intriguingly, this signal has not remained uniform among simian primates. New World 
monkey Tetherin appears to have recurrently evolved at residue 9, which shows some 
variability among Old World monkeys but is fixed in hominoids. In contrast, residues 17 and 
43 appear to be rapidly evolving in Old World monkeys and hominoids but not in New 
World monkeys. This makes a strong case that mutually exclusive types of antagonists have 
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shaped Tetherin in the 3 lineages of simian primates. This suggests that an unknown 
antagonist with a specificity unlike that of Nef or Vpu was the primary driver of Tetherin 
evolution in New World monkeys. It is somewhat surprising that only three residues have 
been under positive selection, considering that Tetherin restricts a broad diversity of viruses 
(116, 119, 144, 176, 222) and that recent work shows that a Tetherin with substantial 
changes in the transmembrane and coiled-coiled domains can still act to block virus release 
(199). However, there may be additional constraints on tetherin evolution due to some 
other function of Tetherin (36). In addition, many viruses may have evolved alternative 
strategies that circumvent Tetherin without necessitating a direct antagonistic interaction. 
For example, viruses that target induction of the interferon (IFN) pathway (19) might not 
need to antagonize Tetherin directly if they can prevent its induction following infection. 
A single substitution at residue 17 of AGM Tetherin conferred susceptibility to 
SIVagm Nef, whereas the reciprocal substitution at residue 17 of chimpanzee Tetherin 
conferred resistance to SIVcpz Nef. Thus, the amino acid under the most intense selective 
pressure is responsible for both the gain and the loss of antagonism by Nef. These results 
argue strongly that a Nef-like factor is responsible for the recurrent viral escape from 
Tetherin during simian primate evolution. By “Nef-like” factor, we mean a viral antagonist 
with exactly the same specificity toward Tetherin as that of Nef, if not Nef itself. This line of 
reasoning suggests that more ancient lentiviruses have been in primate populations before 
the currently known primate lentiviruses (245). This hypothesis is supported by the recent 
discovery of much older endogenous lentiviruses (75, 76). We cannot, however, rule out the 
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possibility that unrelated viruses encode a Tetherin antagonist with exactly the same 
specificity as the Nef from primate lentiviruses. 
In contrast to the positive selection observed on amino acid 17 that correlates with 
Nef function, amino acid 52 in the transmembrane domain, which encodes much of the 
susceptibility of primate Tetherin to Vpu antagonism (88), is not subject to positive 
selection (Figure 22B) and indeed is conserved as a isoleucine (in all Old World monkeys) or 
a threonine (in all hominoids). This is highly reminiscent of residue 128 in APOBEC3G, which 
encodes its susceptibility to Vif antagonism (28, 236) but was not found to be evolving 
under positive selection in primates (230). Thus, as with the APOBEC3G-Vif interactions, we 
argue that Vpu antagonism by recent lentivirus proteins did not drive tetherin evolution. We 
also found no evidence that the single residue under positive selection in the 
transmembrane domain (amino acid 43) was driven by a factor similar to SIVmus Vpu. 
These results argue that, unlike the Nef-like factor that drove selection on amino acid 17, 
Vpu and Vpu-like factors (i.e., factors with the same specificity as modern Vpu proteins) are 
too recent to have had an effect on tetherin evolution. 
Human Tetherin is unique among primates due to a 5-amino-acid deletion (including 
residue 17) in the cytoplasmic tail domain of Tetherin that has been fixed in the human 
population (NCBI single-nucleotide polymorphism [SNP] database). This deletion was most 
likely adaptive, since it includes the amino acid under the strongest selective pressure in Old 
World monkeys and hominoids. It is not clear why a deletion event to escape Nef-like 
antagonism would occur exclusively in human Tetherin, whereas other primates instead 
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show adaptive evolution at residue 17. It is possible that this domain also encodes another 
function in addition to viral restriction, pressure for which was relaxed in the human 
lineage, or that there was a lack of preexisting SNPs in the human population at the time of 
selection. Alternatively, simultaneous selective pressure by multiple Nef-like proteins may 
have driven a deletion instead of an amino acid substitution in human Tetherin. 
Due to the unique deletion in the cytoplasmic tail domain of human Tetherin, the 
Nef protein of the HIV-1 precursor SIVcpz was ineffective as a Tetherin antagonist following 
cross-species transmission to humans. We propose that as a result of the selective pressure 
exerted by Tetherin, the precursor virus evolved Vpu to counteract human Tetherin through 
adaptations in two regions of the N-terminal transmembrane domain of Vpu (Figure 25B). 
Therefore, the most parsimonious explanation points to sequence variations of Vpu (Figure 
26) in SIVcpz that predisposed certain strains to be more adaptable, in particular the strain 
that gave rise to the pandemic HIV-1 group M. Our findings support and extend the 
conclusions of Sauter et al., who performed an extensive study of HIV-1 Vpu proteins from 
groups M, N, and O, and proposed that the ability both to antagonize Tetherin and to 
degrade CD4 facilitated the pandemic spread of group M HIV-1 (229). I show that gain-of-
function antagonism of human Tetherin occurred through adaptations in the N-terminal 
transmembrane domain of Vpu (Figure 26B). In my characterization, I found that the 
determinants were situated in two regions. An alignment of Vpu from multiple strains of 
SIVcpz shows that several strains of SIVcpz (LB7, CAM5, and EK505) would require fewer 
changes. Furthermore, based on the highly divergent sequences currently available, it is 
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highly possible that a strain(s) of SIVcpz responsible for the cross-species transmission has 
yet to be sequenced.  
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CHAPTER FIVE 
The function and evolution of the restriction factor Viperin in primates  
was not driven by lentiviruses 
SUMMARY 
Viperin, also known as RSAD2, is an interferon-inducible protein that potently 
restricts viruses such as influenza, hepatitis C virus, human cytomegalovirus and West Nile 
virus.  Like other host restriction factors that have a broad antiviral range, we find that 
viperin has also been evolving under positive selection in primates. The pattern of positive 
selection is indicative of Viperin's escape from multiple viral antagonists over the course of 
primate evolution. Here, we investigate the possibility that Viperin also restricts human 
immunodeficiency virus and other retroviruses. We find that Viperin is interferon-induced in 
HIV primary target cells. We show that exogenous expression of Viperin restricts the LAI 
strain of HIV-1 at the stage of virus release from the cell, and can be partially counteracted 
by the HIV-encoded Nef protein. However, the effect of Viperin restriction is highly strain-
specific and does not affect most HIV-1 strains or other retroviruses tested. Moreover, 
knockdown of endogenous Viperin in a lymphocytic cell line did not significantly affect the 
spreading infection of HIV-1. Taken together, these findings indicate that Viperin is not a 
major restriction factor against HIV-1 and other retroviruses. Therefore, other viral lineages 
are likely responsible for the evolutionary signatures of positive selection in viperin among 
primates. 
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INTRODUCTION 
Antiviral proteins engaged in virus-host interactions are often locked in evolutionary 
"arms-races", which have been referred to as "Red Queen” conflicts (286). Viral infections 
continuously exert immense selective pressures on the host antiviral proteins to evolve 
adaptively. The signatures of these evolutionary conflicts can be inferred by observing 
signals of adaptive evolution (also called positive selection) in antiviral genes that result 
from repeated episodes of Darwinian selection due to past viral infections (59). Often, the 
exact amino acids under positive selection can describe the sites and domains involved in 
host-virus interaction (141, 142, 231). Thus, a detailed look at the evolutionary trajectory of 
an antiviral gene can provide valuable information about the viral pressures that shaped 
host evolution 
Viperin (Virus inhibitory protein, endoplasmic reticulum-associated, interferon-
inducible, also known as RSAD2) is a host protein with broad antiviral activity (reviewed in 
(64, 161, 240)). Viperin inhibits the release of a wide range of viruses in cell culture 
including Influenza A virus (293), Hepatitis C virus (96, 110), and Japanese Encephalitis virus 
(39). Moreover, viperin knockout mice demonstrate the importance of this protein in 
controlling West Nile Virus pathogenesis in vivo (265). In the case of human 
cytomegalovirus (HCMV), Viperin has been reported not only to inhibit the expression of 
late viral gene products (43) but also to enhance HCMV infectivity by remodeling the 
cellular actin cytoskeleton (241).  
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The precise mechanism of the broad spectrum antiviral function of Viperin remains 
unclear. However, one model for Viperin antiviral activity links lipid rafts disruption to the 
restriction of Influenza virus release (293). Lipid rafts are sphingolipid- and cholesterol-
enriched microdomains on the plasma membrane that have also been implicated in a 
number of processes including membrane signaling, polarization, and immunological 
synapse function (186, 250). Additionally, lipid rafts also play an important role in the entry 
and assembly stages of viral replication (162, 186) and the host sterol biosynthesis pathway 
is downregulated in response to viral infections as part of the innate immune response via 
type I interferon signaling (27). Viperin has also been shown to directly inhibit farnesyl 
diphosphate synthethase (FPPS), a cellular enzyme critically involved in the biosynthesis of 
isoprenoid-derived lipids (293). This suggests that the disruption of cellular lipid raft 
formation may represent a generalized host defense against viruses.  
We find that viperin, like other host restriction factors against viruses, has evolved under 
positive selection in primates. As lipid rafts are thought to be sites of assembly and budding 
for HIV and other retroviruses (181, 185, 186, 206), we investigated whether Viperin 
restricts HIV-1 and other retroviruses. We find that Viperin inhibits the release of the LAI 
strain of HIV-1 and is partially counteracted by Nef. However, we show that HIV-1 and SIV 
strains have intrinsic differences in their sensitivity to Viperin and most are unaffected by 
over-expression of Viperin. Furthermore, we did not see an effect of Viperin knockdown on 
HIV-1 growth. Collectively, our findings suggest that Viperin is not a major restriction factor 
against HIV-1 and retroviruses, and thus its positive selection must have been driven by 
other viral pathogens. 
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RESULTS 
Viperin has been evolving under positive selection in primates 
A recurring theme of host restriction factors is that they exhibit a strong signature of 
positive selection (166). Given the remarkable breadth of viruses restricted by Viperin (43, 
110, 161, 240, 293), we hypothesized that viperin might also be evolving under positive 
selection. To investigate this possibility, we sequenced the viperin gene from 18 species of 
primates and obtained 2 sequences of prosimian viperin from Genbank (Figure 27A). 
Together, these primate species span around 60 million years of divergence. The phylogeny 
constructed from the primate viperin sequences was congruent with the generally accepted 
primate phylogeny (198), confirming that the sequences are orthologous. There was no 
evidence of recombination as ascertained by a GARD analysis (127).  
In order to determine the lineage-specific pressures on the primate viperin gene, we 
performed a free-ratio analysis using the PAML program suite (308), which allows an 
independent assignment of omega (dN/dS) ratios to each evolutionary branch of the 
primate phylogeny, where dN/dS ratios > 1 are indicative of positive selection. Several 
branches of the phylogeny within the New World monkeys, Old World monkeys, and 
hominoids showed dN/dS ratios > 1 (Figure 27A, bold branches). For instance, the branches 
leading up to human-chimpanzee common ancestor and African green monkey have dN/dS 
ratios > 1, indicative of positive selection. To test whether Viperin was subject to episodic or 
constant selective pressures over primate evolution, we compared the likelihood ratios of 
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the free-ratio model (Figure 27B, Model 1) where all branches were allowed to have their 
own independent dN/dS, versus a model where the entire phylogeny had the same dN/dS 
value (Figure 27B, Model 0). We found that the free-ratio model fit the data better although 
this was marginally significant (p=0.08). We therefore conclude that primate viperin has 
been ancient, episodic positive selection.  
We also performed a maximum likelihood analysis using codeml from the PAML 
program suite (308) that allows for different dN/dS ratios across individual codons, and 
found strong evidence that the viperin gene has been evolving under positive selection in 
primates (Figure 27C). In order to determine which domain(s) in Viperin are responsible for 
the signal of positive selection we examined each domain separately (the N-terminal alpha 
helix domain, a short middle region, the Radical S-adenosylmethionine (SAM) domain and a 
flexible C-terminal domain (Figure 27D)). While the N-terminal alpha helix was not under 
positive selection, the middle region, Radical SAM domain and C-terminal flexible domain 
showed signs of positive selection with high confidence (Figure 27D). In particular, five 
amino acid positions stood out with strong signals of positive selection (corresponding to 
residues 42, 51, 142,145, 352 in human Viperin). These five amino acid residues were 
independently confirmed to be under positive selection with strong significance by random-
effect likelihood (REL) analyses (data not shown) (126). Importantly, removal of these five 
amino acids from the analyses resulted in a loss of any statistically significant signals of 
adaptive evolution (Figure 27C), validating that the majority of the positive selection was 
acting on these sites. The dispersed nature of these positively selected residues are 
reminiscent of other broadly acting antiviral genes like Protein Kinase R (PKR), wherein 
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escape from viral antagonism drives the positive selection of PKR (58). This is in contrast to 
other rather than restriction factors like TRIM5alpha, where a cluster of positive selectively 
selected residues identifies the viral specificity domains (231). Therefore, we conclude that 
viperin has evolved under positive selection, likely to escape viral antagonism by a variety of 
viral lineages over the course of primate evolution.  
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Figure 27 
(A) Cladogram of 20 primate viperin genes sequenced for the evolutionary analyses. Free 
ratio analysis in PAML was used to calculate the ω (dN/dS) ratios of individual branches. The 
corresponding ω ratios are shown above each branch, and the number of non-synonymous 
changes and synonymous changes are indicated in parentheses. Branches with ω > 1 are 
highlighted in bold. In the case of no observed synonymous changes, the ω ratio (inf) could 
not be calculated.  
(B) Likelihood ratio test statistics for models of variable selective pressures along branches 
of primate viperin genes are shown, in comparison between M0 (same dN/dS ratio for all 
branches) and M1 (different dN/dS ratio for each branch).    
(C) A schematic of Viperin protein domain structure is shown. Residues under positive 
selection with high confidence (P > 0.95) are indicated in symbols above the protein. The 
table summarizes the likelihood ratio test statistics for models of variable selective pressure 
among viperin sites (M7 vs M8). Similar results were obtained in a comparison of M1 
(neutral) versus M2 (selection) (data not shown). The amino acid positions are annotated in 
reference to the human Viperin sequence. 
(D) The table summarizes likelihood ratio test statistics performed between the M7 
(neutral) and M8 (selection) models for the individual protein domains of viperin gene from 
20 primate species. 
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Viperin inhibits HIV-1 Lai virus release and is partially counteracted by Nef  
Given the broad antiviral range of Viperin, we wished to investigate whether Viperin 
might also be relevant to restricting HIV-1 infection. We first studied whether Viperin is 
expressed at the protein level in HIV-1 target cells. Primary CD4+ T cells and monocytes 
were isolated from peripheral blood mononuclear cells of two donors and treated with 
interferon β for twenty hours. We found that both primary CD4+ T cells and monocytes 
express endogenous Viperin after induction with interferon (Figure 28A), but expression 
levels were undetectable in the absence of interferon.  
Given that Viperin is under positive selection and expressed in HIV-1 primary target 
cells after interferon induction, we investigated whether Viperin restricts HIV-1. To begin 
these studies, we first compared levels of endogenous Viperin expression with levels 
achieved by transfection of the cloned human viperin gene into 293T cells. We found that 
untransfected 293T cells express undetectable levels of endogenous Viperin. However, the 
transient expression of Viperin in 293T cells transfected with between 0.3 and 1 μg of DNA 
bracketed the amount of endogenous Viperin expression in primary CD4+ T cells and U937 
cells when induced with interferon (Figure 28B). Therefore, in subsequent studies, we used 
amounts of the plasmid encoding the human viperin gene that gave levels of Viperin 
expression just below and just above the levels expressed in primary cells.  
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Figure 28 
(A) Viperin expression in HIV-1 primary target cells was determined by western blot 
analysis. CD4+ T cells and monocytes isolated from two donor-derived peripheral blood 
mononuclear cells were treated with or without interferon β1b induction (500 IU/ml) for 
twenty hours.  
(B) Western blot analysis of endogenous Viperin expression in primary CD4+ T cells and 
U937 cells treated with interferon β1b (500 IU/ml) was compared to the transient 
expression of Viperin (3-fold serial dilutions: 0, 0.01, 0.03, 0.1, 0.3, 1.0 μg) transfected in 
293T cells. 
 
We tested whether exogenous Viperin expression could restrict HIV-1 by co-
transfecting 293T cells with a full-length HIV-1 Lai strain with increasing amounts of the 
human viperin gene. Additionally, we tested HIV-1 Lai lacking a nef gene, since Nef has been 
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implicated in modulating cellular cholesterol levels (281, 318). We measured the antiviral 
activity of Viperin was by infecting TZM.BL indicator cells with released virus, and assaying 
for β-galactosidase reporter activity (See Materials and Methods). We found that wild-type 
HIV-1 virus was marginally affected at low amounts of Viperin, but was inhibited at the 
highest dose of Viperin (Figure 29A, closed circles). Consistent with the known defect on 
virion infectivity in the absence of Nef (11), the HIVΔNef virus had a lower infectivity even in 
the absence of Viperin as measured by the β-galactosidase activity (Figure 29A left, 
compare closed circles and open circles at 0 μg viperin). Despite that initial observation, the 
HIVΔNef virus was restricted further by viperin in a dose-dependent manner (Figure 29A, 
open circles). To compare the degree of restriction between the two viruses, we normalized 
the β-galactosidase reporter activity of each virus to their measurements in the absence of 
Viperin (Figure 29A right). We observed that the wildtype HIV virus was only restricted at 
the highest levels of Viperin expression, whereas the HIVΔNef virus was more sensitive to 
Viperin restriction than wildtype HIV, even at the lower levels of Viperin expression.  
Because Viperin restricts influenza virus at the step of virus release (293) and HCMV 
by inhibiting the production of viral structural proteins (43), we investigated whether HIV-1 
production and/or release is affected by Viperin by western blotting for cell-associated and 
cell-free Gag proteins. We hypothesized that if Viperin affects HIV production, we expected 
to see a decrease in intracellular p55gag expression that correlates with a decrease in cell-
free p24gag. Conversely, if Viperin affects virus release, we would see lower levels of cell-
free p24gag while levels of p55gag would remain unchanged.  
 
 
135 
 
We found that cell-associated HIV-1 p55gag for both WT and Nef virus was only 
marginally affected by the expression of Viperin (Figure 29B). Moreover, cell-free levels of 
p24gag from wild type HIV-1 were modestly affected by the expression of Viperin (Figure 
29B) in a manner consistent with a slight decrease in the amount of supernatant HIV p24gag 
when measured with an enzyme linked immunosorbent assay (ELISA) assay (Figure 29C, 
middle). However, Viperin expression showed a drastic reduction in cell-free HIVΔNef 
p24gag (Figure 29B, right), with only a small effect on intracellular p55gag levels (Figure 
29B, left). This suggests that Viperin affects release of HIVΔNef virus. 
Since Viperin might also be affecting the quality of the virus particles, we quantified 
the specific infectivity of virus particles by measuring the ratio of infectious titer to relative 
particle production (by p24 ELISA). Consistent with other studies, we find that wildtype HIV 
virus was more infectious than HIVΔNef virus (Figure 29C). However, viperin expression did 
not affect the specific infectivity (infectivity divided by p24gag) of either wildtype HIV virus 
or HIVΔNef virus particles (Figure 29C, right), indicating that the Viperin-mediated 
restriction of HIV-1 is not due to a reduction in viral infectivity.  
Since Viperin seemed to affect virus release, we compared Viperin restriction to that 
of Tetherin, a well-characterized host restriction factor that inhibits virus release (176, 282). 
Virus restriction by a combination of Viperin and Tetherin expression was roughly additive 
(Figure 29D). Furthermore, the response of Viperin and Tetherin is different since HIV-1 Vpu 
abrogates Tetherin restriction but has no effect on Viperin restriction, whereas HIV-1 Nef 
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abrogates Viperin restriction (Fig. 3D). These results suggest that Viperin restricts HIV-1 
release by a mechanism that is distinct from the pathway used by Tetherin. 
Because HIVΔNef was more sensitive to Viperin restriction compared to wildtype 
HIV, we examined whether Nef expressed in trans could rescue the restriction Viperin 
imposed on a Nef mutant. Nef expression from either the HIV-1 Lai and Q23-17 strains 
modestly rescued HIV-1Nef virus release in the presence of Viperin (Figure 30A), indicating 
that the partial Nef rescue of Viperin restriction is consistent with an increase in HIV-1 
release.  The partial Nef counteraction of Viperin restriction is consistent with the observed 
reduction in wildtype HIV-1 release at high levels of Viperin overexpression (Fig. 3). One 
step by which accessory proteins from HIV-1 alleviate restriction is by causing degradation 
of the restriction factors (151). However, we found that the expression of Nef did not affect 
the levels of Viperin expression (Figure 30B), suggesting that Nef abrogation of Viperin was 
via a distinct mechanism from direct protein degradation. Thus, Viperin restriction of HIV-1 
release can be partially counteracted by Nef in a manner that does not directly affect 
Viperin protein expression.  
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Figure 29 
(A) The effect of viperin was measured by the infectious virus yield. 293T cells co-
transfected with 200 ng of HIVLai or HIVLaiΔNef with serial dilutions of human viperin was 
titered by infecting TZM.BL indicator cells. The infectivity readout by β-galactosidase activity 
measured in relative light units (RLU) is shown on the left, and the respective viruses were 
normalized to β-galactosidase activity in the absence of viperin as shown on the right. Error 
bars indicate standard deviations from three infection replicates; this data is representative 
of five independent experiments.  
 (B) Western blot analysis was performed on the cell-free virus and cellular extracts, and 
probed with α-p24 antibody. Viperin expression in the cellular extracts is shown, and actin 
was probed as a loading control. This blot is representative of four independent 
experiments.  
(C) The effect of Viperin on the specific infectivity of virus particles was calculated. HIVLai or 
HIVLaiΔNef virus from 293T cells co-transfected with or without Viperin (700 ng) was titered 
by infecting TZM.BL indicator cells as shown on the left. Virus release in the cell-free 
supernatant was quantified by p24 ELISA as shown in the middle. The specific infectivity was 
calculated as ratio of β-galactosidase activity (RLU) over the amount of p24 (ng/ml), as 
shown on the right. Error bars indicate standard deviations of triplicate infections, this data 
is representative of at least three independent experiments. 
(D) Virus yield from 293T cells co-transfected with a combination of Tetherin (50 ng) or 
Viperin (700 ng) was titered on TZM.BL cells. Fold inhibition was calculated in comparison to 
virus yield in absence of Tetherin/Viperin. Error bars indicate standard deviations of 
triplicate infections, this data is representative of three independent experiments. 
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Figure 30 
(A) HIVLaiΔVpuΔNef (200 ng) was complemented in trans with 200 ng of HIV-1 Lai Vpu, HIV 
Lai Nef or HIV Q23-17 Nef, in the presence or absence of Viperin (700 ng). Virus release was 
measured from the cell-free supernatant by p24 ELISA quantification. Error bars indicate 
standard deviations of three replicates, and is representative of three independent 
experiments. 
(B) Viperin protein expression was analyzed by western blot twenty-four hours after co-
transfection of 293T cells with human Viperin (700 ng) and 5-fold serial dilutions of native 
HIVLai Nef or HIVQ23-37 Nef (10, 50, 250 ng). Native untagged Nef expression is shown, and 
Tubulin was probed as a loading control. 
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Most HIV strains, SIVs and retroviruses are resistant to Viperin restriction 
To examine the breadth of Viperin restriction on HIV-1, we tested several strains of 
HIV-1 for their susceptibility to Viperin restriction on virus release. The proviruses were 
deleted of their nef gene to exclude the possible confounding effects of Nef specificity. 
Consistent with the earlier experiments (Figure 28C), HIVLaiΔNef virus release was inhibited 
by human Viperin. However, virus release of the HIVΔNef NL4-3, SF162 (both HIV-1 subtype 
B) and Q23-17 strains (HIV-1 subtype A) were unaffected by Viperin expression (Figure 31A). 
To verify these observations, we performed a western blot analysis comparing the cell-
associated and cell-free HIV-1 Gag protein levels. In contrast to the dose-dependent 
inhibition of HIVLaiΔNef virus release, cell-free HIVNL4-3ΔNef virus release remained 
unaffected (Figure 31B). While there was an observable effect on intracellular HIVNL4-
3ΔNef virus p55 levels, this difference was not reflected in the cell-free Gag p24 levels or 
the ELISA assay. In addition, we tested a widely used HIV-1 vector encoded from a codon-
optimized Gag-pol sequence called pCNC-SynGP (103). We observed that the cell-free HIV-1 
pCNC-SynGP Gag was unaffected by Viperin expression. Instead, cell-associated p55gag 
protein production was slightly increased in the presence of Viperin expression. As for the 
HIVΔNef SF162 and Q23-17 strains, there were no significant effects on cell-free p24gag or 
cell-associated p55gag expression levels. One exception is a noticeable decrease in the 
partially processed, cell-associated, HIVΔNef SF162 p40gag levels. However, while Viperin 
might have a subtle effect on the intracellular Gag levels of certain HIVΔNef strains, the 
difference was not reflected in the cell-free virus or measured in the ELISA assay. Thus, it 
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appears that Viperin does not significantly impact the virus release of most HIVΔNef strains 
tested except for the HIV-1 Lai strain. 
We next investigated the ability of Viperin to restrict related simian 
immunodeficiency virus (SIV). In addition to their nef gene deletion, the proviruses were 
also pseudotyped with VSV-G so that the entry of all viruses would be equal. Using an 
infectivity assay, we found that SIVmac239Nef was as sensitive to Viperin as HIV-1LaiNef 
(Figure 31C, open squares). However, SIVagmTAN1Nef, SIVcpzTAN3.1Nef and HIV-
2ROD9Nef were resistant to Viperin restriction. Since Viperin did not appear to restrict the 
majority of primate lentiviruses we tested, we also examined two additional divergent 
retroviruses – murine leukemia virus (MLV) and feline immunodeficiency virus (FIV). In 
contrast to the control HIVΔNef Lai virus, MLV and FIV were unaffected by Viperin 
expression (Figure 31D), indicating that Viperin does not generally restrict retroviruses. 
Thus, while Viperin may inhibit a limited subset of primate lentivirus strains (HIV-1Lai and 
SIVmac239, for example), the majority of HIV-1 strains, SIVs and retroviruses that we tested 
are not affected by Viperin expression. 
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Figure 31 
(A) A panel of HIV-1ΔNef strains were tested for their sensitivity to Viperin overexpression. 
Virus release was assayed by p24 ELISA quantification of cell-free supernatant forty-eight 
hours after co-transfection of 293T cells. Error bars indicate standard deviations of three 
replicates, and is representative of three independent experiments. 
(B) Western blot analysis was performed on the cell-free virus and cellular extracts of (A). 
HIV-1 Gag expression was accessed by α-p24 antibody. Viperin expression in the cellular 
extracts is shown, and Actin was probed as a loading control. This blot is representative of 
at least three independent experiments. 
(C) Single-cycle infectious virus yield of VSV-G pseudotyped primate lentiviruses from 293T 
cells co-transfected with and serial titration of Viperin was titered on TZM.BL indicator cells. 
Proviruses were deleted of the nef gene. The infectivity readout by β-galactosidase activity 
was measured in relative light units (RLU).  
(D) The effect of Viperin on retroviruses was measured by co-transfecting 293T cells with 
MLV, FIV or HIVLaiΔNef with serial titrations of viperin. Viruses were pseudotyped with VSV-
G and titered by infecting HeLa cells. The expression of virus-encoded GFP was quantified by 
flow cytometry. This analysis is representative of at three independent experiments. 
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Endogenous Viperin does not inhibit HIV-1 Lai 
To determine the effect of endogenous Viperin on HIV-1, we sought to knock-down 
Viperin expression with shRNAs. We were unable to obtain suitable stable or transient 
knockdown in primary T cells (data not shown). Many T cell lines such as SupT1 cells also do 
not express Viperin after interferon induction (data not shown). However, CD4+ U937 
monocytic cells do express Viperin after interferon induction (Figure 28B). Using a stably 
transduced shRNA construct, we were able to partially knockdown expression of Viperin in 
U937 cells (Figure 32A). U937 cells that were either knocked-down for Viperin (shRNAVip) 
or transduced with a control shRNA (shCON) were infected with HIV-1LAI and HIV-1LAINef 
at a multiplicity of infection of 0.5. Infections were done in the presence of interferon to 
induce Viperin expression. Viral supernatant was collected periodically over 11 days and 
spreading infection was monitored by p24 ELISA. We found that there was no significant 
difference between WT and ΔNef virus growth in the cells knocked-down for Viperin 
expression (Figure 32B). Considering that the HIVLaiΔNef is the most sensitive strain in 
Viperin overexpression experiments (Figure 28 and Figure 30), these results suggest that 
endogenous levels of Viperin do not affect spreading infection by HIV-1. 
 
 
144 
 
 
 
Figure 32 
(A) Viperin expression in U937 cells stably transduced with empty pGIPZ shRNA vector (Ctl) 
or viperin targeting shRNA (Vip) was analyzed by western blot twenty hours after interferon 
β1b treatment (500 IU/ml).  
(B) Spreading infection of wildtype HIVLai or HIVLaiΔNef was quantified by p24 ELISA at 
indicated time points after infecting shRNA-transduced U937 cells at an moi of 0.5. Cells 
were maintained in interferon β1b (500 IU/ml) for the duration of the experiment. 
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No functional divergence in lentiviral restriction among primate Viperin orthologs  
Most of the experiments that we have carried out were using the human viperin 
allele. However, since viperin evolves rapidly under positive selection, we might not be 
accurately capturing the potential ability of Viperin proteins to restrict lentiviruses. The 
species-specificity of action is one of the key features that have emerged from the study of 
rapidly evolving restriction factors. To address the possibility that the human Viperin might 
not accurately capture the restrictive potential of Viperin, we carried out two expriments to 
measure any functional divergence between primate Viperin orthologs that may have arisen 
from the positive selection. 
First, we tested 5 additional Viperin orthologs against the HIVLaiNef (Figure 33A). 
We found that all six Viperin orthologs are able to restrict this virus to approximately the 
same extent, despite some variation in the degree of restriction. This means that the 
positive selection of viperin does not manifest a functional difference in the degree of 
restriction of HIVLaiNef.   Second, we compared the human and rhesus orthologs against a 
panel of viruses to assess whether we could discern any key restriction differences between 
these two Viperin orthologs (Figure 33B). It is notable that human versus rhesus differences 
have been found in the majority of positively selected restriction factors that have been 
tested so far (58, 62, 231). However, in the case of Viperin, we found no significant 
differences between the restriction profiles of human and rhesus Viperin. 
These results imply that Viperin's lack of restriction of the majority of lentiviruses and 
retroviruses tested is not a consequence of testing only one Viperin allele. Moreover, this 
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strongly implies that gain or loss of lentivirus restriction is not correlated with the dramatic 
evolutionary changes we observed in the viperin gene in primates. 
 
Figure 33 
(A) The antiviral activity of primate Viperin orthologs was assayed. 293T cells were co-
transfected with HIVLaiΔNef that encodes a luciferase reporter gene (200 ng) and indicated 
primate Viperin (700 ng).  Virus yield was measured by infecting SupT1 cells and assayed for 
luciferase expression. Error bars represent standard deviations of four infection replicates, 
and is representative of three independent experiments. 
(B) Single-cycle infectious virus yield of VSV-G pseudotyped primate lentiviruses from 293T 
cells co-transfected with 700 ng of human Viperin, rhesus Viperin or empty vector was 
titered on TZM.BL indicator cells. The infectivity readout by β-galactosidase activity was 
measured in relative light units (RLU). Error bars indicate standard deviations of four 
infection replicates, and is representative of at least three independent experiments. 
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DISCUSSION 
Primate Viperins are not lentiviral restriction factors  
The restriction factor Viperin recognizes and restricts a wide diversity of viruses, 
including both single-stranded RNA and double-stranded DNA viruses (64, 161, 240). This 
broad repertoire of antiviral activity prompted us to investigate Viperin’s restrictive activity 
against retroviruses, specifically the primate lentivirus lineage. We found that Viperin is 
highly interferon-induced in primary target cells of HIV. Viperin overexpression is able to 
inhibit HIV-1 Lai replication by affecting virus release and this restriction is partially 
counteracted by the Nef protein. However, most other strains of HIV-1, SIV and other 
retroviruses are unaffected by primate Viperin orthologs. Finally, endogenous Viperin does 
not inhibit the spreading infection of HIV-1 Lai. Therefore, we conclude that Viperin is not a 
major restriction factor against HIV-1 and other primate lentiviruses. 
Our overall findings are consistent with a previous study that showed that poly I:C-
induced Viperin only had a subtle effect on HIV-1 infection in astrocytes (218). Our findings 
of Viperin restriction of the Lai strain of HIV-1 but not the NL4-3 strains is unexpected since 
NL4-3 is a recombinant virus of NY5 and Lai strains (2). At present, we do not have an 
explanation for why only the HIV-1 Lai strain is Viperin sensitive, but we have mapped the 
genetic basis of the susceptibility difference to a non-coding region of the virus (data not 
shown). One possible explanation is that LTR promoter efficiency may affect viral Gag 
production in a manner that renders it sensitive to Viperin. Nonetheless, considering that 
most strains of HIV-1, SIVs (excluding SIVmac239), tested are resistant to Viperin, we favor 
 
 
148 
 
the most parsimonious conclusion is that Viperin is not a significant player in the immune 
defense against lentiviruses. 
 
Insight into Viperin function from its positive selection 
Antagonistic genetic conflict between hosts and viruses have driven rapid adaptive 
evolution of antiviral proteins (59, 99), which is characteristic of many retroviral restriction 
factors (166) as well as other antiviral factors that target a broad range of viruses (58, 194). 
Like many host restriction factors, we find that viperin has been evolving under positive 
selection in primates. The signatures of rapid evolution in viperin may provide valuable 
information about the mechanism by which it restricts this broad repertoire of viruses, and 
likely avoids viral antagonism. This is analogous to the dynamics of the host restriction 
factor Tetherin, where the highest recurrent signal of positive selection corresponds to the 
amino acid that is a determinant for antagonism by Nef (142). In the antagonist-driven 
scenario, we speculate that the amino acid residues under positive selection on Viperin 
might have been driven by pressures to evade viral antagonists and would be indicative of 
sites directly involved in viral protein interactions. A promising candidate would be 
Japanese encephalitis virus which encodes an unidentified viral antagonist that degrades 
Viperin in a proteasome-dependent mechanism (39).  
Thus, although Viperin does not encode a restriction factor for lentiviruses, our 
study documents an ancient, episodic and recurrent history of adaptive evolution in Viperin 
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over primate evolution, which was likely driven by selective pressures imposed by virus 
families other than the lentiviruses.  
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CHAPTER SIX 
The Ability of Primate Lentiviruses to Degrade the Monocyte Restriction Factor SAMHD1 
Preceded the Birth of the Viral Accessory Protein  
 
SUMMARY 
The SAMHD1 protein potently restricts lentiviral infection in dendritic cells and 
monocytes, but is antagonizes by the primate lentiviral protein Vpx SAMHD1 which targets 
it for degradation. However, Vpx is only encoded by some lineages of primate lentiviruses 
whereas its paralog, Vpr, is conserved across extant primate lentiviruses. Nonetheless, I find 
that not only multiple Vpx but also some Vpr proteinsare able to degrade SAMHD1. I show 
that such antagonism led to dramatic positive selection of SAMHD1 in the primate 
subfamily Cercopithecinae. Residues evolving under positive selection precisely determine 
sensitivity to Vpx/Vpr degradation by altering binding specificities. By overlaying these 
functional analyses on a phylogenetic framework of Vpr and Vpx evolution, we can decipher 
the chronology of acquisition of SAMHD1-degrading abilities in lentiviruses. We conclude 
that vpr neofunctionalized to degrade SAMHD1 even prior to the birth of a separate vpx 
gene, thereby initiating an evolutionary arms race with SAMHD1. 
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INTRODUCTION 
The evolutionary analysis of both host and viral proteins combined with functional 
analysis can reveal the evolutionary dynamics of this arms race, both in terms of its birth 
and its more recent adaptations. Host defense genes like SAMHD1 involved in antagonistic 
virus-host interactions often display strong signatures of diversifying selection as a result of 
repeated episodes of selection by viral antagonists (59, 166). This methodology can be used 
to pinpoint the exact amino acid residues involved in the viral-host interaction (142, 163, 
231), and when applied to a phylogenetic tree, can provide a temporal context for when 
these interactions have taken place (59).  
The recent identification of SAMHD1 as the target of Vpx allows us to characterize 
Vpx function from diverse lentiviruses with SAMHD1 from different hosts. Such an analysis 
can distinguish between the possibility that SAMHD1 degradation had an ancient origin and 
was subsequently lost in some lineages due to lack of selective pressure from SAMHD1, or 
that it was a recent adaptation of some viruses. 
Our functional analyses reveal that multiple Vpx proteins share the ability to 
degrade SAMHD1 but that this ability is often host-specific.  Furthermore, we find that some 
Vpr proteins from Vpx-lacking lentiviruses also can potently degrade SAMHD1. Moreover, 
our evolutionary analyses reveal a burst of diversifying selection that shaped SAMHD1 in 
the Cercopithecinae subfamily of old world monkeys which was driven by its antagonism 
with Vpr/Vpx proteins.  By tracing the evolution of Vpr and Vpx function on a phylogenetic 
framework, we show that the ability to degrade SAMHD1 is the result of 
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neofunctionalization of Vpr that preceded the acquisition of Vpx in primate lentiviruses. We 
conclude that vpr gained a new function to degrade SAMHD1 once during viral evolution, 
thereby initiating an evolutionary arms race with SAMHD1. However, many lentiviral 
lineages, including those leading to HIV-1, never acquired this function. 
 
RESULTS 
Species-specific antagonism of SAMHD1 by diverse Vpx proteins  
A recent study found that SIVrcm Vpx could not degrade human SAMHD1 (133), 
suggesting that this function might be very limited among primate lentiviruses. I first wished 
to test if the ability of Vpx to degrade SAMHD1 is conserved, and if there is species-
specificity to the interaction. Thus, I cloned SAMHD1 from a panel of primates and assayed 
for Vpx-mediated SAMHD1 degradation by western blot analysis  after transient co-
transfection of epitope-tagged SAMHD1 proteins with vpr or vpx from different lentiviruses.  
Consistent with previous reports, I found that HIV-2 (Rod9) Vpx degraded human 
SAMHD1 and SIVmac Vpx degraded rhesus SAMHD1 (101, 133), (Figure 34A and Figure 
34B). I also found that Vpx from a primary strain of HIV-2 7312a degraded SAMHD1 (Figure 
34A). Surprisingly, I found that while the HIV-2 (Rod9) had a relatively narrow specificity, 
only degrading SAMHD1 from human and De Brazza’s monkeys among a broader panel of 
primate SAMHD1 proteins (Table I), HIV-2 (7312a) Vpx could degrade SAMHD1 from 
humans and all of the Old World monkeys tested (Table I). The corresponding Vpr proteins 
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of both viruses were unable to degrade human SAMHD1 (Figure 34A), similar to Vpr 
proteins from HIV-1 and SIVcpz strains (Figure 34A).  
SIVrcm also encodes both Vpx and Vpr. However, SIVrcm Vpx is only 42% identical to 
HIV-2/SIVsmm Vpx at the amino acid level. Nonetheless, I found that SIVrcm Vpx potently 
degraded SAMHD1 from the host species it naturally infects – the red-capped mangabey 
(RCM) (Figure 34B). Furthermore, I found that SIVrcm Vpx can degrade SAMHD1 from other 
Old World monkeys, but not from sooty mangabeys or humans (Table 1). The corresponding 
Vpr protein of SIVrcm did not have this activity (Figure 34B). Thus, my findings not only 
suggest that the ability to degrade SAMHD1 is conserved in other clades of Vpx, but also 
shows species-specificity (Table I).  
HIV-1 encodes only vpr, while HIV-2 encodes both vpr and vpx, yet both infect 
humans. There is an analogous situation in mandrills which are naturally infected by two 
highly divergent lentiviruses, SIVmnd1 which encodes only vpr, and SIVmnd2 which encodes 
both vpr and vpx (254, 269, 279). I found that the Vpx protein from SIVmnd2 was able to 
degrade mandrill SAMHD1, but neither SIVmnd2 Vpr nor SIVmnd1 Vpr could degrade 
mandrill SAMHD1 (Figure 34C). Thus, even within a given host, some lentiviruses have a 
protein with the ability to degrade SAMHD1, while others do not.  
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Figure 34  
Vpx from diverse primate lentiviruses degrade SAMHD1.  
(A) The ability of Vpx and Vpr to degrade SAMHD1 was assayed by western blot analysis of 
HA-epitope tagged SAMHD1 from respective primate species co-transfected with 3xFLAG-
epitope tagged Vpr or Vpx constructs as indicated. Actin was probed as a loading control. 
Indicated Vpr and Vpx constructs were expressed in the presence of human SAMHD1 (left) 
or chimpanzee SAMHD1 (right).  
(B) Similar western blots as in (A) are shown, analyzing rhesus macaque SAMHD1 (left) and 
red-capped mangabey (RCM) SAMHD1 (right) expression in the presence of indicated Vpr 
and Vpx constructs.  
(C) Similar western blots as in (A) are shown, analyzing mandrill SAMHD1 expression in the 
presence of indicated Vpr and Vpx from SIVmnd1 or SIVmnd2.  
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Some Vpr proteins also antagonize SAMHD1  
Thus far, analyses suggest a clear separation of function between the vpr and vpx 
genes examined (14) implying that vpx alone evolved the ability to degrade SAMHD1. 
However, the evolutionary history of these genes is far from clear, in part due to the high 
diversity of sequences (246, 277, 278). This raises the possibility that at least some 
divergent lentiviral vpr genes might share the property of degrading SAMHD1. We used 115 
vpr and vpx gene sequences from diverse HIV and SIV isolates to construct phylogenies 
using both maximum likelihood (ML) and Bayesian (BI) methods; both methods yielded 
congruent unrooted topologies (Figure 35A, Figure 36A). The primate lentivirus vpr and vpx 
sequences grouped into seven phylogenetic clusters (cutoff at ML bootstrap >75, BI 
posterior probability > 0.8; shaded by colors in Figure 35A). Phylogenies obtained from an 
application of the Fast Statistical Alignment (FSA) algorithm that is more conservative in 
terms of homology assignment (33), or trimmed to the minimal 44 shared amino acid 
positions from the FSA alignment yielded the similar seven phylogenetic clades (Figure 35B).  
In all cases, a subset of the vpr genes clustered closer to the vpx genes than they did to 
other vpr genes (for example, the yellow and green groups in Figure 35A). Thus, we tested 
the vpr genes from each of the diverse primate lineages against their own host SAMHD1 as 
well as other primate SAMHD1 genes.  
  The Vpr protein from SIVolc (from the grey color group in Figure 35A), which infects 
olive colobus monkeys and does not carry Vpx, cannot degrade colobus SAMHD1, similar to 
HIV-1/SIVcpz Vpr and SIVmnd1 Vpr.  On the other hand, however, I found that Vpr from 
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SIVdeb that infects De Brazza’s monkeys (from the green color group in Figure 35A) not only 
degraded De Brazza’s monkey SAMHD1 (Figure 35B) but it also potently degraded SAMHD1 
from all primate species including humans (Table I).  Vpr from SIVmus, in the same group as 
SIVdeb, also had a broad specificity against primate SAMHD1 proteins (Table I). Extending 
these analyses further, we found that Vpr proteins from both SIVagm Grivet (677 strain) and 
SIVagm Vervet (9648 strain) (yellow group in Figure 35A) also degraded SAMHD1 from their 
African green monkey (AGM) host (Figure 35B). SIVagmGri Vpr had a narrow specificity only 
capable of degrading AGM SAMHD1, whereas SIVagmVer Vpr had a broader specificity 
(Table I). These data reveal that phylogenetically distinct Vpr proteins functionally degrade 
SAMHD1, at times with striking species-specificity.  
 
 
157 
 
 
Table 1  
Species-specific SAMHD1 degradation by Vpr and Vpx.  
The table summarizes results of western blot analyses of SAMHD1 degradation phenotype 
by indicated Vpr and Vpx across a panel of primate SAMHD1. The host species SAMHD1 is 
listed in the left column, and the Vpx/Vpr proteins tested against SAMHD1 are listed in the 
top row. ‘‘+’’ indicates combinations that resulted in a greater than 90% decrease in 
SAMHD1 levels. ‘‘–’’ indicates combinations that had no significant changes in SAMHD1 
levels. The following Vpr proteins from HIV-1 Lai, HIV-1 Q23-17, HIV-2 Rod9, HIV-2 7312a, 
SIVcpz 3.1, SIVcpz 2.69, SIVmac239, SIVrcm, SIVmnd1, SIVmnd2, and SIVolc—which are 
inactive against their host species (Figure 34 and Figure 35)—were also unable to degrade 
the panel of primate species’ SAMHD1 (data not shown). The AGM SAMHD1 tested is from 
the Vervet subspecies matching the SIVagmVer 9648 host strain; SAMHD1 from the 
Tantalus subspecies was found to be heterozygous for a second allele that was resistant to 
all HIV/SIV Vpr and Vpx tested (data not shown).  
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We overlaid the functional analysis of Vpr and Vpx proteins that do and do not 
degrade SAMHD1 on the unrooted phlyogenetic tree. Notably, all of the Vpr/Vpx proteins 
that do degrade SAMHD1 are found on one side of the tree (Figure 35A, blue stars), while all 
of the Vpr proteins that do not degrade SAMHD1 are found on the other side (Figure 35A, 
red stars). There is strong bootstrap support for the separation of these two subtrees 
(Bootstrap support (BS) = 90.3, Posterior Probability (PP) = 1) which argues that there was a 
single gain/loss event for the function of degrading SAMHD1 in Vpr/Vpx evolution, and this 
function is not only confined to the previously classified “vpx” genes, but is also observed in 
“vpr” genes from diverse lentiviral lineages.  
 
Binding of diverse Vprs to SAMHD1 correlates with degradation 
Previous studies have shown that Vpx from SIVsm and HIV-2 are able to bind 
SAMHD1 directly in order to promote its degradation (101, 133). To determine if the diverse 
Vpr proteins that degrade SAMHD1 also antagonize through protein-protein interactions, 
we performed co-immunoprecipitations. As the immunoprecipitation was directed against 
SAMHD1, the proteasome inhibitor MG132 was added to the cells in an attempt to prevent 
degradation of SAMHD1.  Consistent with our degradation results, we found that SIVdeb 
Vpr co-immunoprecipitates with SAMHD1 from De Brazza’s monkeys (Figure 35C). Similarly, 
we found that SIVagm Vpr binds AGM SAMHD1. The AGM-SAMHD-1 Vpr complexes, but not 
the SIVdeb Vpr, also interacted with the Cul4 ubiquitin ligase complex protein, DDB1 (Figure 
35C), which is consistent with the mechanism previously shown for degradation of human 
 
 
159 
 
SAMHHD1 by HIV-2 Vpx (21, 244). In contrast, SIVmnd1 Vpr did not bind to Mandrill 
SAMHD1 (Figure 35C), indicating that only Vprs that degrade SAMHD1 are able to bind 
SAMHD1. Thus, the ability of Vpr to cause degradation of SAMHD1 correlates with its ability 
to bind SAMHD1, and is at least partially conserved with the known mechanism of Vpx 
interaction with SAMHD1.   
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Figure 35  
Some Vpr proteins degrade SAMHD1.  
(A) Unrooted phylogeny of 115 vpr and vpx sequences among diverse primate lentiviruses. 
Bootstrap values indicates maximum likelihood proportions that are highly supported by 
Bayesian inference (Figure S1A). Seven phylogenetic clusters are shaded in colors (cutoff at 
ML bootstrap >75, Bayesian posterior probability > 0.87). Vpx sequences form 2 clades 
(Light blue and dark blue shaded) that have strong support of monophyly from all other vpr 
sequences. Functional phenotype of Vpr and Vpx (Table I) that degrade SAMHD1 (Blue 
stars) or do not degrade SAMHD1 (Red stars) are overlaid on the phylogeny. See also Figure 
S1B.  
(B) Western blot analysis of Colobus monkey, De Brazza’s monkey, and African green 
monkey (AGM) SAMHD1 in the presence of indicated Vpr constructs. The AGM SAMHD1 
tested is from the Vervet subspecies matching the SIVagmVer 9648 host strain, the Colobus 
SAMHD1 tested is from the Colobus guereza subspecies. 
(C) Association of SAMHD1 with Vpr and DDB1 by co-immunoprecipitation was detected by 
western blot analysis of HA-immunoprecipitated SAMHD1 for FLAG-epitope tagged Vpr and 
DDB1 association (IP), or input expression (Input). After transfection, cells were treated with 
25µM MG-132 for 12 hours prior to immunoprecipitation. SIVdeb Vpr interacts with De 
Brazza’s monkey SAMHD1 (IP), but SAMHD1 expression was not rescued by MG132 
treatment (Input). SIVmnd1 Vpr, which fails to degrade mandrill SAMHD1, was assayed as a 
negative control. Actin and the antibody light chain (Lc) are shown as loading controls.  
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Figure 36  
(A) Unrooted phylogeny of 115 vpr and vpx sequences (Figure 2A) among diverse primate 
lentiviruses using Bayesian inference. Seven monophylytic clusters shaded in colors.  
(B) Unrooted phylogeny of vpr and vpx sequences from the FSA alignment trimmed to the 
minimal 44 shared amino acid positions, using Bayesian MCMC inference. A similar topology 
was obtained with the maximum likelihood method, with lower bootstrap support. 
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Vpr/Vpx antagonism drove positive selection of SAMHD1 in Old World monkeys 
One key to the question of whether antagonism of a host protein by a viral protein is 
ancient or recent is to determine the selective pressures that have shaped the host protein 
evolution. Therefore, I looked if SAMHD1 is under positive selection by sequencing the 
coding region of SAMHD1 from 31 primate species representing approximately 40 million 
years of evolutionary divergence (Figure 37A). The phylogeny constructed from the primate 
SAMHD1 sequences was congruent with the generally accepted primate species phylogeny 
(198), confirming that the sequences are orthologous. I found that there was strong 
evidence of recurrent positive selection on SAMHD1 during primate evolution (Figure 37B, P 
< 0.001), and this conclusion was corroborated with other methods (Figure 38). This 
signature of positive selection clearly stemmed from the Old World monkeys (OWM) clade 
(p < 0.001), as neither New World monkeys (NWM) (p > 0.19) or hominoids (p > 0.35) clades 
showed significant evidence of positive selection. The lack of positive selection in NWM or 
hominoids was not a result of low statistical power from limited evolutionary depth as the 
tree length (number of substitutions per codon) of the NWM clade (0.20) and hominoid 
clade (0.15) was greater than that of the OWM clade (0.13).  
In order to investigate the selective pressures across the different primate lineages, I 
calculated the omega ratio (dN/dS) along each branch by performing a free ratio analysis 
using PAML, where omega (dN/dS) ratios > 1 are indicative of positive selection (Figure 37A 
and Figure 38B). Aside from OWM, only the branch leading to orangutans had statistically 
significant dN/dS > 1 (Figure 38C). Strikingly, SAMHD1 has evolved by positive selection in 
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multiple branches of the OWM subfamily Cercopithecinae (Figure 37A, Figure 37D). This 
suggests that the most dramatic signatures of recurrent positive selection are exhibited by 
members of the Cercopithecinae primate subfamily, and occurred after this lineage split 
from the Colobinae subfamily. 
Positive selection analysis identified six amino acid residues (aa 32 and 36 in the N-
terminal domain, aa 46, 69 and 107 in the SAM domain and aa 486 in the C-terminal 
domain) as having evolved under recurrent positive selection with strong confidence 
(posterior probability > 0.95) (Figure 37C, Figure 40). Furthermore, if I removed all 6 residue 
positions from the primate SAMHD1 alignment, the bulk of the gene-wide signature of 
positive selection was lost (p > 0.11), indicating that these amino acids are largely 
responsible for the signal across the entire gene (Figure 37C). 
 
 
164 
 
 
Figure 37  
Primate SAMHD1 has been evolving under positive selection.  
(A) Cladogram of 31 primate SAMHD1 genes sequenced for the evolutionary analyses. The 
panel of primates comprised of 8 hominoids, 16 Old World monkeys and 7 New World 
monkeys.  No evidence of recombination was detected by a GARD analysis (127). Values of 
ω (dN/dS) along each branch were calculated by a free ratio analysis using PAML (Figure 
38B). Branches with statistically significant ω values > 1 are highlighted in red, branches 
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highlighted in grey indicate lineages that show ω values > 1, but are not statistically 
significant based on two-ratio likelihood tests (Figure 38).  
(B) Likelihood ratio test statistics were used to determine if SAMHD1 evolution across 
various primate lineages was associated with dN/dS ratios significantly greater than 1 
(hence under positive selection). Neutral models (M7) were compared to selection models 
(M8) under the F61 model of codon substitution. Similar results were obtained in a 
comparison of M1 (neutral) versus M2 (selection) (data not shown). See also Figure 38.  
(C) Six positively selected codons were identified (32, 36, 46, 69, 107, 486) with significant 
posterior probability (Figure 38A) using PAML. The analysis was performed on SAMHD1 
sequences from the panel of 16 Old World monkeys, which showed the strongest burst of 
positive selection in primates (Figure 37B). Likelihood ratio tests were performed between 
the M7 (neutral) and M8 (selection) models for the full SAMHD1 gene, without the SAM 
domain or with amino acids 32, 36, 46, 67, 107, 486 omitted from the alignment. Domains 
were analyzed for signatures of positive selection, with the strongest signals located in the 
SAM domain. See also Figure 38. 
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Figure 38 
(A) Likelihood ratio test statistics to determine if the SAMHD1 gene from 31 primates is 
evolving under positive selection, using PARRIS from the HyPhy package.  
(B) Values for ω (dN/dS) along each branch for SAMHD1 were calculated by using the free 
ratio analysis from PAML. ω values are shown on branches, with the number of non-
synonymous to synonymous changes indicated in parentheses.  
(C) Likelihood ratio statistics were used to determine if SAMHD1 evolution across the 
specific primate lineage was associated with dN/dS ratios significantly greater than 1 (hence 
under positive selection) compared to neutral, dN/dS = 1. Outside of OWM, only the branch 
leading to orangutans had statistically significant dN/dS > 1.  
(D) Likelihood ratio tests were performed between the M7 (neutral) and M8 (selection) 
models for the full SAMHD1 gene within the Cercopithecinae subfamily of primates in 
OWM. 
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If amino acid residues under positive selection determine sensitivity to Vpx 
antagonism, this would strongly argue that a Vpx-like factor was responsible for the 
signature of positive selection acting on SAMHD1. Alternatively, if the sites under recurrent 
positive selection did not affect SAMHD1’s susceptibility to Vpx antagonism, this would 
strongly suggest that Vpx and Vpx-like factors are too recent to significantly affected 
SAMHD1 evolution. Of the 6 sites identified under strong positive selection, residues 46 and 
69 in the SAM domain showed unmistakably strong signals of recurrent positive selection 
(Figure 39A and Figure 40). These residues also differ in certain primate species’ SAMHD1 
that show opposite susceptibility to Vpx.  In particular, AGM and mandrill SAMHD1 differ at 
positions 46 and 69, with mandrill encoding the ‘ancestral state’ at both sites while AGM 
encodes the ‘derived’ state (Figure 39A).   
To determine if the changes at position 46 and 69 are responsible for the species-
specificity of SAMHD1 antagonism by Vpx, we investigated SAMHD1 degradation by 
SIVmnd2 Vpx, which can degrade mandrill but not AGM SAMHD1 (Table I). I made D46G 
and Q69R mutations in the AGM ‘resistant’ SAMHD1 backbone, reverting these two 
positions to their ‘ancestral’ state. I found that the introduction of either mutation resulted 
in increased susceptibility to degradation by SIVmnd2 Vpx (Figure 39B, see AGM D46G, 
AGM Q69R). This increased sensitivity of SAMHD1 correlated with increased binding to 
SIVmnd2 Vpx since SIVmnd2 Vpx strongly co-immunoprecipitated with mandrill SAMHD1, 
but its interaction with AGM SAMHD1 was much weaker (Figure 39C). However, either 
single reversion point mutation (AGM D46G, AGM Q69R) resulted in a stronger interaction 
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with SIVmnd2 Vpx (Figure 39C; compare last three lanes). Thus, changes at the positively 
selected residues 46 and 69 in SAMHD1 determine both binding and susceptibility to Vpx.  
I also tested the reciprocal G46D and R69Q mutations in the ‘sensitive’ Mandrill 
SAMHD1. I found that while neither mutation alone was sufficient to confer resistance to 
SIVmnd2 Vpx degradation (Figure 39D, Mnd R69Q and Mnd G46D), a combination of both 
mutations together resulted in the gain of resistance against degradation by SIVmnd2 Vpx. 
Thus, these results demonstrate that changes in amino acids evolving under positive 
selection in SAMHD1 are necessary and sufficient to determine specificity of Vpx 
antagonism. This strongly suggests that a Vpx-like factor was responsible for the recurrent 
positive selection on SAMHD1 during primate evolution. 
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Figure 39  
SAMHD1 positive selection residues map to Vpx sensitivity.  
(A) Alignment of N-terminal and SAM domain regions from indicated primates. Symbols 
(circle on a stick) represent the positively selected residues marked on the SAMHD1 
domains. Sites 46 and 69 which displayed highly significant signals of positive selection are 
boxed in the alignment. Stars represent the codons under positive selection with strong 
support (Figure S3A, S3B and S3C). The N terminal region of SAMHD1 from grey mouse 
lemur is included to represent amino acid residues encoded by a distantly related prosimian 
primate. 
(B) Expression of mandrill, AGM and AGM point mutants (AGM D46G and AGM Q69R) were 
analyzed by western blot, in the presence or absence of SIVmnd2 Vpx expression.  
(C) Western blot analysis of HA-immunoprecipitated SAMHD1 for FLAG-epitope tagged 
SIVmnd2 Vpx association. Cells were treated with 25µM MG-132 for 12 hours prior to 
immunoprecipitation. Heavy chain (Hc) is shown as a loading control.   
(D) Western blot shows expression of SAMHD1 from mandrill and mandrill-derived 
mutations (Mnd G46D, Mnd R69Q, and Mnd G46D, R69Q) in the presence or absence of 
SIVmnd2 Vpx. 
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Figure 40  
(A) Codons with a posterior probability of >95% were highlighted in a PAML analysis of 
SAMHD1 genes from Old World monkeys (16 species) which showed the strongest burst of 
positive selection in primates (Figure 37B).  
(B) Summary of the REL analysis of whole SAMHD1 gene from 16 Old World monkeys.  
(C) The SAM domain showed the strongest signatures of positive selection within Old World 
monkeys using PAML (Figure 37C). Therefore, REL analysis was repeated using only the SAM 
domain from Old World monkeys.  
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The ability to degrade SAMHD1 preceded the birth of Vpx in primate lentiviruses 
I wished to determine whether the ability to degrade SAMHD1 was an ancestral trait 
common to all Vpr/Vpx proteins, and that function was subsequently lost by some Vpr 
lineages across evolution; or alternatively, whether the ancestral Vpr/Vpx lacked the ability 
to degrade SAMHD1, but the trait was gained (neofunctionalized) over the course of 
primate lentivirus evolution. However, in order to interpret whether there was a gain or a 
loss of the ability of Vpr/Vpx to degrade SAMHD1, it was necessary to root the vpr/vpx 
phylogenetic tree from Figure 35A. Previous studies demonstrated that the endogenous 
lentivirus in the genomes of lemurs, pSIVgml, is 2 to 6 million years old and unambiguously 
forms an outgroup to all extant primate lentiviruses (75, 76, 145). However, pSIVgml does 
not encode a vpr or vpx gene. Therefore, we performed a phylogenetic analysis of pol 
sequences and found that SIVolc and SIVwrc, which infect the primate species of the 
Colobinae subfamily of OWM, are the closest relative to SIVgml that contain an existing 
vpr/vpx gene (Figure 42A), consistent previous studies (75, 76)). Analysis of env sequences 
(which are 3’ of vpr and pol) showed that the pSIVgml nests with the similar cluster of 
sequences (Figure 42B). Therefore, we used SIVolc/SIVwrc vpr sequences to root the 
vpr/vpx tree, reflecting the high likelihood that this clade represented the earliest branching 
event of extant primate lentiviruses.   
Using this rooted tree, I overlaid the SAMHD1 degradation phenotype onto the 
phylogeny and found that the vpr genes that lacked SAMHD1 degrading ability (Figure 41, 
red stars) were clearly separable from the SAMHD1 degrading vpr and vpx genes (Figure 41, 
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blue stars). Strikingly, all vpr and vpx genes that shared the ability to degrade SAMHD1 nest 
within the same monophyletic clade with high confidence (Figure 41, BS = 90.3; Figure 36A, 
PP = 0.97).  Since Vpr from HIV-1, HIV-2, SIVmac, SIVrcm, and SIVmnd2 were unable to 
degrade SAMHD1 (Figure 41, red stars), the most parsimonious explanation is that the Vpr 
of their common ancestor (Figure 41, Node 3) lacked the SAMHD1 degradation capability. 
Given that the outgrouping SIVmnd1 Vpr and SIVolc Vpr proteins were incapable of 
degrading SAMHD1 (Figure 34 and Figure 35), this strongly supports the hypothesis that the 
ancestral Vpr was “inactive” against SAMHD1 (Figure 41, Node 1) and the ability to degrade 
SAMHD1 subsequently arose only once during vpr and vpx evolution.  
Based on the phylogeny, I can clearly pinpoint that the neofunctionalization of Vpr 
to degrade SAMHD1 occurred on the branch leading up to the split of SIVagm, 
SIVdeb/mus/mon lineages (Figure 41, Node 2). Importantly, based on phylogeny, our results 
suggest that the birth of the vpx recombination/duplication dated after the 
neofunctionalization occurred (Figure 41, Node 4). Thus, the combined phylogenetic and 
functional study presented here strongly supports a scenario in which the degradation of 
SAMHD1 by Vpx was preceded by the neofunctionalization of Vpr in a transitional SIV 
lineage. Furthermore, this phylogenetic framework argues against a subsequent loss of 
SAMHD1-degrading ability in any lentiviral Vpr protein; that is, those Vpr proteins that 
currently lack this ability including HIV-1 Vpr likely never possessed it. 
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Figure 41  
SAMHD1 degradation by some Vpr proteins preceded the birth of Vpx.  
(A) The phylogeny shown in Figure 35 was rooted to common ancestor of SIVolc/SIVwrc, as 
determined by the phylogenetic positioning of the flanking pol and env genes in relation to 
pSIVgml (Figure 42), and is consistent with previous reports that the Colobinae SIVs are 
outgroup to the Cercopithecinae SIVs (75, 76, 145). Important nodes that infer ancestral 
traits are boxed in numbers.  
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Figure 42  
(A) Unrooted phylogeny of 92 pol sequences (1,103 aa region) from diverse primate 
lentiviruses using maximum likelihood method to determine the earliest branching event of 
extant primate lentiviruses.  
(B) Similar branching order of pSIVgml was observed from the env sequences using a 
maximum likelihood method; however, there was low bootstrap support due to the short 
sequence alignment (55 aa region). Therefore, the phylogeny was constructed using a 
Bayesian MCMC inference.   
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DISCUSSION 
Here I show that diverse Vpx proteins as well as some Vpr proteins have the ability 
to target their host species’ SAMHD1 for degradation. Both Vpx and Vpr antagonists display 
species-specific degradation of SAMHD1 which are in some cases quite specific to the virus's 
extant host.  Such species specificity is a hallmark of an antagonistic 'arms race' between 
host and virus, in which both sides rapidly evolve to gain an advantage.  Indeed, I show that 
SAMHD1 has been evolving under positive selection in primates. I demonstrate that the 
residues under positive selection in the SAM domain of SAMHD1 determine the specificity 
of degradation by Vpx, directly implicating Vpr/Vpx antagonism as the source of the 
remarkable signature of positive selection detected in SAMHD1, which is most pronounced 
in the Cercopithecina subfamily of Old World monkeys. By combining our functional results 
with phylogenetic analyses, we show that the ability to degrade SAMHD1 is a 
neofunctionalization of Vpr which preceded the birth of Vpx by recombination/duplication.  
Based on our combined phylogenetic and functional analyses, the common ancestor 
of SIV viruses most likely encoded a single Vpr that was “inactive” against SAMHD1. The 
ability to recruit a protein degradation complex is important for Vpr-mediated cell cycle 
arrest (reviewed in (51)) and thus may represent the ancestral function of Vpr/Vpx. 
Interestingly, although cell cycle arrest and SAMHD1 degradation functions are segregated 
into two separate proteins in those viruses that encode Vpr and a Vpx (14), SIVagm Vpr is 
able to cause both cell cycle arrest (207, 257) and SAMHD1 degradation (Figure 35A). This 
indicates that the two functions are not mutually exclusive. Furthermore, since cell cycle 
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arrest by Vpr has species-specificity (257), it is likely that the substrate used by Vpr to cause 
cell cycle arrest will, like SAMHD1, have evolved under positive selection. 
While the cellular protein targeted by Vpr to cause cycle cell arrest is not yet known, 
the adaptive evolution of SAMHD1 might provide a clue as to why some viruses evolved to 
encode a separate Vpx and Vpr gene. One scenario we propose is that the 
neofunctionalization of the ancestral Vpr/x to target SAMHD1 exerted a strong selective 
pressure on old world monkeys’ SAMHD1. As a result, variants of SAMHD1 that conferred 
protection from Vpr/x antagonism were selected for, leading to the signatures of rapid 
evolution in SAMHD1, especially localized within the SAM domain. This posed a unique 
challenge to the ancestral Vpr/x that had to recognize both the cell cycle arrest-factor and 
multiple rapidly evolving variants of SAMHD1. In order to maintain both functional 
capabilities, a recombination/duplication of Vpr might have given rise to Vpx. This 
subsequently allowed the subfunctionalization of Vpx to maximize its SAMHD1-targeting 
capability, while preserving the cell cycle arrest phenotype in Vpr. This model might explain 
the complicated evolutionary history of vpr and vpx (246, 277, 278). Thus, we speculate that 
the “birth” of a new gene in some lineages leading to both vpr and vpx in the same viral 
genome, was a more modern event compared to the neofunctionalization of Vpr, may have 
been directly driven by the rapid evolution of the SAMHD1 protein. 
Why HIV-1 does not encode Vpx  
HIV-1 lacks the capability of degrading SAMHD1 since its Vpr protein is unable to 
degrade SAMHD1 and it does not encode Vpx. Since SIVcpz Vpr also lacks SAMHD1-
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degrading ability (Figure 35A), this function was missing in HIV-1 even prior to its cross-
species transmission from chimpanzees into humans (). Moreover, human SAMHD1 is not 
special in terms of its resistance to Vpr antagonism as it is readily degraded by HIV-2 Vpx. 
This situation is directly analogous to the two lentiviruses that infect mandrills. SIVmnd1 
contains only a Vpr gene that has no activity against mandrill SAMHD1 (Figure 34C), 
whereas SIVmnd2 has both Vpr and Vpx, the latter of which is capable of degrading mandrill 
SAMHD1 (Figure 34C). Intriguingly, SIVmnd1 appears more pathogenic than SIVmnd2 similar 
to the higher pathogenicity of HIV-1 relative to HIV-2 (255). One possible explanation is that 
both HIV-1 and viruses like SIVmnd1 evolved unique antagonistic functions (or more 
effective countermeasures) that collectively allow HIV-1 to achieve sufficient replicative 
potential in target cells (including SAMHD1-expressing monocytes) even in the absence of 
SAMHD1-degrading abilities. On the other hand, Vpx-encoding viruses may have become 
more dependent on the ability to counteract SAMHD1 to achieve successful replication in 
target cells and have relaxed selection on alternate measures used by viruses like HIV-1.  
 
 
179 
 
 
Figure 43  
Vpr and Vpx functions and evolution in primate lentiviruses. The ancestral trait of Vpr in 
primate lentiviruses is likely to cause cell cycle arrest. During its course of evolution, Vpr 
from some lineages gained the ability to degrade SAMHD1. Subsequently, through 
recombination or duplication, certain lineages acquired and subfunctionalized Vpx and Vpr.   
 
What the confined signatures of positive selection mean 
Most of the signatures of positive selection in primate SAMHD1 appear to originate 
from the old world monkey lineages, specifically the subfamily Cercopithecinae after its split 
from Colobinae. This highly localized positive selection on the primate phylogeny is unusual. 
Most previously analyzed host immune genes, such as TRIM5alpha, Tetherin, PKR and 
APOBEC3G, display signatures of positive selection throughout many primate lineages 
including hominoids and new world monkeys (58, 142, 163, 166, 230, 231) while others 
have been restricted to hominoids and old world monkeys alone (TRIM22). Such a localized 
signature of positive selection might signal the advent of a highly specialized and unique 
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antagonist. Intriguingly, our phylogenetic framework (Figure 41) strongly argues that the 
Vpr/Vpx proteins’ ability to degrade SAMHD1 arose within the primate lentiviruses, and 
specifically among lentiviruses that infect Cercopithecinae and jumped into Hominidae, but 
not viruses that infect Colobinae.  
An interesting observation is that SAMHD1 in orang utans are the only primate 
species outside of the Cercopithecinae subfamily that also has a strong signature of positive 
selection. Yet, to date, there is no evidence of SIVs in orang utans. However, the caveat is 
that most studies have focused on looking for foamy virus and herpesviruses (122, 287), and 
lentiviruses might not have been assayed for. Given their unique geographical isolation in 
south eastern Asia, discovering a primate lentivirus from orang utans or species in that 
geographical location would be very informative. Alternatively, there are also reports of 
simian T-lymphotropic virus (STLV) and simian type D retrovirus (SRV) infections in orang 
utans (287, 294). It might be worth investigating if these viruses encode an antagonist 
against SAMHD1. 
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Figure 44  
SAMHD1 from multiple primate lineages in Cercopithecinae subfamily species have been 
evolving under positive selection. Since the adaptive evolution of SAMHD1 was driven by 
Vpr/Vpx, this infers the presence of ancient primate lentiviruses since antiquity. 
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CHAPTER SEVEN 
SUMMARY AND DISCUSSION 
 
 In summary, my research has provided a detailed interdisciplinary perspective of  
host-virus arms races. By integrating evolutionary biology with virology, I have 
reconstructed the chronological context of how hosts evolve around viral pressures and 
ways viruses counter-evolve. First, lentiviruses are able to evolve new functions within 
existing gene repertoires to counteract rapidly host antiviral genes. Secondly, hosts escape 
from viral pressure either by single amino acid changes or by deletions of a 'susceptibility 
domain'. Finally, this work has allowed us to pinpoint the origin of the evolutionary “arms 
race” between primates and lentiviruses. Thus, my thesis research has helped define the 
rules by which host-virus arms races ensue. 
The astronomical viral diversity that challenges the immune system poses a problem 
of recognition and specificity. An interesting challenge is that, unlike adaptive immunity 
which involves somatic learning and memory, host restriction factors are germline-encoded. 
Therefore, how do germline host restriction factors evolve to escape from viral pressures? 
And how do antiviral proteins maintain the ability to target the wide spectrum diversity and 
short time-scale evolution of viruses? In turn, what strategies do viruses employ to counter-
evolve to their hosts? Thus, host antiviral restriction is fundamentally an evolutionary 
problem. That is why this combined approach is very effective and yields significant insights.  
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In this chapter, I will: 
 Describe implications of 2 specific host-virus “arms race” 
 Detail future research directions that address these implications 
 Define features of host restriction factors 
 
Modern consequences for HIV in the Tetherin “arms race” 
 The Tetherin “arms race” is the best example to date of how past viral pressures 
have real consequences for modern infections. HIV-1 uses its Vpu accessory protein to 
counteract Tetherin, but the immediate precursor SIVcpz uses a different accessory protein, 
Nef, to antagonize its host chimpanzee Tetherin instead. This means that HIV-1 adapted to 
humans by switching from using Nef to antagonize Tetherin to using another protein, Vpu 
to do this job. I resolved the mystery of how and why this occurred. 
I have found that tetherin has been evolving under positive selection in primates. 
The residue under the strongest recurrent positive selection is the site of functional 
interaction of Tetherin with Nef. In fact, an amino acid substitution at this single position 
can determine the susceptibility of Tetherin to Nef antagonism. However, human Tetherin 
has a unique 5-amino-acid deletion that lost this residue, rendering it immune to Nef. These 
are significant findings because it demonstrates that hosts escape from viral pressure either 
by single amino acid changes or by deletions of a 'susceptibility domain'. 
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As a result of the unique deletion, SIVcpz Nef could not antagonize human Tetherin, 
and I showed that HIV-1 Vpu evolved to counteract Tetherin upon its transmission to 
humans through changes at its N-terminus. Thus, we can infer that positive selection to 
resist a Nef-like antagonist resulted in the unique deletion in human Tetherin, which in 
turn drove HIV-1 to switch from Nef to Vpu as its Tetherin-antagonist. This has two 
important implications. First, HIV-1’s adaptation was a direct consequence of an adaptive 
escape (5aa deletion) from a past antagonist. This means that the evolutionary history and 
trajectory of host genes directly influence contemporary host-virus interactions. Second, 
viruses evolve new functions within existing gene repertoires to counteract rapidly host 
antiviral genes. The Nef to Vpu “switch” goes against the norms and expectation that 
adaptation would occur within the precursor Nef antagonist, instead HIV-1 
neofunctionalized a separate and distinct Vpu accessory protein. This is the strongest 
evidence of the remarkable genetic flexibility that HIV and lentiviruses possess. The 
significance of this is further emphasized by the observation that SIVmus Vpu also has this 
capacity to antagonize Tetherin (Chapter Three, (144)), indicating that this adaptation has 
occurred at least twice in different viral lineages.  
 
HIV-1 Nef has unlocked a new and unknown function? 
The immediate health relevance of the Nef to Vpu “switch” applies to the pandemic 
HIV-1. While the evolution of SIVcpz Nef was originally constrained in its role as an 
antagonist of Tetherin, the evolution of HIV-1 Vpu to antagonize Tetherin may have allowed 
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HIV-1 Nef to evolve novel functions in humans and to contribute to the pathogenicity of the 
virus (229). For example, Nef has been implicated in the enhancement of viral infectivity, 
the downregulation of CD4, major histocompatibility complex class I (MHC-I), and other cell 
surface receptors, and the remodeling of the actin cytoskeleton (12, 50, 124, 151, 258). It 
will be informative to observe if some of these functions have evolved in the transition of 
SIVcpz to humans in ways that increase HIV-1 pathogenicity (124). Importantly, only the 
pandemic Group M precursor virus made this Vpu switch (229), suggesting that this could 
be a critical adaptation to the pandemicity of HIV-1 Group M. 
To address this, we would first have to identify the determinants for Nef’s Tetherin-
antagonist activity. That is, what allows SIVcpz Nef to antagonize Tetherin? The expectation 
is that this phenotype can be conferred onto the inactive HIV-1 Nef by constructing chimeric 
proteins. One study has since implicated the C-terminal of SIVcpz Nef in this function (314). 
Furthermore, sequence prediction will be very effective since this motif should be highly 
conserved in SIVcpz strains. The identity of the Nef determinant might have known 
functions associated with it and thus inform us of concrete phenotypes to test for. In this 
model, we would predict that HIV-1 Nef has adapted becoming more effective at an existing 
function than the precursor SIVcpz Nef. This should be a significant difference that can be 
quantified. 
However, the evidence that HIV-1 Nef has lost its precursor antagonistic activity 
against Tetherin (Figure 21) strongly suggests that it has neofunctionalized. In this model, 
we predict that the relaxation of selective constraint allowed HIV-1 Nef to adapt a new 
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function that the precursor SIVcpz Nef does not possess. Nef is characteristic for its adaptor 
role in which it directly binds a cellular protein (CD4 or MHC I) and recruits a trafficking 
complex (AP2 or AP1). Likewise, the hypothesis is that HIV-1 Nef is binding a novel 
substrate. Therefore, the best method for this problem will be a mass spectrometry analysis 
of affinity purified proteins that interact with HIV-1 Nef. The key to the success of this 
approach lies in the specificity of the Nef chimeric proteins. We will capitalize on the profile 
from their other conserved functions to render background sensitivity irrelevant. 
Furthermore, we will have a strict definition to identify the candidate proteins since the 
anti-Tetherin activity of Nef chimeras will be a directly inverse surrogate for the novel 
function. Ultimately, the single immediate focus is to identify the novel Nef function behind 
the pathogenicity of HIV-1. 
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Figure 45  
Summary of evolutionary events leading up to HIV-1 neofunctionalization of Vpu to 
counteract human Tetherin. 
Primate tetherin gene has been evolving under positive selection due to selective pressures 
from viral antagonists. To evade an ancient Nef-like antagonist, a 5 amino acid deletion in 
human tetherin was selected for. As a result, upon the cross-species transmission of HIV-1, 
the precursor Nef protein was unable to antagonize human tetherin and had to evolve Vpu 
to counteract tetherin. Since then, HIV-1 Nef has lost the ability to recognize tetherin and I 
speculate that it might have adapted a new function.  
 
On the Origin of the SAMHD1 “arms race” 
The SAMHD1 arms race reinforces the novel findings that neofunctionalization is a 
viral strategy of host adaptation. The most important question that was answered through 
the SAMHD1 study is whether SAMHD1 antagonism was an ancestral trait that was lost in 
some lineages or a newly acquired function. While Vpx is only encoded by some lineages of 
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primate lentiviruses, its paralog, Vpr, is conserved across all. I have found that while the 
ability to degrade SAMHD1 is conserved across multiple lineages’ Vpx, some Vpr proteins 
can also degrade SAMHD1. The discovery of these Vpr SAMHD1-antagonists is very 
significant because it allowed me to conclusively pinpoint when this transitional state arose 
along the evolution of Vpr and Vpx. By overlaying their functions on a phylogenetic 
framework of Vpr and Vpx evolution, we can conclude that Vpr neofunctionalized to 
degrade SAMHD1 even prior to the birth of a separate Vpx.   
I have also shown that residues in SAMHD1 under positive selection directly 
determine Vpx sensitivity. This suggests that the birth of the SAMHD1-degrading ability 
within primate lentiviruses initiated the evolutionary arms-race that led to such a highly 
localized signature of positive selection within Cercopithecinae (Figure 37). Taken together, 
this means that both the positive selection of SAMHD1 and consequently the birth of Vpx 
may have been driven by the neofunctionalization of Vpr to antagonize SAMHD1. This 
subsequently allowed the subfunctionalization of Vpx to target rapidly evolving variants of 
SAMHD1. Thus, the reconstruction of the SAMHD1 and Vpr/Vpx genetic conflict is very 
exciting because it has given us an unprecedented view into how evolutionary “arms races” 
are initiated.  
 
Implications for the recombinant origin of HIV-1/SIVcpz ancestor 
  The findings of the SAMHD1 study also raise important questions about the origin of 
the hybrid recombinant common ancestor of HIV-1/SIVcpz. Move up one paragraph so that 
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it follows the other SAMHD1 discussion The common ancestor HIV-1/SIVcpz lineage is the 
result of a double recombination between SIVrcm (5’ coding region) and (3’ end), and 
SIVmus/gsn lineage (Vpu and Env region). Importantly, the two distinguishing features of 
the recombinant are that it lacks a Vpx but does encode Vpu. Prior to this work, 
phylogenetic inference of the genes around the region of recombination (Vif, Vpx, Vpr and 
Vpu) would suggest a two-step process (Figure 46, Scenario 1). First, since the Vif and Vpr 
from HIV-1/SIVcpz and SIVrcm are more phylogenetically related, this suggests that the 
precursor recombinant would have acquired both the Vpx and Vpr since Vpx lies 5’ 
upstream of Vpr. However, the recombinant HIV-1/SIVcpz ancestor lacked Vpx. The 
phylogeny strongly argues against the current HIV/SIVcpz Vpr being a misnamed Vpx. In 
that scenario, I would expect that HIV/SIVcpz Vpr to be more closely related to SIVrcm Vpx 
than SIVrcm, but that is not the case. Instead, SIVcpz/HIV-1 Vpr clusters with Vpr genes, and 
clearly separate from Vpx genes, supporting that it has been named accurately as a Vpr. Yet, 
there is no evidence of Vpx-like sequence erosion between Vif and Vpr. In fact, the first 60-
80 bp of Vpr that overlaps into 3’ end of Vif is maintained. Therefore, in the second stage, 
Vpx had to be lost subsequently by another recombination event or mechanism that 
allowed the Vif/Vpr overlap to be restored (Figure 46). While this might be possible, it is 
highly unlikely. 
Instead, I propose an alternative hypothesis that the recombination was with a 
SIVmus/gsn lineage and an ancestral SIVrcm that encoded a single Vpr, which existed prior 
to the birth of Vpx and was incapable of degrading SAMHD1 (Figure 46, Scenario 2). This 
would explain why the Vif/Vpr overlap is still maintained. More importantly, this means that 
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HIV-1 Vpr does not degrade SAMHD1 because it never acquired this function. There are two 
lines of evidence to support the plausible existence of such an ancestral SIVrcm. First, 
phylogenetic and functional analyses in Chapter Six support that prior to the 
neofunctionalization of vpr and birth of vpx, primate lentiviruses had a single vpr that was 
incapable of degrading SAMHD1. Secondly, while none of the extant SIVrcm sequenced to 
date encode only a single vpr gene, there are non-recombinant primate lentiviruses such as 
SIVolc and SIVsun/SIVlst that fit this description. This is in contrast to an evolutionary 
scenario where primate lentiviruses had both vpx and vpr, but vpx was lost in some 
lineages. Furthermore, this implies that the current SIVrcm (Vpx- and Vpr-encoding) has 
replaced the ancestral single vpr SIVrcm (Figure 46). However, I note that this is based on 
the inference that the acquisition and subfunctionalization of vpx and vpr is more 
evolutionarily fit for the virus than having a single vpr. Nonetheless, this means that the fate 
of the ancestral single vpr SIVrcm virus lead to either an acquisition of vpx (current SIVrcm) 
or vpu (HIV-1/SIVcpz lineage). Together, this strongly suggests that ancestral recombinant of 
SIVcpz/HIV-1 was much older and likely pre-dated the cross-species transmission into 
chimpanzees. This implies that the recombination event did not occur in chimpanzees (a 
recent event), as widely hypothesized. 
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Figure 46  
Hypothetical scenarios for the origin of the recombinant precursor of SIVcpz/HIV-1. 
Phylogenies of Vif, Vpx, Vpr and Vpu (top) show that the precursor of SIVcpz/HIV-1 resulted 
from multiple recombinations (dotted lines) between SIVrcm and SIVmus/gsn lineages. In 
scenario 1, the recombination event was followed by the loss of Vpx which 
maintained/restored the Vif/Vpr overlap. In scenario 2, the recombination was with an 
ancestral SIVrcm that existed prior to the birth of Vpx. This virus has since been replaced by 
the Vpx encoding strains. The viral origins of the different segments can be traced by colors: 
SIVmus (blue), SIVrcm (red), the neofunctional vpr/vpx (cyan).  
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The discovery of Vpr proteins that can antagonize SAMHD1 raises several immediate 
research questions. First, what are the viral determinants for Vpr’s recognition of SAMHD1? 
To address this, we will construct chimeric Vpr proteins to assay for a gain of function 
activity. Our diverse panel of characterized Vpr proteins combined with our vpr sequence 
analyses will allow us to make informative decisions on how to map the phenotype. The 
expectation is that the ‘active’ Vpr proteins encode a conserved SAMHD1-interacting motif 
that is poorly conserved or absent from the ‘inactive’ Vpr proteins. Secondly, how does the 
single Vpr protein maintain its ability to degrade SAMHD1 and also cause cell cycle arrest? I 
have found that SIVagm Vpr can degrade AGM SAMHD1. Previous work from our lab has 
also found SIVagm Vpr can exert a G2 cell cycle arrest in AGM cells (257). Therefore, 
mapping the determinants of Vpr will directly impact our understanding of the cell cycle 
arrest mechanism. For instance, if both functions map to the same region of Vpr, this would 
suggest that the G2 arrest target could be another SAM-domain containing protein. 
Alternatively, if Vpr determinants of SAMHD1-binding are distinctly separable from G2 
arrest function, this would explain how the neofunctionalization of Vpr occurred. Our 
contribution here will be a crucial part of the larger goal to identify the unknown cellular 
protein behind the Vpr cell cycle arrest phenotype.  
 
Exploiting the evolutionary signatures of host restriction factors 
 Finally, host antiviral restriction is fundamentally an evolutionary problem. I have 
reconstructed two specific examples that convincingly show that host restriction factors are 
locked in a Red Queen’s arms race with viruses. This means that we can exploit the 
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evolutionary signatures of positive selection to screen for novel host restriction factors. This 
will involve cross-reference existing interferon stimulated gene databases for genes 
evolving under positive selection to generate an exclusive list of candidate genes. By 
distinguishing the bona fide host restriction factors repertoire, we will be poised to 
characterize antiviral strategies and effectivel y design complementing therapeutics.  
 There are two considerations to this approach. First, the host restriction factor 
activity may be dependent on the virus model system. For instance, although Viperin 
potently restricts Influenza virus and HCV, I have found that it does not inhibit HIV-1 at 
biologically-relevant levels. Second, evolutionary analyses must take deletions/insertions 
into consideration. For instance, the adaptive evolution of human Tetherin involved a 
unqiue deletion. Thus, the strategies and detailed examples featured in this dissertation is a 
practical guide on how to effectively integrate evolutionary biology with virology.  
 
Closing remarks 
 In conclusion, the broad themes that emerge from my research are two-fold. First, 
lentiviruses are able to evolve new functions within existing gene repertoires to counteract 
rapidly host antiviral genes. Secondly, hosts escape from viral pressure either by single 
amino acid changes or by deletions of a 'susceptibility domain'. Using a reconstruction of 
the evolutionary “arms race” between primates and lentiviruses, my thesis research has 
helped define the rules by which host-virus arms races ensue. Based on my findings, we 
contend that the host evolutionary framework is a fundamental pillar of antiviral restriction. 
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